var title_f31_30_32224="Relative incidence eumycetoma organisms";
var content_f31_30_32224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Etiological agents of eumycetoma, worldwide*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 352px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only reports with at least 5 cases confirmed by culture or by histopathology are considered.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol 2008; 51:154-5.",
"       </li>",
"       <li>",
"        Bendl, BJ, Mackey D, Al-Saati F, Sheth KV, Ofole SN, Bailey TM. Mycetoma in Saudi Arabia. J Trop Med Hyg 1987; 90:51-9.",
"       </li>",
"       <li>",
"        Buot G, Lavalle P, Mariat F, Suchil P. &Eacute;tude &eacute;pid&eacute;miologique des myc&eacute;tomes au Mexique. Bull Soc Pathol Exot 1987; 80:329-39.",
"       </li>",
"       <li>",
"        Castro LG, Belda Junior W, Salebian A, Cuce LC. Mycetoma: A retrospective study of 41 cases seen in S&atilde;o Paulo, Brazil, from 1978 to 1989. Mycoses 1993; 36:89-95.",
"       </li>",
"       <li>",
"        Castro LG, Piquero-Casals J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from S&atilde;o Paulo, Brazil. Int J Dermatol. 2008; 47:160-3.",
"       </li>",
"       <li>",
"        Ch&aacute;vez G, Arenas R, P&eacute;rez-Polito A, Torres B, Estrada R. Eumycetic mycetoma due to Madurella mycetomatis. Report of six cases. Rev Iberoam Micol 1998; 15:90-3.",
"       </li>",
"       <li>",
"        Daoud M, Ezzine Sebai N, Badri T, Mokhtar I, Fazza B, Kamoun M R. Mycetoma: retrospective study of 13 cases in Tunisia. Acta Dermatoven APA, 2005; 14:153-6.",
"       </li>",
"       <li>",
"        Destombes P, Mariat L, Rosati G, Segretain G. Les myc&eacute;tomes en Somalie - conclusions d'une enqu&ecirc;te men&eacute;e de 1959 &agrave; 1964. Acta Tropica 1977; 34:335-73.",
"       </li>",
"       <li>",
"        Develoux M, Audoin J, Treguer J, Vetter JM, Warter A, Cenac A. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg. 1988; 38:386-90.",
"       </li>",
"       <li>",
"        Dieng MT, Sy MH, Diop BM, Niang SO, Ndiaye B. [Mycetoma: 130 cases] Ann Dermatol Venereol. 2003; 130:16-9.",
"       </li>",
"       <li>",
"        Green WO Jr, Adams TE. Mycetoma in the United States. A review and report of seven additional cases. Am J Clin Path 1964; 42:75-91.",
"       </li>",
"       <li>",
"        Gumaa SA, Mahgoub ES, el Sid MA. Mycetoma of the head and neck. Am J Trop Med Hyg. 1986; 35:594-600.",
"       </li>",
"       <li>",
"        Hazra B, Bandyopadhyay S, Saha SK, Banerjee DP, Dutta G. A study of mycetoma in eastern India. J Commun Dis 1998; 30:7-11.",
"       </li>",
"       <li>",
"        Khatri ML, Al-Halali HM, Fouad Khalid M, Saif SA, Vyas MC. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol 2002; 41:586-93.",
"       </li>",
"       <li>",
"        Klokke AH, Swamidasan G, Anguli R, Verghese A. The causal agents of mycetoma in South India. Trans R Soc Trop Med Hyg. 1968; 62:509-16.",
"       </li>",
"       <li>",
"        Lopez-Martinez R, Mendez-Tovar LJ, Lavalle P, Welsh O, Sa&uacute;l A, Macotela Ruiz E. Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac Med Mex 1992; 128:477.",
"       </li>",
"       <li>",
"        Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of Mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002; 7:788-92.",
"       </li>",
"       <li>",
"        Mariat, F. On the geographic distribution and incidence of Mycetoma agents. Bull Soc Pathol Exot Filiales. 1963; 56:35-45.",
"       </li>",
"       <li>",
"        Novoa-Montero D, Serrano JA. review On human mycoses in Venezuela. Rev Soc Ven Microbiol 2001; 21..46-68.",
"       </li>",
"       <li>",
"        Negroni R, L&oacute;pez Daneri G, Arechavala A, Bianchi MH, Robles AM. Clinical and microbiological study of mycetomas at the Mu&ntilde;iz hospital of Buenos Aires between 1989 and 2004. Rev Argent Microbiol 2006; 38:13-18.",
"       </li>",
"       <li>",
"        Ravisse P, Huerre M, De Bi&egrave;vre C, et al. Les myc&eacute;tomes en Mauritanie: &Eacute;tude histologique de 150 cas. J Mycol Med 1992; 2:154-59.",
"       </li>",
"       <li>",
"        Venugopal PV, Venugopal TV. Treatment of eumycetoma with ketoconazole. Australas J Dermatol 1993; 34:27-9.",
"       </li>",
"       <li>",
"        Yu Am, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 1993; 48:812-7.",
"       </li>",
"       <li>",
"        Hashemi SJ, Nasrollahi A, Guerami M, et al. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 2008; 1:77-81.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32224=[""].join("\n");
var outline_f31_30_32224=null;
var title_f31_30_32225="Incorrect tennis backhand";
var content_f31_30_32225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incorrect tennis backhand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous contraction of wrist extensors, insufficient follow-through, and leading with the elbow (red arrow) are three common faults with the beginner's backhand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32225=[""].join("\n");
var outline_f31_30_32225=null;
var title_f31_30_32226="Patient information: Nuclear heart testing (The Basics)";
var content_f31_30_32226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16425\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/21/32085\">",
"          Person having a stress test",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nuclear heart testing (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nuclear-heart-testing-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27251800\">",
"      <span class=\"h1\">",
"       What is nuclear heart testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nuclear heart testing is a way for doctors to check how healthy your heart is. A nuclear heart test is an imaging test that can show:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much blood flows to your heart muscle",
"       </li>",
"       <li>",
"        How well your heart pumps blood to the rest of your body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Usually, people have a test called a &ldquo;stress test&rdquo; along with a nuclear heart test. A stress test measures how well the heart works when it is pumping very fast. When the heart pumps fast, it needs more blood. A stress test shows if the heart gets enough blood during these times. When a stress test is done with a nuclear heart test, it&rsquo;s called a &ldquo;nuclear stress test.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251807\">",
"      <span class=\"h1\">",
"       Why might my doctor order a nuclear heart test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might order a nuclear heart test or a nuclear stress test to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check if your heart muscle is getting enough blood",
"       </li>",
"       <li>",
"        Look for certain heart conditions or follow a known heart condition",
"       </li>",
"       <li>",
"        Check your heart after a heart attack or heart surgery",
"       </li>",
"       <li>",
"        See how well your heart pumps blood to the rest of your body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251814\">",
"      <span class=\"h1\">",
"       How do I prepare for a nuclear heart test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you have a nuclear heart test, your doctor will ask about all of the medicines you take. He or she might have you stop or change some of your medicines before the test. He or she will tell you when to stop eating and drinking before your test. Your doctor also might ask you not to drink anything that has caffeine in it for 24 hours beforehand.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251821\">",
"      <span class=\"h1\">",
"       What happens during a nuclear heart test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, the doctor, nurse, or technician will do a test called an &ldquo;ECG.&rdquo; An ECG records your heart rate and rhythm by measuring the electrical activity in your heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"mobipreview.htm?6/63/7154\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Then, the doctor, nurse, or technician will have you lie down on a table. He or she will put an IV (needle) in your arm and put a radioactive substance, called a &ldquo;tracer,&rdquo; into the IV. The tracer will travel through the blood to your heart. A camera outside your body will follow the tracer&rsquo;s signals. The camera will take pictures and create images that show the blood flowing to and through your heart.",
"     </p>",
"     <p>",
"      If you have a nuclear stress test, you will have 1 set of pictures done while you rest and 1 set done when your heart is pumping fast. To &ldquo;stress&rdquo; your heart and raise your heart rate, the doctor will do 1 of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have you run or walk on a treadmill (",
"        <a class=\"graphic graphic_figure graphicRef60855 \" href=\"mobipreview.htm?31/21/32085\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Have you pedal a stationary bike (a bike that doesn&rsquo;t move, except for the pedals)",
"       </li>",
"       <li>",
"        Give you medicine to make your heart pump faster &mdash; People who can&rsquo;t exercise can get medicine instead.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After the stress test, the doctor will take another set of pictures. That way, he or she can compare the results from the 2 different times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251828\">",
"      <span class=\"h1\">",
"       What are the downsides of nuclear heart tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nuclear heart tests do involve a small amount of radiation. Too much radiation can cause serious health problems, like cancer. The small amount of radiation in nuclear tests will not cause any long-term problems in many people. But your doctor will talk with you about the possible long-term side effects of radiation.",
"     </p>",
"     <p>",
"      Other downsides of nuclear heart tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain or redness where the IV was in the arm",
"       </li>",
"       <li>",
"        Side effects from the stress test &mdash; When people exercise and their heart pumps very fast, they can get symptoms such as chest pain, trouble breathing, an abnormal heartbeat, or feeling dizzy or faint.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251835\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, let your doctor know. He or she might postpone the nuclear heart test until after your baby is born.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27251932\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/30/32226?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16425 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32226=[""].join("\n");
var outline_f31_30_32226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251800\">",
"      What is nuclear heart testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251807\">",
"      Why might my doctor order a nuclear heart test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251814\">",
"      How do I prepare for a nuclear heart test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251821\">",
"      What happens during a nuclear heart test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251828\">",
"      What are the downsides of nuclear heart tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251835\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27251932\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/21/32085\">",
"       Person having a stress test",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32227="Equipment configuration for magnetic endoscopic imaging";
var content_f31_30_32227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Equipment configuration for magnetic endoscopic imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mobile integrated unit containing a magnetic field generator, central microprocessor unit, and sensor (receiver) coils (arrow). Images showing the colonoscope's configuration are displayed on a monitor alongside the live endoscopic images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32227=[""].join("\n");
var outline_f31_30_32227=null;
var title_f31_30_32228="Brimonidine: Pediatric drug information";
var content_f31_30_32228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brimonidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?15/32/15877?source=see_link\">",
"    see \"Brimonidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/40/28292?source=see_link\">",
"    see \"Brimonidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg; P",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine P&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine&reg;;",
"     </li>",
"     <li>",
"      PMS-Brimonidine Tartrate;",
"     </li>",
"     <li>",
"      ratio-Brimonidine;",
"     </li>",
"     <li>",
"      Sandoz-Brimonidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Agonist, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glaucoma, Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/32/15877?source=see_link\">",
"      see \"Brimonidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Glaucoma, ocular hypertension:",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults: Ophthalmic: Instill 1 drop into lower conjunctival sac of affected eye(s) 3 times daily (approximately every 8 hours)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tartrate [drops]: 0.15% (5 mL, 10 mL, 15 mL); 0.2% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphagan&reg; P: 0.1% (5 mL, 10 mL, 15 mL); 0.15% (5 mL, 10 mL, 15 mL) [contains Purite&reg;]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill into conjunctival sac avoiding contact of bottle tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects. Administer other topical ophthalmic medications at least 5 minutes apart; generic formulation contains benzalkonium chloride which may be absorbed by soft contact lenses; wait at least 15 minutes after administration to insert soft contact lenses.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 25&deg;C  (59&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lowering of IOP in patients with open-angle glaucoma or ocular hypertension (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Brimonidine may be confused with bromocriptine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Alertness decreased (children), dizziness, fatigue, headache, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic conjunctivitis, blepharitis, blepharoconjunctivitis, blurred vision,  burning sensation, cataract, conjunctival edema, conjunctival folliculosis, conjunctival hemorrhage, conjunctival hyperemia, conjunctivitis, dry eye, epiphora, eye discharge, eye pruritus, eyelid disorder, eyelid edema, eyelid erythema, follicular conjunctivitis, foreign body sensation, irritation, keratitis, ocular allergic reaction, pain, photophobia, stinging, superficial punctate keratopathy, visual disturbance, visual acuity worsened, visual field defect, vitreous detachment, vitreous floaters, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, pharyngitis, rhinitis, sinus infection, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anterior uveitis, bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (erythema, eyelid pruritus, vasodilation), tachycardia; apnea, bradycardia, hypothermia, and hypotonia have been reported in infants",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brimonidine or any component; use in neonates, infants, and children &lt;2 years",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving concomitant MAO inhibitor therapy or with severe cardiovascular disease, hepatic or renal impairment (not studied), depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis. Some formulations may contain benzalkonium chloride which may be adsorbed by soft contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause CNS depression, particularly in young children; the most common adverse effect reported in a study of pediatric glaucoma patients was somnolence and decreased alertness (50% to 83% in children 2-6 years of age); these effects resulted in a 16% discontinuation of treatment rate; children &gt;7 years (&gt;20 kg) had a much lower rate of somnolence (25%); apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving brimonidine",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F986416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IOP",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brimonidine is an alpha-adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Ophthalmic: Within 0.5-2.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/40/28292?source=see_link\">",
"      see \"Brimonidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brimonidine may cause dizziness, drowsiness, visual disturbances, and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berlin RJ, Lee UT, Samples JR, et al, &ldquo;Ophthalmic Drops Causing Coma in an Infant,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(3):441-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32228/abstract-text/11241061/pubmed\" id=\"11241061\" target=\"_blank\">",
"        11241061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlsen JO, Zabriskie NA, Kwon YH, et al, &ldquo;Apparent Central Nervous System Depression in Infants After the Use of Topical Brimonidine,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1999, 128(2):255-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32228/abstract-text/10458196 /pubmed\" id=\"10458196 \" target=\"_blank\">",
"        10458196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Enyedi LB and Freedman SF, &ldquo;Safety and Efficacy of Brimonidine in Children With Glaucoma,&rdquo;",
"      <i>",
"       J AAPOS",
"      </i>",
"      , 2001, 5(5):281-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32228/abstract-text/11641636/pubmed\" id=\"11641636\" target=\"_blank\">",
"        11641636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12899 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32228=[""].join("\n");
var outline_f31_30_32228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056952\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056945\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142460\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056955\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056948\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056954\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142530\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142529\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056959\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056944\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056943\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298882\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142469\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142471\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F986416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056951\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056942\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056957\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056958\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056950\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/32/15877?source=related_link\">",
"      Brimonidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/40/28292?source=related_link\">",
"      Brimonidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32229="Triamcinolone (topical): Drug information";
var content_f31_30_32229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/46/36580?source=see_link\">",
"    see \"Triamcinolone (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=see_link\">",
"    see \"Triamcinolone (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oralone&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; TA;",
"     </li>",
"     <li>",
"      Trianex&trade;;",
"     </li>",
"     <li>",
"      Triderm&reg;;",
"     </li>",
"     <li>",
"      Zytopic&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9606514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oracort;",
"     </li>",
"     <li>",
"      Triaderm",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9608405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9606707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatoses (steroid-responsive, including contact/atopic dermatitis):",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cream, Ointment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.025% or 0.05%: Apply thin film to affected areas 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.1% or 0.5%: Apply thin film to affected areas 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spray: Apply to affected area 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral inflammatory lesions/ulcers:",
"     </b>",
"     Oral topical: Press a small dab (about",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     inch) to the lesion until a thin film develops; a larger quantity may be required for coverage of some lesions. For optimal results, use only enough to coat the lesion with a thin film; do not rub in.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9606708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9606835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;: 0.2 mg/2-second spray (63 g, 100 g) [contains dehydrated ethanol 10.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide: 0.025% (15 g, 80 g, 454 g); 0.1% (15 g, 30 g, 80 g, 454 g); 0.5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triderm&reg;: 0.1% (30 g, 85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediaderm&trade; TA: 0.1% (30 g) [packaged with protective emollient]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zytopic&trade;: 0.1% (85 g) [packaged with cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as acetonide: 0.025% (60 mL); 0.1% (60 mL); 0.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetonide: 0.025% (15 g, 80 g, 454 g); 0.05% (430 g); 0.1% (15 g, 80 g, 454 g); 0.5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trianex&trade;: 0.05% (17 g, 85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral topical, as acetonide: 0.1% (5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oralone&reg;: 0.1% (5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9606542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9606749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral topical: Apply small dab to lesion until a thin film develops; do not rub in. Apply at bedtime or after meals if applications are needed throughout the day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ointment: Apply a thin film sparingly. Do not use on open skin or wounds. Do not occlude area unless directed; if using occluding dressing, monitor for infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spray: Avoid eyes and do not inhale if spraying near face. Occlusive dressing may be used if instructed; monitor for infection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9606543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral topical: Adjunctive treatment and temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Inflammatory dermatoses responsive to steroids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kenalog&reg; may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9606581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, dryness, folliculitis, hypertrichosis, hypopigmentation, miliaria, perioral dermatitis, pruritus, skin atrophy, skin infection (secondary), skin maceration, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine: HPA axis suppression; metabolic effects (hyperglycemia, hypokalemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9606550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamcinolone or any component of the formulation; fungal, viral, or bacterial infections of the mouth or throat (oral topical formulation)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9606551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; discontinue if skin irritation or contact dermatitis should occur; do not use in patients with decreased skin circulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High-potency products: Avoid the use of high-potency steroids on the face.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral cavity application: When used as a topical agent in the oral cavity, if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9606610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9606545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids were found to be teratogenic following topical application in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk, however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9887156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9887157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in human milk; information specific to triamcinolone has not been located. The amount of triamcinolone absorbed systemically following topical administration is variable. Hypertension in the nursing infant has been reported following corticosteroid ointment applied to the nipples. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9606837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Triamcinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 g): $4.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $5.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 g): $10.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Triderm External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (28.4 g): $19.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Pediaderm TA External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (115 g): $212.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Triamcinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (60 mL): $37.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 mL): $42.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Triamcinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (80 g): $10.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 g): $10.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Trianex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (17 g): $96.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Oralone Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 g): $89.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Triamcinolone Acetonide Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 g): $68.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aftab (DE);",
"     </li>",
"     <li>",
"      Ahbina (KP);",
"     </li>",
"     <li>",
"      Aristo (HK);",
"     </li>",
"     <li>",
"      Aristocort A (MY, TH);",
"     </li>",
"     <li>",
"      Centocort (TH);",
"     </li>",
"     <li>",
"      Cortiflex (PE);",
"     </li>",
"     <li>",
"      Delphi Creme (BE, NL);",
"     </li>",
"     <li>",
"      Delphicort (AT, DE);",
"     </li>",
"     <li>",
"      Dermacort (HK, MY);",
"     </li>",
"     <li>",
"      Facort (TH);",
"     </li>",
"     <li>",
"      Ftoracort (EE);",
"     </li>",
"     <li>",
"      Gemicort (KP);",
"     </li>",
"     <li>",
"      Generlog (TH);",
"     </li>",
"     <li>",
"      Glytop (AR);",
"     </li>",
"     <li>",
"      Invert Plaster (KP);",
"     </li>",
"     <li>",
"      Kanolone (MY);",
"     </li>",
"     <li>",
"      Kena-Lite (TH);",
"     </li>",
"     <li>",
"      Kenacort (PH, VE);",
"     </li>",
"     <li>",
"      Kenacort A (NL);",
"     </li>",
"     <li>",
"      Kenacort A in Orabase (CH);",
"     </li>",
"     <li>",
"      Kenacort E (PE);",
"     </li>",
"     <li>",
"      Kenacort T (FI, SE);",
"     </li>",
"     <li>",
"      Kenacort-A (BH, EG, ID, KE, TW, TZ, UG);",
"     </li>",
"     <li>",
"      Kenacort-A in Orabase (NL);",
"     </li>",
"     <li>",
"      Kenalog (CL, DK, PK);",
"     </li>",
"     <li>",
"      Kenalog Gel (CL);",
"     </li>",
"     <li>",
"      Kenalog in Orabase (ID, ZA);",
"     </li>",
"     <li>",
"      Keno (SG);",
"     </li>",
"     <li>",
"      Ketricin (ID);",
"     </li>",
"     <li>",
"      Laver (TH);",
"     </li>",
"     <li>",
"      Ledercort (AR, IN, PK);",
"     </li>",
"     <li>",
"      Ledermix (NO);",
"     </li>",
"     <li>",
"      Manolone (TH);",
"     </li>",
"     <li>",
"      Metoral (MY, TH);",
"     </li>",
"     <li>",
"      Nincort (CL, TW);",
"     </li>",
"     <li>",
"      Oracort (NZ);",
"     </li>",
"     <li>",
"      Oramedy (HK, KP, SG);",
"     </li>",
"     <li>",
"      Orrepaste (MY, SG);",
"     </li>",
"     <li>",
"      Sinocort (ID);",
"     </li>",
"     <li>",
"      Tess (IN);",
"     </li>",
"     <li>",
"      Tramsone (SG);",
"     </li>",
"     <li>",
"      Tricin (PH);",
"     </li>",
"     <li>",
"      Tricort (FI, PH);",
"     </li>",
"     <li>",
"      Tricortone (AU);",
"     </li>",
"     <li>",
"      Volon A Antibiotikafrei (AT, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9606655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9606657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biologic: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~40%); feces (~60%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs: &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32229/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32229/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32229/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9964 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32229=[""].join("\n");
var outline_f31_30_32229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606513\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606514\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9608405\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606707\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606708\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606542\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606749\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606543\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606581\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606551\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300168\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606610\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606545\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887155\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887156\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887157\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606837\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962009\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606655\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606657\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32230="Codeine: Pediatric drug information";
var content_f31_30_32230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Codeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"    see \"Codeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/44/14021?source=see_link\">",
"    see \"Codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      February 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The product labeling for codeine is being updated with a contraindication and boxed warning regarding its use as an analgesic in children undergoing tonsillectomy and/or adenoidectomy. Healthcare professionals should not prescribe codeine to children for pain after these procedures. Alternative analgesics should be used in this setting. For management of other types of pain in children, codeine should only be used if the benefits are anticipated to outweigh the risks.  Parents and caregivers who observe signs of overdose in a child (eg, unusual sleepiness, confusion, or difficult or noisy breathing) should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm339112.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm339112.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Codeine Contin&reg;;",
"     </li>",
"     <li>",
"      PMS-Codeine;",
"     </li>",
"     <li>",
"      ratio-Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"      see \"Codeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effect; when changing routes of administration, note that oral dose is",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     as effective as parenteral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Analgesic: Oral, I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum dose: 60 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Usual: 30 mg/dose; range: 15-60 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antitussive: Oral (for nonproductive cough):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years: 1-1.5 mg/kg/day in divided doses every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternatively dose according to age:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years: 2.5-5 mg every 4-6 hours as needed; maximum dose: 30 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: 5-10 mg every 4-6 hours as needed; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 10-20 mg/dose every 4-6 hours as needed; maximum dose: 120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as phosphate: USP: 100% (10 g, 25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as phosphate: 30 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate: 30 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 30 mg [DSC], 60 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 15 mg, 30 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F154217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14280402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302557.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302557.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or water to decrease nausea and GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M., SubQ: Not intended for I.V. use due to large histamine release and cardiovascular effects",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F6042623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store injection between 15&deg;C to 30&deg;C; avoid freezing. Do not use if injection is discolored or contains a precipitate. Protect injection from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild to moderate pain; antitussive in lower doses (for nonproductive cough)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Codeine may be confused with Cardene&reg;, Cordran&reg;, iodine, Lodine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, circulatory depression, flushing, hyper-/hypotension, palpitation, shock, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, agitation, anxiety, apprehension, chills,  coordination impaired, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, faintness, fatigue, hallucinations, headache, insomnia, intracranial pressure increased, lightheadedness, nervousness, sedation, shakiness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps/pain, anorexia, biliary tract spasm, constipation, diarrhea, nausea, pancreatitis, taste disturbance, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary hesitancy/retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, rigidity, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, miosis, nystagmus, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, laryngospasm, respiratory arrest, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to codeine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone), adrenal insufficiency, biliary tract impairment, CNS depression/coma, morbid obesity, prostatic hyperplasia, urinary stricture, thyroid dysfunction, or severe liver or renal insufficiency. Use with caution in patients with two or more copies of the variant CYP2D6*2 allele (ie, CYP2D6 \"ultra-rapid metabolizers\"); these patients may have extensive conversion of codeine to morphine with resultant increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Not recommended for use for cough control in patients with a productive cough; not recommended as an antitussive for children &lt;2 years of age. Debilitated patients may be particularly susceptible to adverse effects of narcotics.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use codeine with caution in lactating women. Codeine and its metabolite (morphine) are found in breast milk and can be detected in the serum of nursing infants. Exposure to the nursing infant is generally considered to be low; the relative dose to a nursing infant has been calculated to be ~1% of the weight-adjusted maternal dose. Higher levels of morphine may be found in the breast milk of lactating mothers who are \"ultra-rapid metabolizers\" of codeine; patients with two or more copies of the variant CYP2D6*2 allele may have extensive conversion to morphine and thus increased opioid-mediated effects. In one case, excessively high serum concentrations of morphine were reported in a breast-fed infant following maternal use of acetaminophen with codeine (Koren, 2006). The mother was later found to be an \"ultra-rapid metabolizer\" of codeine; symptoms in the infant included feeding difficulty and lethargy, followed by death. Because exposure to the nursing infant is generally low, the AAP considers codeine to be \"usually compatible with breast-feeding.\" However, caution should be used since most persons are not aware if they have the genotype resulting in \"ultra-rapid metabolizer\" status. When codeine is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for increased sleepiness, difficulty in feeding or breathing, or limpness. Medical attention should be sought immediately if the infant develops these symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Respiratory depression may occur even at therapeutic dosages; use with extreme caution in patients with respiratory diseases including asthma, emphysema, COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function. Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. May cause hypotension; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Codeine may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures. Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduce analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Interactions with other CNS drugs may occur. Healthcare provider should be alert to problems of abuse, misuse, and diversion. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting. Some preparations contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5182686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Opioid analgesics cross the placenta. In humans, birth defects (including some heart defects) have been associated with maternal use of opioid analgesics, including codeine, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, heart rate, blood pressure, pain relief, CNS status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 10-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 60-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Adequate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to morphine (active); undergoes hydroxylation and O-demethylation via cytochrome P450 isoenzyme CYP2D6 and demethylation via CYP3A3/4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.5-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 3% to 16% in urine as unchanged drug, norcodeine, and free and conjugated morphine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/44/14021?source=see_link\">",
"      see \"Codeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase fluid and fiber intake to avoid constipation. Avoid alcohol. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use for cough control in patients with a productive cough; equianalgesic doses: 120 mg codeine phosphate I.M. approximately equals morphine 10 mg I.M.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10950994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 3 mg/mL oral suspension may be made with codeine phosphate powder, USP. Add 600 mg of powder to a 400 mL beaker. Add 2.5 mL of Sterile Water for Irrigation, USP, and stir to dissolve the powder. Mix for 10 minutes while adding Ora-Sweet&reg; to make 200 mL; transfer to a calibrated bottle. Stable 98 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Dentinger PJ and Swenson CF, \"Stability of Codeine Phosphate in an Extemporaneously Compounded Syrup,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2007, 64(24):2569-73.",
"     <span class=\"pubmed-id\">",
"      18056945",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Khan K and Chang J, \"Neonatal Abstinence Syndrome Due to Codeine,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1997, 76(1):F59-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32230/abstract-text/9059191/pubmed\" id=\"9059191\" target=\"_blank\">",
"        9059191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Cairns J, Chitayat D, et al, \"Pharmacogenetics of Morphine Poisoning in a Breastfed Neonate of a Codeine-Prescribed Mother,\"  Lancet, 2006, 368(9536):704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32230/abstract-text/16920476/pubmed\" id=\"16920476\" target=\"_blank\">",
"        16920476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds EW, Riel-Romero RM, and Bada HS, \"Neonatal Abstinence Syndrome and Cerebral Infarction Following Maternal Codeine Use During Pregnancy,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 2007, 46(7):639-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32230/abstract-text/17704497/pubmed\" id=\"17704497\" target=\"_blank\">",
"        17704497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and H&auml;gg S, \"Analgesics and Breast-Feeding: Safety Considerations,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32230/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration Center for Drug Evaluation and Research, \"FDA Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead to Life-Threatening Side Effects in Nursing Babies,\" available at: file://www.fda.gov/cder/drug/advisory/codeine.htm.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13178 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32230=[""].join("\n");
var outline_f31_30_32230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854336\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154177\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051888\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051881\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154154\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154217\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14280402\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051893\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6042623\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051892\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154226\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154223\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051897\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051880\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051879\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154209\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154149\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182686\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051887\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051878\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051895\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051896\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051885\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051898\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10950994\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13178|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=related_link\">",
"      Codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/44/14021?source=related_link\">",
"      Codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32231="Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)";
var content_f31_30_32231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Aoife M Waters, MD, PhD FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Norman D Rosenblum, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32231/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/30/32231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 20 to 30 percent of all anomalies identified in the prenatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/1\">",
"     1",
"    </a>",
"    ]. Routine antenatal ultrasonography during pregnancy detects the majority of CAKUT.",
"   </p>",
"   <p>",
"    Antenatal screening for CAKUT and the postnatal evaluation of infants diagnosed prenatally with CAKUT are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTENATAL SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of renal malformations are detected antenatally because of the widespread use and sensitivity of fetal ultrasonography. In 2002, a prenatal ultrasound was performed in about two-thirds of all live births in the United States. The frequency of congenital anomalies of the kidney and urinary tract (CAKUT) as detected sonographically in unselected populations has been reported to be between 0.1 to 0.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the optimal timing recommended for a screening antenatal ultrasound is between 16 to 20 weeks of gestation because of the following factors at this gestational age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is good visualization of anatomy with a high sensitivity in detecting anomalies.",
"     </li>",
"     <li>",
"      It is early enough in the pregnancy to allow completion of prenatal diagnostic procedures (eg, fetal karyotype, additional imaging studies) while legal termination of pregnancy is possible, if desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=see_link\">",
"     \"Routine prenatal ultrasonography as a screening tool\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between the 12th and 15th week of gestation, the fetal kidney can be detected by transabdominal ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/1\">",
"     1",
"    </a>",
"    ]. On transverse ultrasound images, normal fetal kidneys are hypoechoic ovoid masses located in the renal fossa on either side of the spine corresponding to the level of the second lumbar vertebrae. The renal cortex and medulla are distinctly demonstrated by ultrasound by the 20th to 25th week of gestation. Fetal renal length based upon gestational age is a marker of renal growth and is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef74636 \" href=\"mobipreview.htm?1/11/1213\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normally, the fetal ureters are not seen on ultrasonography. However, if they are visualized, it may be indicative of ureteric or bladder obstruction, or vesicoureteral reflux (VUR).",
"   </p>",
"   <p>",
"    The urine-filled bladder is normally identified at 13 to 15 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/6\">",
"     6",
"    </a>",
"    ]. Urine in the bladder suggests at least one functioning kidney. The normal bladder wall is normally thin. If the bladder wall is thick, urethral obstruction such as posterior urethral valves in a male fetus may be present. If the bladder is not seen, consider the diagnosis of classic or cloacal bladder exstrophy.",
"   </p>",
"   <p>",
"    The sensitivity of detecting renal malformations by antenatal ultrasonography depends upon the gestational age and the skill of the ultrasonographer. In one study, the sensitivity of antenatal screening for renal malformations was reported as 82 percent at a mean gestational age of 23 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amniotic fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of amniotic fluid volume and analysis of biochemical markers are used to evaluate fetal renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fetal urine production begins at nine weeks of gestation, its contribution to amniotic fluid volume becomes significant at the start of the second trimester. By 20 weeks gestation, fetal urine accounts for more than 90 percent of the amniotic fluid volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, a decrease in amniotic fluid volume (oligohydramnios) at or beyond the 20th week of gestation is an excellent predictor of abnormal fetal renal function and CAKUT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe oligohydramnios due to CAKUT either involves both kidneys or occurs in a solitary kidney in the fetus. Bilateral renal agenesis or severe dysgenesis, bilateral ureteric obstruction, or obstruction of the bladder outlet or urethra, can result in severe oligohydramnios as early as 18 weeks gestation. Because an adequate amniotic fluid volume is critical for lung development, severe oligohydramnios due to abnormal fetal renal function in the second trimester can result in lung hypoplasia, a potentially fatal disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In its most severe form, this sequence of events results in Potter's syndrome, which consists of a typical facial appearance characterized by pseudoepicanthus, recessed chin, posteriorly rotated, flattened ears and flattened nose, decreased fetal movement, musculoskeletal features including clubfoot and clubhand, hip dislocation and joint contractures, and pulmonary hypoplasia (",
"    <a class=\"graphic graphic_picture graphicRef72847 \" href=\"mobipreview.htm?22/12/22721\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The assessment of amniotic fluid volume is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although oligohydramnios is the most reliable predictor of abnormal fetal renal function, its absence does not assure normal fetal renal function. Because amniotic fluid is predominantly composed of fetal urine, measurement of biochemical markers contained in amniotic fluid (fetal urine) can be used to assess fetal renal function.",
"   </p>",
"   <p>",
"    With increasing gestational age, renal tubular resorptive function increases. As a result, the urinary levels of sodium and beta-2-microglobulin decrease with increasing gestational age, while urine osmolality increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Impaired resorption is seen in fetuses with bilateral renal dysplasia or severe bilateral obstructive uropathy resulting in abnormal urinary levels of electrolytes, beta-2-microglobulin, and osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, high urinary electrolyte excretion, sodium and chloride concentration greater than 90",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and urinary osmolality less than 210",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    H2O (210",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    H2O) in the amniotic fluid are indicative of fetal renal tubular impairment and poor renal prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/14\">",
"     14",
"    </a>",
"    ]. When analyzing the results, it is important to use gestation specific cut-offs because with increasing gestational age, renal tubular resorptive function increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/15\">",
"     15",
"    </a>",
"    ]. However, in a systematic review of fetal urine analysis, none of the urinary tests provide significant clinical accuracy to correctly predict poor postnatal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tests to assess fetal glomerular function include fetal serum measurement of cystatin C and beta-2-microglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these tests are not used in clinical practice because of technical difficulties in obtaining fetal blood.",
"   </p>",
"   <p>",
"    In addition, amniocentesis can be used to detect chromosomal abnormalities often associated with renal defects such as trisomy 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling of families with fetuses with CAKUT should be universally available. If the fetal prognosis is poor, as determined by severe bilateral disease, bilateral renal agenesis, oligohydramnios, or unfavorable amniotic fluid analysis, legal termination, if possible, can be offered.",
"   </p>",
"   <p>",
"    In all other cases, continued counseling throughout the pregnancy including discussion on postnatal management is required. In particular, discussion with parents regarding their wishes on the level of support given to offspring with severe oligohydramnios, who are at risk for lung hypoplasia that may be incompatible with life, is helpful in establishing guidelines for initial postnatal care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     In utero intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervening in pregnancy to attempt definitive or temporary correction of fetal renal anomalies would be reasonable if one could prevent the development of renal dysplasia, renal scarring, chronic renal failure, or the occurrence of pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Although there have been case series of antenatal surgery in fetuses with severe hydronephrosis and oligohydramnios, this intervention has not been shown to improve renal outcome. These procedures may increase the amount of amniotic fluid, thus potentially improving lung development and survival rate. In these rare cases, the procedure should only be performed in select centers with expertise and in infants with severe bilateral hydronephrosis, absent of severe renal parenchymal or cystic disease, favorable urinary electrolyte levels and osmolality, and normal karyotype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42824?source=see_link\">",
"     \"Overview of antenatal hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTNATAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery, a detailed maternal and pregnancy history and careful physical examination should be performed in all infants with an antenatally detected renal malformation. The examination should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary evaluation especially in infants with severe oligohydramnios who are at risk for lung hypoplasia. In these severely affected children, decisions on the use of intensive supportive care are often made in the delivery room. If at all possible, prior discussion with the family regarding management decisions is helpful in establishing guidelines for initial postnatal care.",
"     </li>",
"     <li>",
"      Examination of the abdomen to detect the presence of a mass that could represent an enlarged kidney due to obstructive uropathy or multicystic dysplastic kidney (MCDK).",
"     </li>",
"     <li>",
"      A palpable bladder in a male infant, especially after voiding, may suggest posterior urethral valves.",
"     </li>",
"     <li>",
"      A male infant with prune belly syndrome will have deficient abdominal wall musculature and undescended nonpalpable testes. The presence of associated anomalies should be investigated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"       \"Assessment of the newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of outer ear abnormalities is associated with an increased risk of congenital anomalies of the kidney and urinary tract (CAKUT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12055?source=see_link&amp;anchor=H14#H14\">",
"       \"Congenital anomalies of the ear\", section on 'Association with renal anomalies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A single umbilical artery is associated with an increased risk of CAKUT, particularly vesicoureteral reflux. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link&amp;anchor=H38#H38\">",
"       \"Assessment of the newborn infant\", section on 'Umbilical cord'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Timing of postnatal renal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal evaluation by ultrasonography is performed within the first 24 hours of life for infants with bilateral involvement, a solitary affected kidney,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of oligohydramnios because they are at increased risk for a serious renal anomaly that may be amenable to intervention. As an example, a distended bladder with thickened bladder wall and bilateral hydronephrosis may be caused by posterior urethral valves (PUV) that requires surgical intervention. (See",
"    <a class=\"local\" href=\"#H274879343\">",
"     'Solitary kidney'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Renal growth can be assessed by measuring the renal length with the infant in the prone position.",
"   </p>",
"   <p>",
"    In general, conditions, which have unilateral involvement, do not need immediate attention. Renal ultrasonography is recommended after the infant returns to birth weight (after 48 hours of age and within the first week of life) to ensure volume repletion and increased urine output as renal plasma flow and glomerular filtration rate rise in the first 48 hours of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, in an infant with hydronephrosis, the level of severity might be underestimated if ultrasonography is performed before 48 hours of life. In addition, hydronephrosis may not be present on renal ultrasonography in an infant with obstructive uropathy that has intrinsic anuric renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing includes measurement of serum creatinine to assess renal function and other radiologic tests that can be useful in determining underlying renal pathology, renal function, and the presence of other urological anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the renal function by measurement of the serum creatinine concentration is used clinically to assess the presence and extent of renal impairment and to follow the infant's renal function. Measurement of creatinine should be considered when there is bilateral renal disease or an affected solitary kidney.",
"   </p>",
"   <p>",
"    The serum creatinine concentration at birth is similar to that in the mother (usually &le;1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    It declines to normal values (serum creatinine 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [27 to 44",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    in approximately one week in term infants and two to three weeks in preterm infants. Serum creatinine should be measured after the first 24 hours to avoid overestimation of creatinine that may be high and reflective of maternal creatinine values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=see_link&amp;anchor=H13#H13\">",
"     \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Serum creatinine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Voiding cystourethrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voiding cystourethrography (VCUG) is the definitive method for assessment of the lower urinary tract. It requires urethral catheterization and injection of a contrast agent. Indications include any suspicion of a thick-walled bladder, ureteric dilatation, hydronephrosis, and in male infants, any urethral pathology (eg, posterior urethral valves).",
"   </p>",
"   <p>",
"    VCUG is the definitive study to demonstrate vesicoureteral reflux (VUR), which often accompanies other CAKUT (eg, multicystic dysplastic, hypoplastic, or ectopic kidney). VUR is one of the most common causes of antenatal hydronephrosis and infants with hydronephrosis (without any other apparent cause) should undergo VCUG. Infants who are at high risk for VUR should be given prophylactic antibiotics. Infants with significant VUR demonstrated by VCUG are continued on prophylactic antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=see_link\">",
"     \"Postnatal management of antenatal hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dynamic renal scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dynamic radionuclide scans assess renal excretory function and utilize 99mTc-mercaptotriglycylglycine (MAG-3 or MAG3) as a radiotracer. MAG-3 is injected intravenously, absorbed from the blood by the proximal tubules, and secreted into the tubular lumen and then into the bladder.",
"   </p>",
"   <p>",
"    Dynamic renal scans are used to differentiate between obstructive versus nonobstructive causes of hydronephrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=see_link&amp;anchor=H7#H7\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Diuretic renography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Static renal scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Static radionuclide scan is most useful for detection of focal renal parenchymal abnormalities and the differential assessment of renal function between the two kidneys. 99mTc&ndash;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA) is used as the radiotracer. Following intravenous injection, DMSA is taken up by proximal tubular cells with only a minimal amount excreted in the urine, so the tracer accumulates over several hours within the tubule, providing a static image of functioning nephrons. There is no minimum age at which a DMSA scan can be performed. However, the quality of both dynamic and static radionuclide scans improves with renal maturity.",
"   </p>",
"   <p>",
"    DMSA scan is used to assess whether a suspected renal lesion contains normal-functioning nephrons, the differential function of the two kidneys",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    detection of renal scarring. If possible, the DMSA renal scan should be performed four to six weeks after birth in a full-term infant as poor function measured by DMSA renal scan does not necessarily imply irreversible damage in a neonate but may be a reflection of immature renal function. A repeat scan should be undertaken over three months of age or following therapeutic intervention because there may be recovery of renal function after surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Serial ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial ultrasounds are used to assess compensatory renal growth of unaffected kidneys in patients with unilateral CAKUT. In addition, serial ultrasounds are used to monitor for progressive hydronephrosis in patients with",
"    <span class=\"nowrap\">",
"     mild/moderate",
"    </span>",
"    obstructive uropathy or changes in the affected kidneys (eg, size of multicystic dysplastic kidney).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274879343\">",
"    <span class=\"h2\">",
"     Solitary kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a solitary kidney is detected, it is usually an incidental finding as a result of an ultrasound performed antenatally or as part of an evaluation for a urinary tract infection. The evaluation begins with a history and physical examination that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of impaired hearing or abnormal hearing test, which may be suggestive of Branchio-oto-renal syndrome (BOR syndrome, MIM 113650), also referred to as Melnick-Fraser syndrome. BOR syndrome is an autosomal dominant genetic disorder characterized by hearing loss, branchial cysts and fistulas, ear pits, and renal anomalies including renal aplasia. The majority of cases are caused by mutations in the EYA1 gene with fewer cases due to mutations in SIX1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10935?source=see_link&amp;anchor=H12#H12\">",
"       \"Renal hypoplasia\", section on 'Branchio-oto-renal syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history of renal disease and deafness also is suggestive of BOR syndrome.",
"     </li>",
"     <li>",
"      Measurements of weight, height, and blood pressure to detect any growth impairment or increased blood pressure, which may be indicative of renal function impairment. &nbsp;",
"     </li>",
"     <li>",
"      Detection of other congenital anomalies, which may indicate an underlying genetic disorder, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Coloboma &ndash; Renal-coloboma syndrome (MIM 120330) is a genetic disorder characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve coloboma, and is due to mutations in the PAX2 gene (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10935?source=see_link&amp;anchor=H11#H11\">",
"       \"Renal hypoplasia\", section on 'Renal-coloboma syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Branchial defects are suggestive of BOR syndrome, discussed above. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10935?source=see_link&amp;anchor=H12#H12\">",
"       \"Renal hypoplasia\", section on 'Branchio-oto-renal syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      M&uuml;llerian abnormalities &ndash; M&uuml;llerian defects are common in girls with renal agenesis because the wolffian and m&uuml;llerian ducts are contiguous. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16296?source=see_link&amp;anchor=H17#H17\">",
"       \"Prenatal diagnosis of renal agenesis\", section on 'Associated abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microphallus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cryptorchidism &ndash; Microphallus and cryptorchidism are findings noted in infants with congenital gonadotropin-releasing hormone deficiency. Older affected children may present with anosmia (lack of sense of smell), cleft",
"      <span class=\"nowrap\">",
"       lip/palate,",
"      </span>",
"      or syndactyly. Unilateral renal agenesis is commonly found in these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2170?source=see_link\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other chromosomal disorders have been associated with renal agenesis including trisomies 13 and 18, and Turner syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16296?source=see_link&amp;anchor=H17#H17\">",
"       \"Prenatal diagnosis of renal agenesis\", section on 'Associated abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all patients with a solitary kidney, a renal ultrasound is the initial imaging study that measures the size of the solitary kidney and determines if there are any apparent renal abnormalities. If there is no compensatory renal hypertrophy, further imaging particularly in the pelvic area should be performed to identify the presence of an ectopic kidney. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28487?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal ectopic and fusion anomalies\", section on 'Renal ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the asymptomatic child with a normal appearing kidney (ie, no hydronephrosis, normal corticomedullary differentiation, and normal renal contour), especially if there is compensatory growth of the contralateral kidney, we suggest no further work-up is required. Other experts in the field obtain a voiding cystourethrogram in infants who are diagnosed by antenatal ultrasound because of the association of vesicoureteral reflux (VUR) with unilateral renal agenesis. However, VUR is typically low-grade and appears to have little clinical significance.",
"   </p>",
"   <p>",
"    Although many pediatric nephrologists recommend against participation of children with a solitary kidney in",
"    <span class=\"nowrap\">",
"     contact/collision",
"    </span>",
"    sports, the low incidence of renal injury in contact sports does not support such a recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32231/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=see_link&amp;anchor=H36#H36\">",
"     \"The preparticipation sports examination in children and adolescents\", section on 'Genitourinary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/45/3794?source=see_link\">",
"       \"Patient information: Prenatal hydronephrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 20 to 30 percent of all anomalies identified in the prenatal period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine antenatal ultrasonography during pregnancy detects CAKUT in most affected patients.",
"     </li>",
"     <li>",
"      The fetal kidney can be detected by the 12th and 15th week of gestation, however, the renal cortex and medulla are not distinctly differentiated from one another until the 20th to 25th week of gestation. Fetal renal length based upon gestational age is a marker of renal growth (",
"      <a class=\"graphic graphic_table graphicRef74636 \" href=\"mobipreview.htm?1/11/1213\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fetal kidney'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      By 20 weeks gestation, fetal urine accounts for more than 90 percent of the amniotic volume. A decrease in amniotic volume (oligohydramnios) at or beyond 20 weeks gestation is an excellent predictor of abnormal fetal renal function and indicates bilateral fetal renal dysfunction or, rarely a poorly functioning solitary kidney. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biochemical analysis of amniotic fluid is useful in assessing fetal renal function. Sodium and chloride concentration &gt;90",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (90",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and urinary osmolality less than 210",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      H2O (210",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      H2O) in the amniotic fluid are indicative of poor fetal renal prognosis. Amniotic beta-2-microglobulin concentration &ge;6",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      is also associated with severe renal damage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling should be available to all families with fetuses who have a CAKUT. If the fetal prognosis is poor, legal termination, if appropriate and available, can be offered. In all other cases, continued counseling including discussion on postnatal management is required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial postnatal evaluation by ultrasonography is performed within the first 24 hours of life for infants with bilateral involvement, a solitary affected kidney,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of oligohydramnios. Infants with unilateral involvement should be evaluated after 48 hours of life. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Timing of postnatal renal studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further postnatal diagnostic testing includes measurement of serum creatinine to assess renal function in cases of bilateral kidney disease or in an affected solitary kidney, and the following radiological studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Voiding cystourethrography (VCUG) is indicated in patients with hydronephrosis and in male infants suspected to have urethral pathology (eg, posterior urethral valves). It detects vesicoureteral reflux and abnormalities of the male urethra. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=see_link\">",
"       \"Postnatal management of antenatal hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the post period, 99mTc-mercaptotriglycylglycine (MAG-3) renal scan can be used to differentiate between obstructive versus nonobstructive causes of hydronephrosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Dynamic renal scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      99mTc-",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8548?source=see_link\">",
"       dimercaptosuccinic acid",
"      </a>",
"      (DMSA) is used to detect ectopic renal tissue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to determine differential function between the two kidneys, or detect renal dysplasia or scarring. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Static renal scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial ultrasounds are used to monitor compensatory renal growth of unaffected kidneys in patients with unilateral CAKUT, progressive hydronephrosis in patients with",
"      <span class=\"nowrap\">",
"       mild/moderate",
"      </span>",
"      obstructive uropathy, or changes in the affected kidneys. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/1\">",
"      Dugoff L. Ultrasound diagnosis of structural abnormalities in the first trimester. Prenat Diagn 2002; 22:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/2\">",
"      Madarikan BA, Hayward C, Roberts GM, Lari J. Clinical outcome of fetal uropathy. Arch Dis Child 1988; 63:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/3\">",
"      Livera LN, Brookfield DS, Egginton JA, Hawnaur JM. Antenatal ultrasonography to detect fetal renal abnormalities: a prospective screening programme. BMJ 1989; 298:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/4\">",
"      Sanghvi KP, Merchant RH, Gondhalekar A, et al. Antenatal diagnosis of congenital renal malformations using ultrasound. J Trop Pediatr 1998; 44:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/5\">",
"      Cohen HL, Cooper J, Eisenberg P, et al. Normal length of fetal kidneys: sonographic study in 397 obstetric patients. AJR Am J Roentgenol 1991; 157:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/6\">",
"      Cohen HL, Kravets F, Zucconi W, et al. Congenital abnormalities of the genitourinary system. Semin Roentgenol 2004; 39:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/7\">",
"      Vanderheyden T, Kumar S, Fisk NM. Fetal renal impairment. Semin Neonatol 2003; 8:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/8\">",
"      Leibovitch L, Kuint J, Rosenfeld E, et al. Short-term outcome among term singleton infants with intrapartum oligohydramnios. Acta Paediatr 2012; 101:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/9\">",
"      POTTER EL. Bilateral renal agenesis. J Pediatr 1946; 29:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/10\">",
"      Mehler K, Beck BB, Kaul I, et al. Respiratory and general outcome in neonates with renal oligohydramnios--a single-centre experience. Nephrol Dial Transplant 2011; 26:3514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/11\">",
"      Nicolini U, Fisk NM, Rodeck CH, Beacham J. Fetal urine biochemistry: an index of renal maturation and dysfunction. Br J Obstet Gynaecol 1992; 99:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/12\">",
"      Muller F, Dommergues M, Bussi&egrave;res L, et al. Development of human renal function: reference intervals for 10 biochemical markers in fetal urine. Clin Chem 1996; 42:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/13\">",
"      Muller F, Dommergues M, Mandelbrot L, et al. Fetal urinary biochemistry predicts postnatal renal function in children with bilateral obstructive uropathies. Obstet Gynecol 1993; 82:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/14\">",
"      Glick PL, Harrison MR, Golbus MS, et al. Management of the fetus with congenital hydronephrosis II: Prognostic criteria and selection for treatment. J Pediatr Surg 1985; 20:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/15\">",
"      Morris RK, Quinlan-Jones E, Kilby MD, Khan KS. Systematic review of accuracy of fetal urine analysis to predict poor postnatal renal function in cases of congenital urinary tract obstruction. Prenat Diagn 2007; 27:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/16\">",
"      B&ouml;kenkamp A, Dieterich C, Dressler F, et al. Fetal serum concentrations of cystatin C and beta2-microglobulin as predictors of postnatal kidney function. Am J Obstet Gynecol 2001; 185:468.",
"     </a>",
"    </li>",
"    <li>",
"     Limwongse C, Cassidy SB. Syndromes and malformations of the urinary tract. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Williams &amp; Wilkins, Philadelphia 2004. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/18\">",
"      Mandell J, Blyth BR, Peters CA, et al. Structural genitourinary defects detected in utero. Radiology 1991; 178:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/19\">",
"      Josephson S. Suspected pyelo-ureteral junction obstruction in the fetus: when to do what? II. Experimental viewpoints. Eur Urol 1991; 19:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/20\">",
"      Elder JS, Duckett JW Jr, Snyder HM. Intervention for fetal obstructive uropathy: has it been effective? Lancet 1987; 2:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/21\">",
"      Freedman AL, Johnson MP, Smith CA, et al. Long-term outcome in children after antenatal intervention for obstructive uropathies. Lancet 1999; 354:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/22\">",
"      Fawer CL, Torrado A, Guignard JP. Maturation of renal function in full-term and premature neonates. Helv Paediatr Acta 1979; 34:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/23\">",
"      Krug P, Morini&egrave;re V, Marlin S, et al. Mutation screening of the EYA1, SIX1, and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations. Hum Mutat 2011; 32:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32231/abstract/24\">",
"      Grinsell MM, Showalter S, Gordon KA, Norwood VF. Single kidney and sports participation: perception versus reality. Pediatrics 2006; 118:1019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6106 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32231=[""].join("\n");
var outline_f31_30_32231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTENATAL SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amniotic fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - In utero intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTNATAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Timing of postnatal renal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Voiding cystourethrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dynamic renal scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Static renal scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Serial ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274879343\">",
"      Solitary kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6106|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/12/22721\" title=\"picture 1\">",
"      Potters syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6106|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/11/1213\" title=\"table 1\">",
"      Fetal kidney length",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/62/41961?source=related_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42824?source=related_link\">",
"      Overview of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/45/3794?source=related_link\">",
"      Patient information: Prenatal hydronephrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16296?source=related_link\">",
"      Prenatal diagnosis of renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28487?source=related_link\">",
"      Renal ectopic and fusion anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10935?source=related_link\">",
"      Renal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=related_link\">",
"      Routine prenatal ultrasonography as a screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32232="Treatment of anthrax";
var content_f31_30_32232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of anthrax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Kenneth H Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/30/32232/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/30/32232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H193168587\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of anthrax in humans has decreased during the past century, and it is now very rare in developed countries including the United States. From 1980 through 2000, only seven cases of anthrax were reported to the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in 2001, 22 confirmed or suspected anthrax cases occurred in the United States after Bacillus anthracis spores were sent through the mail in powder-containing envelopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sporadic cases of inhalation and cutaneous anthrax also occurred between 2006 and 2008 in persons using contaminated imported animal hides for drum making, including two cases of cutaneous anthrax in the United States in a drum maker and a family member [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both cutaneous and inhalation anthrax have also been associated with the playing of goatskin drums contaminated with Bacillus anthracis spores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=see_link&amp;anchor=H10#H10\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Bioterrorism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Natural infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spores can persist in the soil for years to decades. Decontamination of the soil is generally not practical; thus, sporadic cases of epizootic anthrax continue to occur in areas of high endemicity, such as Iran, Iraq, Turkey, Pakistan, and sub-Saharan Africa, where the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    in animals is not comprehensive. Animals become infected with B. anthracis by ingesting spores while grazing on contaminated grass or feed. Naturally-occurring transmission to humans occurs through direct exposure to infected animals or animal products through skin exposure, ingestion, or inhalation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Natural infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of anthrax will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, diagnosis, and prevention of anthrax are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7224?source=see_link\">",
"     \"Clinical manifestations and diagnosis of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link\">",
"     \"Prevention of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169871\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. anthracis is highly susceptible to a variety of antimicrobial agents including penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and fluoroquinolones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. B. anthracis is NOT susceptible to cephalosporins or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]; thus, these agents should not be used for the treatment or prevention of anthrax.",
"   </p>",
"   <p>",
"    The empiric treatment recommendations presented here are in agreement with the recommendations of the United States Centers for Disease Control and Prevention (CDC).",
"   </p>",
"   <p>",
"    Healthcare providers should consult their local or state public health departments for specific recommendations for the prevention or treatment of bioterrorism-related anthrax. This is critically important in order to ensure that an antimicrobial regimen is selected to which the isolate is fully susceptible. For example, isolates from the bioterrorism-related cases in the United States in 2001 were susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8\">",
"     8",
"    </a>",
"    ]. Although susceptible to penicillin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , the presence of inducible beta-lactamase in the isolates led the CDC to advise against the use of these drugs as single agents for therapy of anthrax cases related to the 2001 bioterrorism event. The CDC's recommendations for treatment of cases and management of exposures related to the 2001 bioterrorism event were based upon expert opinion because of the paucity of clinical data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suspected cases of anthrax should be reported to the local or state health department immediately. (See",
"    <a class=\"local\" href=\"#H185609414\">",
"     'Public health reporting'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169878\">",
"    <span class=\"h2\">",
"     Cutaneous anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-fatality rates as high as 20 percent have been reported for untreated cutaneous anthrax, but fatalities are now unusual with appropriate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Penicillin has been used most extensively for the treatment of naturally-occurring cutaneous anthrax. Organisms are rapidly cleared from skin lesions following the initiation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/11\">",
"     11",
"    </a>",
"    ]. However, antibiotics do not prevent progression to the eschar phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169885\">",
"    <span class=\"h3\">",
"     Localized or uncomplicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;For localized or uncomplicated naturally-occurring cutaneous anthrax cases in individuals &gt;2 years of age, use one of the following regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg twice daily in adults; 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily in adults; in children &gt;8 yrs and &gt;45 kg: 100 mg twice daily; in children &gt;8 yrs and &le;45 kg: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily; in children &le;8 years: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 100",
"      <span class=\"nowrap\">",
"       mg/dose])",
"      </span>",
"     </li>",
"     <li>",
"      If antimicrobial susceptibility results reveal susceptibility, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      (500 mg every 6 hours in adults and children &ge;12 years; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 6 hours [to not exceed 3",
"      <span class=\"nowrap\">",
"       g/day]",
"      </span>",
"      in children &lt;12 years) OR oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg every 8 hours in adults; 45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 8 hours [not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children) may be used to complete the course of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/13,15,16\">",
"       13,15,16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total duration of therapy is 7 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169892\">",
"    <span class=\"h3\">",
"     Severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;For more severe cases of naturally-occurring cutaneous anthrax with systemic involvement, extensive edema, lesions of the head and neck, or for cutaneous anthrax in children &lt;2 years of age, use one of the following regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg twice daily in adults; 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 400",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily in adults; in children &gt;8 years and &gt;45 kg: 100 mg twice daily; in children &gt;8 yrs and &le;45 kg: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 100",
"      <span class=\"nowrap\">",
"       mg/dose];",
"      </span>",
"      or &lt;8 years: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 100",
"      <span class=\"nowrap\">",
"       mg/dose])",
"      </span>",
"     </li>",
"     <li>",
"      If antimicrobial susceptibility testing results reveal susceptibility, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (4 to 6 million units every 6 hours in adults; 250,000 to 400,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day in divided doses every 4 to 6 hours [not to exceed 24 million",
"      <span class=\"nowrap\">",
"       units/day]",
"      </span>",
"      in children) may be used to complete the course of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total duration of therapy is 7 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical excision of the cutaneous lesions is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169899\">",
"    <span class=\"h3\">",
"     Bioterrorism-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with bioterrorism (BT)-related cutaneous anthrax are at risk for inhalation anthrax due to potential aerosol exposure; thus, the duration of antimicrobial therapy should be 60 days to provide a full course of postexposure prophylaxis (PEP) against inhalation anthrax.",
"   </p>",
"   <p>",
"    For empiric treatment of localized or uncomplicated BT-related cutaneous anthrax, use one of the following regimens (",
"    <a class=\"graphic graphic_table graphicRef79272 \" href=\"mobipreview.htm?3/39/3709\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg twice daily in adults; 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children) (preferred agent)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily in adults; in children: &gt;8 years and &gt;45 kg: 100 mg twice daily; in children &gt;8 yrs and &le;45 kg: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily; in children &lt;8 years: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 100",
"      <span class=\"nowrap\">",
"       mg/dose]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is the preferred oral antimicrobial agent for treatment of BT-related cutaneous anthrax or for PEP in pregnant women and nursing mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents are recommended for children despite usual contraindications against their use in pediatric patients because of the seriousness of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      (500 mg every 8 hours in adults; 45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses every 8 hours for children, not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      may be used to complete the remainder of the 60 day treatment regimen after clinical improvement if the B. anthracis strain is proven susceptible with an amoxicillin MIC &lt;0.125",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      to provide a full course of PEP against inhalation anthrax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8,15,20\">",
"       8,15,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link&amp;anchor=H24#H24\">",
"       \"Prevention of anthrax\", section on 'PEP antibiotic regimens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with cutaneous disease and signs of systemic involvement or in patients with extensive edema involving lesions on the head and neck, it is necessary to use a multidrug regimen and supportive care as for inhalation anthrax and severe disease, as discussed in the following section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8,14\">",
"     8,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169906\">",
"    <span class=\"h2\">",
"     Inhalation anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inhalation anthrax (IA) frequently present late in the course of their illness. Even with antimicrobial therapy, the majority of these cases are fatal due to the severity of the illness, since antimicrobial agents do not act on the toxins produced by B. anthracis.",
"   </p>",
"   <p>",
"    However, in the 1979 outbreak in Sverdlovsk in the former Soviet Union, 11 survivors were reported in addition to at least 66 individuals who died, indicating that IA is not universally fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/21\">",
"     21",
"    </a>",
"    ]. In 2001, 6 of 11 bioterrorism-related IA cases (55 percent) in the United States were successfully treated with aggressive antimicrobial and supportive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimicrobial therapy should be promptly initiated in any patient with suspected IA. Three antimicrobial agents have received United States Food and Drug Administration (FDA) approval for the treatment of anthrax, including IA:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12661?source=see_link\">",
"     penicillin G procaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/22\">",
"     22",
"    </a>",
"    ]. For patients with serious systemic illness including IA, intravenous ciprofloxacin (in combination with one or two intravenous antimicrobials with good central nervous system penetration) is preferred to doxycycline unless there is a major contraindication to ciprofloxacin, since the fluoroquinolones are bactericidal. (See",
"    <a class=\"local\" href=\"#H193169913\">",
"     'Regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, given the high likelihood of meningeal involvement in cases of systemic anthrax,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    as the first-line antimicrobial agent due to its superior penetration of the central nervous system (CNS) compared with doxycycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Once culture and susceptibility results are available, treatment should be modified based upon the susceptibility results of the isolate.",
"   </p>",
"   <p>",
"    A systematic review of IA cases that were reported between 1900 and 2005 identified the following differences in treatment of survivors compared with treatment of those who died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Therapy initiated during the prodromal phase (75 versus 10 percent)",
"     </li>",
"     <li>",
"      Multidrug antimicrobial treatment regimen (67 versus 21 percent)",
"     </li>",
"     <li>",
"      Pleural fluid drainage (83 versus 9 percent)",
"     </li>",
"     <li>",
"      Anthrax antiserum therapy (among cases prior to 2001; 25 versus 3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The failure of single-drug therapy for inhalation anthrax has previously been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], providing the rationale for multidrug therapy in IA despite the lack of clinical trials proving efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169913\">",
"    <span class=\"h3\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multidrug regimens found to be effective in the treatment of patients with IA during the 2001 bioterrorism attacks included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      &nbsp;",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommended empiric therapy consists of one of the following regimens (",
"    <a class=\"graphic graphic_table graphicRef74184 \" href=\"mobipreview.htm?39/36/40525\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (400 mg intravenously twice daily; 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 400",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children)",
"      <strong>",
"       OR",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      only if there is a major contraindication to the use of ciprofloxacin",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      One or two of the following intravenous antimicrobials: imipenem or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ; penicillin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least one of the agents should have good CNS penetration and in vitro activity against B. anthracis (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ), due to the potential for clinical or subclinical meningeal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15,26\">",
"     15,26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is often suggested as a third agent due to its potential inhibition of toxin production.",
"   </p>",
"   <p>",
"    Although initial therapy should be intravenous, patients may be switched to oral therapy once they are stable, usually after 14 to 21 days of intravenous therapy. A total duration of treatment of 60 days (combination of intravenous and oral therapy) should be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest tubes or thoracentesis should be used to drain pleural effusions as adjunctive treatment of all IA cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15,24,27,28\">",
"     15,24,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjunctive measures, such as glucocorticoids and anthrax immunoglobulin, are discussed below. (See",
"    <a class=\"local\" href=\"#H193169934\">",
"     'Glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H193169948\">",
"     'Anthrax immunoglobulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169920\">",
"    <span class=\"h2\">",
"     Gastrointestinal anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few well-studied cases of gastrointestinal anthrax. In the absence of clinical or study data on the therapy of gastrointestinal anthrax, the same antibiotic regimens should be used for patients with gastrointestinal anthrax as is recommended for inhalation anthrax. (See",
"    <a class=\"local\" href=\"#H193169913\">",
"     'Regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some investigators have recommended surgical intervention with wide resection of affected bowel and continuous drainage of ascites as well as aggressive fluid and electrolyte management in patients who do not respond to antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169927\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of anthrax meningitis is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/26\">",
"     26",
"    </a>",
"    ]. There is a high likelihood of clinical or subclinical meningitis in cases of severe systemic anthrax, such as inhalation anthrax (IA) or gastrointestinal anthrax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. Due to the potential for meningeal involvement, systemic cases of anthrax (even in the absence of proof of meningitis) should be treated using intravenous antimicrobial therapy, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    plus one or two additional antimicrobial agents with good central nervous system (CNS) penetration (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ) and in vitro activity against B. anthracis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/15,26\">",
"     15,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the treatment of proven anthrax meningitis, early and aggressive multidrug therapy is crucial due to the rapid progression and high mortality of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/31\">",
"     31",
"    </a>",
"    ]. Intravenous antimicrobial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    plus TWO agents with good CNS penetration (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ) and in vitro activity against B. anthracis is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64397993\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169934\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may be considered as adjunctive therapy for patients with serious systemic illness due to inhalation anthrax, including patients with meningoencephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/26\">",
"     26",
"    </a>",
"    ], and patients with cutaneous anthrax with extensive edema involving the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Supporting data are limited and there may be no benefit for reducing the inflammation resulting from toxin-mediated tissue edema. A retrospective review of 70 cases of anthrax meningoencephalitis from 1966 to 2002 reported an overall mortality rate of 94 percent, but among 10 patients treated with glucocorticoids as an adjunct to antimicrobial therapy, mortality was 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/31\">",
"     31",
"    </a>",
"    ]. However, it is not possible to draw conclusions from such a small study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169941\">",
"    <span class=\"h3\">",
"     Immunotherapeutics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to antibacterial agents with activity against B. anthracis, there has been interest in using adjunctive agents that have antitoxin effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/33\">",
"     33",
"    </a>",
"    ]. Animal origin antiserum was used with some success in the treatment of anthrax prior to the advent of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A systematic review of IA cases from 1900 to 2005 demonstrated that mortality was significantly lower among patients who received antiserum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/24\">",
"     24",
"    </a>",
"    ]. Anthrax immunoglobulin derived from immunized persons is available from the CDC, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061471327\">",
"    <span class=\"h4\">",
"     Raxibacumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     Raxibacumab",
"    </a>",
"    , a human IgG1-gamma monoclonal antibody directed against protective antigen, was found to be effective for the treatment of anthrax in randomized trials involving rabbits, monkeys, and dogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In 2012, raxibacumab was approved by the US Food and Drug Administration for the treatment of inhalation anthrax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/39\">",
"     39",
"    </a>",
"    ]. It should be used in combination with antibiotics and should be initiated when the diagnosis of inhalation anthrax is suspected or confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/40\">",
"     40",
"    </a>",
"    ]. A supply of raxibacumab is held in the United States Strategic National Stockpile for use by the CDC in the event of an anthrax emergency. Clinicians in the United States should contact the",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     CDC",
"    </a>",
"    if raxibacumab is indicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     Raxibacumab",
"    </a>",
"    is given as a single dose following premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ; dosing recommendations for raxibacumab are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults and children &gt;50 kg: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV",
"     </li>",
"     <li>",
"      Children 15 kg to 50 kg: 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV",
"     </li>",
"     <li>",
"      Children 15 kg or less: 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    should be given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    as premedication.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    has been evaluated only in animals since it is not possible to perform efficacy trials in humans given that inhalation anthrax is both rare and lethal. However, in phase 2 safety studies in humans, the therapeutic levels of the antibody achieved in humans are equal to or greater than those that provide protection in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/42\">",
"     42",
"    </a>",
"    ]. Common adverse effects in 326 healthy humans included rash, extremity pain, pruritus, and drowsiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial, rabbits and monkeys were exposed to 200 times the median lethal dose of aerosolized B. anthracis spores and were monitored for the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/37\">",
"     37",
"    </a>",
"    ]. Animals with detectable protective antigen in the serum, an increase in temperature, or both, received a single intravenous dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 40",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo. The primary endpoint was survival at 14 days in rabbits and survival at 28 days in monkeys. Rabbits that received 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of raxibacumab were significantly more likely to survive than those that received placebo (44 percent versus 0 percent). Likewise, monkeys that received 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of raxibacumab were more likely to survive than those that received placebo (64 percent versus 0 percent). The 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose was also associated with improved survival in both rabbits and monkeys. In the same report, raxibacumab was well tolerated in humans who were given a single 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose. It was also effective for the prevention of anthrax in rabbits and monkeys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link&amp;anchor=H64397865#H64397865\">",
"     \"Prevention of anthrax\", section on 'Raxibacumab and other immunotherapeutics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another trial, 40 mechanically ventilated dogs who were challenged with anthrax lethal toxin (LT) were given no treatment, hemodynamic support alone (fluids and norepinephrine),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    alone (administered at the start of the LT infusion or 9 or 12 hours later), or combination therapy with hemodynamic support plus raxibacumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/38\">",
"     38",
"    </a>",
"    ]. Among the animals that received no treatment, all eight died, compared with six of eight animals who received hemodynamic support alone. In contrast, all five animals that received raxibacumab at the start of the LT infusion survived; however, only two of three animals that received raxibacumab at nine hours survived, and none of four animals that received raxibacumab at 12 hours survived. The animals that received both raxibacumab and hemodynamic support had the best outcomes, regardless of the delay in raxibacumab administration. Of the animals that received combined treatment, four of five animals that received raxibacumab at the start of the LT infusion survived, three of three animals that received raxibacumab at nine hours survived, and four of five animals that received raxibacumab at 12 hours survived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193169948\">",
"    <span class=\"h4\">",
"     Anthrax immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin derived from the plasma of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/58/18342?source=see_link\">",
"     Anthrax Vaccine Adsorbed",
"    </a>",
"    (AVA)-immunized persons is available from the CDC (",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     file://www.cdc.gov",
"    </a>",
"    ), through the state and local health departments, under an Investigational New Drug (IND) protocol for the treatment of persons with confirmed cases of life-threatening anthrax. This product was used as a part of the successful treatment of a patient with inhalation anthrax (IA) in February 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/28\">",
"     28",
"    </a>",
"    ]. However, its use in the treatment of a drum maker with IA in the United Kingdom in 2008 did not prevent a fatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/30/32232/abstract/43\">",
"     43",
"    </a>",
"    ]. Clinicians and laboratorians may contact their state and local health departments to request anthrax immunoglobulin from the CDC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1203606\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthrax pre-event vaccination and post-exposure vaccination, antimicrobial prophylaxis, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    prophylaxis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link\">",
"     \"Prevention of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185609414\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthrax is a reportable disease and immediate notification should be made to the local or state health department and public health laboratory even if there is only clinical or laboratory suspicion of anthrax or exposure to B. anthracis.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193170897\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic cases and outbreaks of naturally-occurring anthrax continue to occur worldwide, although they are relatively rare in developed nations. However, the threat of anthrax resulting from bioterrorism activity is a reality. Anthrax is a reportable disease and immediate notification should be made to the local or state health department and public health laboratory even if there is only clinical or laboratory suspicion of anthrax or exposure to B. anthracis. (See",
"      <a class=\"local\" href=\"#H193168587\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H185609414\">",
"       'Public health reporting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of localized or uncomplicated naturally-occurring cases of cutaneous anthrax, use either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      OR oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . If antimicrobial susceptibility testing reveals susceptibility, oral administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      may be used to complete the course of treatment. The recommended duration of therapy is 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H193169885\">",
"       'Localized or uncomplicated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For more severe cases of naturally-acquired cutaneous anthrax, use intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      &nbsp;or intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . If antimicrobial susceptibility testing reveals susceptibility, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      may be used to complete the treatment course. The recommended duration of therapy is 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H193169892\">",
"       'Severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For empiric treatment of localized or uncomplicated bioterrorism-related cutaneous anthrax, either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      is used. Ciprofloxacin is the first-line oral antimicrobial agent for treatment of bioterrorism-related cutaneous anthrax or for post-exposure prophylaxis (PEP) in pregnant women and nursing mothers. The duration of antimicrobial therapy is 60 days to provide a full course of PEP. Patients may be switched to oral therapy when clinically appropriate to complete the 60 day regimen, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      may be used to complete the regimen after clinical improvement if the B. anthracis strain is proven susceptible. (See",
"      <a class=\"local\" href=\"#H193169899\">",
"       'Bioterrorism-related'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link&amp;anchor=H24#H24\">",
"       \"Prevention of anthrax\", section on 'PEP antibiotic regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with possible inhalation anthrax (IA) or other serious systemic illness should be started promptly on multidrug antimicrobial therapy. For patients with serious systemic illness including IA, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      is preferred over intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , unless there is a major contraindication to the use of ciprofloxacin. Empiric treatment regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (preferred) or in ciprofloxacin-intolerant patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"     </li>",
"     <li>",
"      One or two of the following intravenous antimicrobials with demonstrated in vitro activity against B. anthracis: imipenem or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ; penicillin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      <br/>",
"      <br/>",
"      At least one of the agents should have good CNS penetration and in vitro activity against B. anthracis (meropenem or imipenem, rifampin, vancomycin, penicillin or ampicillin) due to the potential for clinical or subclinical meningeal involvement. Clindamycin is often suggested as a third agent due to its potential inhibition of toxin production. (See",
"      <a class=\"local\" href=\"#H193169913\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated for serious systemic illness including IA may be switched to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      when clinically appropriate (eg, when patients have shown a sufficient clinical response to treatment and are stable), usually after 14 to 21 days of intravenous antimicrobial therapy. A total duration of treatment of 60 days (combination of intravenous and oral therapy) should be given. (See",
"      <a class=\"local\" href=\"#H193169906\">",
"       'Inhalation anthrax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest tubes or thoracentesis are recommended as adjunctive treatment in all patients with inhalation anthrax to drain pleural effusions, if present. (See",
"      <a class=\"local\" href=\"#H193169906\">",
"       'Inhalation anthrax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with meningitis, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      <strong>",
"       plus two",
"      </strong>",
"      additional antimicrobial agents with good CNS penetration and in vitro activity against B. anthracis should be used. Additional antimicrobial agents may include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"     </li>",
"     <li>",
"      Penicillin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"     </li>",
"     <li>",
"      Imipenem or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H193169927\">",
"       'Meningitis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids can be considered as adjunctive therapy for patients with serious systemic illness due to inhalation anthrax, including patients with meningoencephalitis and patients with cutaneous anthrax with extensive edema involving the head and neck. (See",
"      <a class=\"local\" href=\"#H193169934\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32755?source=see_link\">",
"       Raxibacumab",
"      </a>",
"      , a human monoclonal antibody against protective antigen, has been approved by the US Food and Drug Administration for the treatment of inhalational anthrax. Raxibacumab should be used in combination with antibiotics. Clinicians in the United States should contact the United States",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       Centers for Disease Control and Prevention (CDC)",
"      </a>",
"      if raxibacumab is indicated. (See",
"      <a class=\"local\" href=\"#H1061471327\">",
"       'Raxibacumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunoglobulin derived from the plasma of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/58/18342?source=see_link\">",
"       Anthrax Vaccine Adsorbed",
"      </a>",
"      (AVA)-immunized persons is available from the",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       CDC",
"      </a>",
"      , through state and local health departments, under an Investigational New Drug (IND) protocol for the treatment of persons with confirmed cases of life-threatening anthrax. (See",
"      <a class=\"local\" href=\"#H193169941\">",
"       'Immunotherapeutics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/1\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/2\">",
"      Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/3\">",
"      Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990; 68:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/4\">",
"      Doanay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/5\">",
"      Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/6\">",
"      Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/7\">",
"      Bakici MZ, Elaldi N, Bakir M, et al. Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909.",
"     </a>",
"    </li>",
"    <li>",
"     Quinn C, Turnbull P. Anthrax. In: Topley and Wilson's Microbiology and Microbial Infection, 9th ed, Hausler WJ, Sussman M (Eds), Edward Arnold, London 1998. p.799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/10\">",
"      Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/11\">",
"      Ronaghy HA, Azadeh B, Kohout E, Dutz W. Penicillin therapy of human cutaneous anthrax. Curr Ther Res Clin Exp 1972; 14:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/12\">",
"      Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Human anthrax associated with an epizootic among livestock--North Dakota, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/14\">",
"      Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002; 35:851.",
"     </a>",
"    </li>",
"    <li>",
"     Stern EJ, Uhde KB, Shadomy SV, et al. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis [serial on the Internet] 2008; 14. file://www.cdc.gov/EID/content/14/4/07-0969.htm (Accessed on February 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/17\">",
"      Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/18\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50:960.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Commentary on non-labeled dosing of oral amoxicillin in adults and pediatrics for post-exposure inhalational anthrax file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm (Accessed on February 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/21\">",
"      Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). In: Federal Register, November 2, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/23\">",
"      Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/24\">",
"      Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/25\">",
"      Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/26\">",
"      Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/27\">",
"      Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/28\">",
"      Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/29\">",
"      Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003; 9:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/30\">",
"      Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993; 90:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/31\">",
"      Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/32\">",
"      Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968; 53:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/33\">",
"      Artenstein AW, Opal SM. Novel approaches to the treatment of systemic anthrax. Clin Infect Dis 2012; 54:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/34\">",
"      Lucchesi, PF. Serum treatment of 19 cases of anthrax including one of external, internal and bacteremic type. Am J Med Sci 1932; 183:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/35\">",
"      Lucchesi, PF, Gildersleeve, N. The treatment of anthrax. JAMA 1941; 116:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/36\">",
"      Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med 1986; 151:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/37\">",
"      Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/38\">",
"      Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 2012; 205:818.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     Anti-Infective Drugs Advisory Committee Meeting - 02 November 2012. Human Genome Sciences, Inc. Briefing Document, Raxibacumab - ",
"Treatment of Inhalational Anthrax. BLA 125349. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     Raxibacumab prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/42\">",
"      Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/30/32232/abstract/43\">",
"      Anaraki S, Addiman S, Nixon G, et al. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill 2008; 13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15309 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32232=[""].join("\n");
var outline_f31_30_32232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H193170897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193168587\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193169871\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193169878\">",
"      Cutaneous anthrax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169885\">",
"      - Localized or uncomplicated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169892\">",
"      - Severe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169899\">",
"      - Bioterrorism-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193169906\">",
"      Inhalation anthrax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169913\">",
"      - Regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193169920\">",
"      Gastrointestinal anthrax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193169927\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64397993\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169934\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193169941\">",
"      - Immunotherapeutics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1061471327\">",
"      Raxibacumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H193169948\">",
"      Anthrax immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1203606\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185609414\">",
"      PUBLIC HEALTH REPORTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193170897\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/39/3709\" title=\"table 1\">",
"      Cutaneous anthrax Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/36/40525\" title=\"table 2\">",
"      Inhalation anthrax Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32233="Morphine sulfate: Pediatric drug information";
var content_f31_30_32233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Morphine sulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"    see \"Morphine sulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/33/14870?source=see_link\">",
"    see \"Morphine sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8775511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8776636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Astramorph/PF&trade;;",
"     </li>",
"     <li>",
"      AVINza&reg;;",
"     </li>",
"     <li>",
"      Duramorph;",
"     </li>",
"     <li>",
"      Infumorph 200;",
"     </li>",
"     <li>",
"      Infumorph 500;",
"     </li>",
"     <li>",
"      Kadian&reg;;",
"     </li>",
"     <li>",
"      MS Contin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8776637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doloral;",
"     </li>",
"     <li>",
"      Kadian&reg;;",
"     </li>",
"     <li>",
"      M-Eslon&reg;;",
"     </li>",
"     <li>",
"      M.O.S.-SR&reg;;",
"     </li>",
"     <li>",
"      M.O.S.-Sulfate&reg;;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 10;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 20;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 30;",
"     </li>",
"     <li>",
"      Morphine Extra Forte Injection;",
"     </li>",
"     <li>",
"      Morphine Forte Injection;",
"     </li>",
"     <li>",
"      Morphine HP&reg;;",
"     </li>",
"     <li>",
"      Morphine LP&reg; Epidural;",
"     </li>",
"     <li>",
"      Morphine SR;",
"     </li>",
"     <li>",
"      Morphine-EPD;",
"     </li>",
"     <li>",
"      MS Contin SRT;",
"     </li>",
"     <li>",
"      MS Contin&reg;;",
"     </li>",
"     <li>",
"      MS-IR&reg;;",
"     </li>",
"     <li>",
"      Novo-Morphine SR;",
"     </li>",
"     <li>",
"      PMS-Morphine Sulfate SR;",
"     </li>",
"     <li>",
"      ratio-Morphine;",
"     </li>",
"     <li>",
"      ratio-Morphine SR;",
"     </li>",
"     <li>",
"      Sandoz-Morphine SR;",
"     </li>",
"     <li>",
"      Statex&reg;;",
"     </li>",
"     <li>",
"      Teva-Morphine SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Doses should be titrated to appropriate effect",
"     </b>",
"     ; when changing routes of administration in chronically treated patients, please note that oral doses are approximately one-half as effective as parenteral dose;",
"     <b>",
"      Note: Use preservative-free formulation",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V., SubQ: Initial: 0.05 mg/kg every 4-8 hours; titrate carefully to effect; maximum dose: 0.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial: 0.01 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (10 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); do",
"     <b>",
"      not",
"     </b>",
"     exceed infusion rates of 0.015-0.02 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     due to decreased elimination, increased CNS sensitivity, and adverse effects;",
"     <b>",
"      Note:",
"     </b>",
"     Some centers may use slightly higher doses, especially in neonates who develop tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     International Evidence-Based Group for Neonatal Pain recommendations (Anand, 2001): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent dose: 0.05-0.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Range: 0.01-0.03 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endotracheal intubation, nonemergent: I.M., I.V.: 0.05-0.1 mg/kg (Kumar, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"      see \"Morphine sulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Doses should be titrated to appropriate effect",
"     </b>",
"     ; when changing routes of administration in chronically treated patients, please note that oral doses are approximately one-half as effective as parenteral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Infants and Children:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Tablet and solution (prompt release): 0.2-0.5 mg/kg/dose every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society (2008) recommends an initial oral dose of 0.3 mg/kg for children with severe pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V., SubQ: 0.1-0.2 mg/kg/dose every 2-4 hours as needed; may initiate at 0.05 mg/kg/dose; usual maximum dose: Infants: 2 mg/dose; Children 1-6 years: 4 mg/dose; Children 7-12 years: 8 mg/dose; Adolescents: 15 mg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     Infants &lt;3 months of age are more susceptible to respiratory depression; use with caution and in reduced doses in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., SubQ continuous infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sickle cell or cancer pain: Initial: Infants: 0.02 mg/kg/hour (20 mcg/kg/hour); Children: 0.03 mg/kg/hour (30 mcg/kg/hour); conversion from intermittent I.V. morphine: Administer the patient's total daily I.V. morphine dose over 24 hours as a continuous infusion; titrate dose to appropriate effect; in one study (Miser, 1980), children with severe pain from terminal cancer required a median dose of 0.04-0.07 mg/kg/hour (40-70 mcg/kg/hour); range: 0.025-2.6 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postoperative pain: 0.01-0.04 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Patient-controlled analgesia (PCA): Opioid-na&iuml;ve:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years and &lt;50 kg:",
"     <b>",
"      Note:",
"     </b>",
"     PCA has been used in children as young as 5 years of age; however, clinicians need to assess children 5-8 years of age to determine if they are able to use the PCA device correctly. All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Usual concentration: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Demand dose: Usual initial: 0.02 mg/kg/dose; usual range: 0.01-0.03 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lockout: Usual initial: 5 doses/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lockout interval: Range: 6-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Usual basal rate: 0-0.03 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents &gt;50 kg: See Adult PCA dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation/analgesia for procedures: I.V.: 0.05-0.1 mg/kg 5 minutes before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural (",
"     <b>",
"      Note: Must use preservative-free",
"     </b>",
"     ): 0.03-0.05 mg/kg (30-50 mcg/kg); maximum dose: 0.1 mg/kg (100 mcg/kg) or 5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Children:",
"     </b>",
"     Oral: Controlled release tablet: 0.3-0.6 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion from prompt release tablets and solution: Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the patient's total daily oral morphine dose every 12 hours or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the patient's total daily oral morphine dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adolescents &gt;12 years:",
"     </b>",
"     Sedation/analgesia for procedures: I.V.: 3-4 mg; may repeat in 5 minutes if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prompt release: 10-30 mg every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Controlled release: 15-30 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Avinza&reg; extended release capsules (chronic pain): Conversion from other oral morphine products: Administer the patient's total daily oral morphine dose as Avinza&reg; capsules once daily; do not administer more often than every 24 hours; supplemental pain medication may be needed (up to 4 days) until response to daily Avinza&reg; dosage has been stabilized; see package insert for more details; maximum dose: 1600 mg/day; higher doses contain quantity of fumaric acid that may result in nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Kadian&reg; extended release capsules (chronic pain): Conversion from other oral morphine products: Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the patient's total daily oral morphine dose as Kadian&reg; capsules every 12 hours or administer the total daily oral morphine dose as Kadian&reg; capsules every 24 hours; do not administer more often than every 12 hours; see package insert for more details",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V., SubQ: 2.5-20 mg/dose every 2-6 hours as needed; usual: 10 mg/dose every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., SubQ continuous infusion: 0.8-10 mg/hour; may increase depending on pain relief/adverse effects; usual range up to 80 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Patient-controlled analgesia (PCA): Opioid-na&iuml;ve: &gt;50 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Usual concentration: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Demand dose: Usual initial: 1 mg; usual range: 0.5-2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lockout interval: Usual initial: 6 minutes; usual range: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural (",
"     <b>",
"      Note: Use preservative-free formulation",
"     </b>",
"     ; use lower doses and with extreme caution in debilitated patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Astramorph/PF&trade;, Duramorph&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single dose: Initial: 5 mg in lumbar region; if inadequate pain relief within 1 hour, give 1-2 mg; maximum dose: 10 mg/24 hours (single doses may provide adequate relief for up to 24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous infusion: Initial: 2 mg/24 hours to 4 mg/24 hours; may give further doses of 1-2 mg if pain relief is not achieved initially; maximum total dose: 10 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society (2008) recommends 1-6 mg/dose as a single epidural dose or an epidural infusion of 0.1-1 mg/hour; adjust dose for age, injection site, and patient's medical condition and degree of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrathecal (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     of epidural dose;",
"     <b>",
"      Note: Must use preservative-free formulation",
"     </b>",
"     ; use lower doses and with extreme caution in debilitated patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single dose: Opioid-naive: 0.2-1 mg/dose (single doses may provide adequate relief for up to 24 hours); repeat doses",
"     <b>",
"      not",
"     </b>",
"     recommended;",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society (2008) recommends 0.1-0.3 mg/dose as a single intrathecal dose for acute pain; adjust dose for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance. Doses of 1-10 mg/day have been used in opioid-tolerant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider use of low-dose continuous I.V. naloxone infusion (0.6 mg/hour) for 24 hours after intrathecal injection to help reduce potential side effects (eg, nausea, vomiting, pruritus, urinary retention); weigh risk of using narcotic antagonist in patients receiving opioids chronically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous microinfusion (Infumorph&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Opioid-naive: Initial: 0.2-1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Opioid-tolerant: Initial: 1-10 mg/day, titrate to effect; usual maximum: ~20 mg/day; doses &gt;20 mg/day may be associated with higher risk of serious adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider use of low-dose naloxone (0.2 mg) to help reduce side effects (eg, nausea, vomiting, pruritus, urinary retention); weigh risk of using narcotic antagonist in patients receiving opioids chronically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use with caution; specific guidelines are not available; clearance is decreased in patients with cirrhosis; accumulation of morphine is not expected with single-dose use, but may occur with multiple doses; lower doses may be needed with multiple dose regimens",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8776907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kadian&reg;: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 130 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate [bi-modal release]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVINza&reg;: 30 mg, 45 mg, 60 mg, 75 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (10 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 5 mg/mL (1 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL, 10 mL); 10 mg/0.7 mL (0.7 mL); 15 mg/mL (1 mL, 20 mL); 25 mg/mL (4 mL, 10 mL); 50 mg/mL (20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL); 25 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [epidural or intrathecal infusion via microinfusion device, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infumorph 200: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infumorph 500: 25 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [epidural, intrathecal, or I.V. infusion, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Astramorph/PF&trade;: 0.5 mg/mL (2 mL, 10 mL); 1 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duramorph: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [for PCA pump]: 1 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [for PCA pump, preservative free]: 1 mg/mL (30 mL); 5 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate: 10 mg/5 mL (5 mL, 100 mL, 500 mL); 20 mg/5 mL (100 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate [concentrate]: 100 mg/5 mL (15 mL, 30 mL, 120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as sulfate: 5 mg (12s); 10 mg (12s); 20 mg (12s); 30 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sulfate: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MS Contin&reg;: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8776646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Avinza&reg; extended release capsule",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F8776634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9845085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     AVINza&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Kadian&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311373.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311373.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     MS Contin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199333.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199333.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food; swallow extended, sustained, and controlled release products whole; do not chew, crush, break, or dissolve (this would result in rapid release and absorption of a potentially toxic dose of drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avinza&reg; and Kadian&reg; capsules may be administered without regard to meals. Do not administer Avinza&reg; with alcohol. Avinza&reg; and Kadian&reg; (extended release capsules) may be opened and contents sprinkled on a small amount of applesauce immediately prior to ingestion; swallow mixture; rinse mouth with water and swallow to ensure all beads have been ingested; do not chew, crush, or dissolve beads or pellets from capsule (this would result in rapid release and absorption of a potentially toxic dose of drug). Kadian&reg; capsules may be opened and contents sprinkled into ~10 mL of water, then flushed while swirling through a pre-wetted 16-French gastrostomy tube fitted with a funnel at the port end; flush with water to transfer all pellets and flush the tube; do not attempt to administer via NG tube.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"     <b>",
"      Note:",
"     </b>",
"     Solutions for injection should be visually inspected for particulate matter and discoloration prior to administration. Do not use if contains a precipitate or is darker in color than pale yellow or discolored in any other way.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: Administer over at least 5 minutes at a final concentration of 0.5-5 mg/mL (rapid I.V. administration may increase adverse effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent infusion: Administer over 15-30 minutes at a final concentration of 0.5-5 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 0.1-1 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, or NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural and intrathecal: Use only preservative-free injections. Adults: Infumorph&reg; was developed for use in continuous microinfusion devices only; it may require dilution before use, as determined by the individual patient's dosage requirements and the characteristics of the continuous microinfusion device; not recommended for single dose I.V., I.M., or SubQ administration; filter through &le;5 micron microfilter before injecting into microinfusion device",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14472939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 mg/mL, 0.5 mg/mL,",
"     <b>",
"      or",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8776767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, aldesleukin, allopurinol, amifostine, amikacin, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, amsacrine, anidulafungin, argatroban, atenolol, atracurium, atropine, aztreonam, bivalirudin, bumetanide, caffeine citrate, calcium chloride, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, cefuroxime, chloramphenicol, cisatracurium, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diazepam, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxycycline, enalaprilat, epinephrine, eptifibatide, erythromycin lactobionate, esmolol, etomidate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, IL-2, insulin (regular), kanamycin, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meropenem, methotrexate, methotrimeprazine, methyldopate, methylprednisolone sodium succinate, metoclopramide, metoprolol, metronidazole, midazolam, milrinone, nafcillin, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pancuronium, pemetrexed, penicillin G potassium, phenobarbital, piperacillin, piperacillin/tazobactam, potassium chloride, propranolol, ranitidine, remifentanil, scopolamine, sodium bicarbonate, tacrolimus, teniposide, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vecuronium, vinorelbine, vitamin B complex with C, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alteplase, alatrofloxacin, amphotericin B cholesteryl sulfate complex, azithromycin, doxorubicin liposome, gallium nitrate, lansoprazole, micafungin, minocycline, phenytoin, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, cefepime, ceftriaxone, furosemide, nesiritide, pantoprazole, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, atropine, bupivacaine, bupivacaine with clonidine, butorphanol, caffeine citrate, cimetidine, clonidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, ketamine with lidocaine, lidocaine, metoclopramide, midazolam, milrinone, ondansetron, pentazocine, ranitidine, rocuronium, scopolamine, ziconotide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Haloperidol, meperidine, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Chlorpromazine, heparin, ketamine, octreotide,  pentobarbital, prochlorperazine edisylate, promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10512358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppositories: Refrigerate; do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at controlled room temperature. Protect from light. Degradation depends on pH and presence of oxygen; relatively stable in pH &le;4; darkening of solutions indicates degradation. Morphine solutions for injection are stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, dextran 6% in dextrose, dextran 6% in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avinza&reg; and Kadian&reg;: Store at controlled room temperature. Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duramorph&reg;: Store in carton at controlled room temperature of 20&deg;C to 25&deg;C (65&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; do not freeze. Discard unused portion of vial (vial does not contain preservative). Do not heat sterilize.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to severe acute and chronic pain (FDA approved in adults); has also been used for pain of MI; relief from dyspnea of acute left ventricular failure and pulmonary edema; preanesthetic medication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astramorph/PF&trade;, Duramorph&reg;: I.V., epidural, or intrathecal (both at the lumbar level) for the  management of pain unresponsive to non-narcotic analgesics (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled, extended, and sustained release products (eg, Avinza&reg;, Kadian&reg;, MS Contin&reg;, Oramorph&reg; SR): Management of moderate to severe",
"     <b>",
"      chronic",
"     </b>",
"     pain when continuous, around-the-clock opioid analgesia is required for an extended amount of time (FDA approved in adults) (",
"     <b>",
"      not",
"     </b>",
"     for PRN use;",
"     <b>",
"      Note:",
"     </b>",
"     Kadian&reg; is",
"     <b>",
"      not",
"     </b>",
"     indicated for relief of pain for the first 12-24 hour after surgery)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infumorph&reg;: Intrathecal (at the lumbar level) or epidural infusion via microinfusion device for the treatment of intractable chronic pain (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8775520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine may be confused with HYDROmorphone, methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine sulfate may be confused with magnesium sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kadian&reg; may be confused with Kapidex [DSC]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MS Contin&reg; may be confused with OxyCONTIN&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MSO",
"       <sub>",
"        4",
"       </sub>",
"       and MS are error-prone abbreviations (mistaken as magnesium sulfate)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AVINza&reg; may be confused with Evista&reg;, INVanz&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Roxanol may be confused with OxyFast&reg;, Roxicet&trade;, Roxicodone&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Use care when prescribing and/or administering morphine solutions. These products are available in different concentrations. Always prescribe dosage in mg;",
"       <b>",
"        not",
"       </b>",
"       by volume (mL).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Use caution when selecting a morphine formulation for use in neurologic infusion pumps (eg, Medtronic delivery systems). The product should be appropriately labeled as &ldquo;preservative-free&rdquo; and suitable for intraspinal use via continuous infusion. In addition, the product should be formulated in a pH range that is compatible with the device operation specifications.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8776724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Individual patient differences are unpredictable. Reactions may be dose-, formulation-, and/or route-dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, bradycardia, chest pain, circulatory depression, edema, flushing, hyper-/hypotension, palpitation, peripheral edema, shock, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, agitation, anxiety, apathy, apprehension, ataxia, chills, coma, confusion, delirium, depression, dizziness, dream abnormalities, drowsiness (tolerance usually develops to drowsiness with regular dosing for 1-2 weeks), dysphonia, euphoria, false sense of well being, fever, hallucination, headache (following epidural or intrathecal use), hypoesthesia, insomnia, lethargy, malaise, nervousness, physical and psychological dependence, restlessness, sedation, seizure, slurred speech, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin, pruritus (may be dose related), rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release, gynecomastia, hypogonadism, hypokalemia, hyponatremia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, anorexia, abdominal pain, biliary colic, constipation (tolerance develops very slowly if at all), diarrhea, dyspepsia, dysphagia, flatulence, gastroenteritis, GERD, GI irritation, nausea (tolerance usually develops to nausea and vomiting with chronic use), paralytic ileus, rectal disorder, taste perversion, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention (may be prolonged, up to 20 hours, following epidural or intrathecal use), bladder spasm, dysuria, ejaculation abnormal, impotence, urination decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (following intrathecal use), hematocrit decreased, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone mineral density decreased, bone pain, foot drop, gait abnormalities, myoclonus, paresthesia, rigors, skeletal muscle rigidity, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, conjunctivitis, eye pain, vision problems/disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, dyspnea, hiccups, hypercapnia, hypoxia, oxygen saturation decreased,pulmonary edema (noncardiogenic), respiratory depression, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, histamine release, infection, thirst, voice alteration, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amenorrhea, anaphylaxis, apnea, biliary tract spasm, blurred vision, bronchospasm, cardiac arrest, cough reflex decreased, dehydration, diplopia, disorientation, hemorrhagic urticaria, intestinal obstruction, intracranial pressure increased, laryngospasm, menstrual irregularities, miosis, myoclonus, nystagmus, paradoxical CNS stimulation, respiratory arrest, sepsis, urinary tract spasm, thermal dysregulation, toxic psychoses",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to morphine sulfate or any component; severe respiratory depression or respiratory depression in a setting without resuscitative equipment or appropriate monitoring; acute or severe asthma; hypercarbia; upper airway obstruction; severe liver or renal insufficiency; GI obstruction especially known or suspected paralytic ileus; pregnancy (prolonged use or high doses at term). Duramorph&reg; is also labeled as being contraindicated in patients with depleted blood volume or concurrent administration of phenothiazines or general anesthetics (severe hypotension may occur).",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone). Use with caution in patients with biliary tract disease or acute pancreatitis (morphine may cause spasm of the sphincter of Oddi); use with caution and decrease the dose in patients with Addison's disease, hypothyroidism, renal impairment, hepatic dysfunction (eg, cirrhosis), urethral stricture, prostatic hypertrophy, or in debilitated patients; use with caution in patients with CNS depression, toxic psychosis, seizure disorders, acute alcoholism, and delirium tremens.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Kadian&reg; should be discontinued 24 hours prior to cordotomy or other interruption of pain transmission pathways (use parenteral short-acting opioids to control pain). Use Kadian&reg; with great caution and decrease the dose in patients who are receiving other CNS depressants (respiratory depression, hypotension, profound sedation, or coma may result). The pharmacokinetics of Avinza&reg; and Kadian&reg; have not been studied in patients &lt;18 years of age; the available capsule mg strength may not be appropriate for pediatric patients who are very young; sprinkling capsule contents on applesauce is",
"     <b>",
"      not",
"     </b>",
"     a suitable alternative for these patients; other oral products should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When administered to a pregnant woman, I.V., epidural, and intrathecal morphine readily pass into the fetal circulation and may result in respiratory depression in the newborn; resuscitative equipment and naloxone should be available for the neonate.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS and respiratory depression may occur; neonates and infants &lt;3 months of age are more susceptible to respiratory depression; use with caution and in reduced doses in this age group. Use only preservative-free injections for epidural or intrathecal administration and in neonates. Use with extreme caution in patients with COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, head injury, increased ICP, or other intracranial lesions. Severe hypotension may occur; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Morphine may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures. Warn patient of possible impairment of alertness or physical coordination. Interactions with other CNS drugs may occur. Healthcare provider should be alert to problems of abuse, misuse, and diversion. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A toxic or potentially fatal dose of morphine may be rapidly released if extended, sustained, or controlled release products are chewed, crushed, broken, or dissolved or if these products are abused by crushing, chewing, snorting, or injecting the dissolved product. Consumption of alcoholic beverages or ethanol-containing products (prescription or nonprescription) while receiving Avinza&reg; therapy may disrupt the extended-release formulation, causing a rapid release of morphine and potentially fatal overdose. Kadian&reg; capsules are indicated for the treatment of moderate to severe chronic pain and are not intended for PRN use. Kadian&reg; 100 mg and 200 mg capsules are for use in opioid-tolerant patients only; fatal respiratory depression may occur if these capsules or their contents are administered to patients who are not tolerant to high-dose opioids. MS Contin&reg; 100 mg and 200 mg tablets are for use only in opioid-tolerant patients requiring &gt;400 mg/day of morphine. Patients should be warned not to let others use these products, since severe adverse effects, including death, may result.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to administration via epidural or intrathecal route, evaluate benefits versus risks in patients with infection at injection site, bleeding diatheses, or anticoagulation therapy. Only physicians experienced in the techniques and familiar with the clinical management of the adverse effects of epidural and intrathecal drug administration should administer drugs via the intraspinal route. When morphine is used via the epidural or intrathecal routes, severe adverse effects may occur, including significant respiratory depression; facilities must be properly equipped to resuscitate patients; monitor patients for delayed sedation. Some adverse effects are more common following epidural or intrathecal administration compared to other routes (eg, I.V. or oral); these may include: Headache, pruritis, urinary retention (may be prolonged up to 20 hours), and urinary tract spasm. Monitor patients closely for a minimum of 24 hours after the initial epidural or intrathecal dose of Duramorph&reg;. When Infumorph&reg; is used, patients must be closely monitored for a minimum of 24 hours after the initial (single) test dose and as appropriate for the first several days after catheter implantation. Due to fewer potential adverse effects, the epidural route is preferred over the intrathecal route (intrathecal route is associated with a higher incidence of respiratory depression). Tolerance to morphine and increased epidural or intrathecal dosage requirements may occur (patients may require hospitalization and detoxification). Seizures may occur with high doses of intraspinal morphine. Myoclonic spasm of the lower extremities has been reported in adults receiving high doses of intrathecal morphine. Safety and efficacy of spinal morphine products have not been established in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral products are designed for administration by specific routes (I.V., intrathecal, epidural). Use caution when prescribing, dispensing, or administering so as to use formulations only by intended route(s). Injection may contain sodium metabisulfite which may cause allergic reactions in susceptible individuals; oral solution may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; avoid use of morphine sulfate products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8776734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8776735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10512357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avinza&reg;: A high-fat meal may delay absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kadian&reg;: Food may decrease the rate, but not the extent, of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MS Contin&reg;: A fatty meal may slightly decrease peak plasma concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Food may increase bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oramorph&reg; SR: Food has little to no effect on bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8776699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8776700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however reduced growth and behavioral abnormalities in offspring have been observed. Morphine crosses the human placenta. The frequency of congenital malformations has not been reported to be greater than expected in children from mothers treated with morphine during pregnancy. However, following",
"     <i>",
"      in utero",
"     </i>",
"     exposure, infants may exhibit withdrawal, decreased brain volume (reversible), small size, decreased ventilatory response to CO",
"     <sub>",
"      2",
"     </sub>",
"     , and increased risk of sudden infant death syndrome. In patients with chronic, noncancer pain, minimal (if any) opioids should be used during pregnancy. Neonates born to mothers receiving chronic opioids during pregnancy should be monitored for neonatal withdrawal syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, oxygen saturation, pain relief (if used for analgesia), level of sedation.",
"     <b>",
"      Note:",
"     </b>",
"     Resedation may occur following epidural administration. Monitor patients receiving Infumorph&reg; closely for &ge;24 hours after initiation and as appropriate for the first several days after catheter implantation.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10512360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Form / Route",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Analgesia",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Peak",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Duration",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Tablets",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 h",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Oral solution",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 h",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Epidural",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 h",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12-20 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Extended release tablets",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 h",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8-12 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Suppository",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20-60 min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-7 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Subcutaneous injection",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         50-90 min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         I.M. injection",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         30-60 min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. injection",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20 min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10512361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to skeletal muscle, liver, kidneys, lungs, intestinal tract, spleen, brain, and into breast milk; crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     , apparent: Children 1.7-18.7 years with cancer: Median: 5.2 L/kg; a significantly higher V",
"     <sub>",
"      d",
"     </sub>",
"     was observed in children &lt;11 years (median: 7.1 L/kg) versus &gt;11 years (median: 4.7 L/kg) (Hunt, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     , apparent: Adults: 1-4.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature Infants: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20% to 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via glucuronide conjugation to morphine-6-glucuronide (active) and morphine-3-glucuronide (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preterm: 10-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 7.6 hours (range: 4.5-13.3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-3 months: 6.2 hours (range: 5-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6 months to Children 2.5 years: 2.9 hours (range: 1.4-7.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preschool Children: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-19 years with sickle cell disease: Mean ~1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted unchanged in urine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 3% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2% to 12%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"     <b>",
"      Note:",
"     </b>",
"     Adult values are reached by 6 months to 2.5 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preterm: 0.5-3 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates 1-7 days: Median: 5.5 mL/minute/kg (range: 3.2-8.4 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates 8-30 days: Median: 7.4 mL/minute/kg (range: 3.4-13.8 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 1-3 months: Median: 10.5 mL/minute/kg (range: 9.8-20.1 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 3-6 months: Median: 13.9 mL/minute/kg (range: 8.3-24.1 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 6 months to Children 2.5 years: Median: 21.7 mL/minute/kg (range: 5.8-28.6 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preschool Children: 20-40 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1.7-18.7 years with cancer: Median: 23.1 mL/minute/kg; a significantly higher clearance was observed in children &lt;11 years (median: 37.4 mL/minute/kg) versus &gt;11 years (median: 21.9 mL/minute/kg) (Hunt, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-19 years with sickle cell disease: Mean &sim;36 mL/minute/kg (range: 6-59 mL/minute/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 10-20 mL/minute/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/33/14870?source=see_link\">",
"      see \"Morphine sulfate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use exactly as directed; do not increase dose or frequency. Do not crush, chew, break, or dissolve any extended, sustained, or controlled release product. Avoid alcohol. Do not drink any alcohol (including beer, wine, distilled spirits) or take OTC or other prescription medications which may contain alcohol, when taking Avinza&reg; (alcohol may cause a sudden and dangerous release of medication from this product which may cause decreased breathing, coma, or death). Morphine may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use. Do not let others use your morphine products; severe adverse effects, including death, may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Morphine may cause itching, low blood pressure, or blurred vision (use caution when climbing stairs or changing position from sitting or lying to standing), loss of appetite, dry mouth, nausea, vomiting, or constipation (consult prescriber about use of stool softeners and/or laxatives). Report chest pain, slow or rapid heartbeat, acute dizziness, or persistent headache; changes in mental status; swelling of extremities or unusual weight gain; changes in urinary elimination or pain on urination; acute headache; back or flank pain; muscle spasms; blurred vision; skin rash; or shortness of breath.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10512367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Less adverse effects are associated with epidural compared to intrathecal route of administration; equianalgesic doses: Codeine: 120 mg I.M. = morphine 10 mg I.M. = single dose oral morphine 60 mg or chronic dosing oral morphine 15-25 mg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avinza&reg; capsules contain both immediate release and extended release beads; also contains fumaric acid (as an osmotic agent and local pH modifier); this product is intended for once daily oral administration only; not for PRN or postoperative use. Kadian&reg; capsules contain extended release pellets that are polymer-coated; this product is intended for every 12- or 24-hour dosing. Kadian&reg; capsules also contain talc; parenteral abuse may result in local tissue necrosis, infection, pulmonary granulomas, endocarditis, and valvular heart injury.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ and International Evidence-Based Group for Neonatal Pain, &ldquo;Consensus Statement for the Prevention and Management of Pain in the Newborn,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2001, 155(2):173-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/11177093/pubmed\" id=\"11177093\" target=\"_blank\">",
"        11177093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dampier CD, Setty BN, Logan J, et al, &ldquo;Intravenous Morphine Pharmacokinetics in Pediatric Patients With Sickle Cell Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(3):461-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/7869211 /pubmed\" id=\"7869211 \" target=\"_blank\">",
"        7869211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henneberg SW, Hole P, Madsen de Haas I, et al, &ldquo;Epidural Morphine for Postoperative Pain Relief in Children,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1993, 37(7):664-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/8249555/pubmed\" id=\"8249555\" target=\"_blank\">",
"        8249555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt A, Joel S, Dick G, et al, &ldquo;Population Pharmacokinetics of Oral Morphine and Its Glucuronides in Children Receiving Morphine as Immediate-Release Liquid or Sustained-Release Tablets for Cancer Pain,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 135(1):47-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/10393603/pubmed\" id=\"10393603\" target=\"_blank\">",
"        10393603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar P, Denson SE, Mancuso TJ, et al, \"Premedication for Nonemergency Endotracheal Intubation in the Neonate,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(3):608-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/20176672/pubmed\" id=\"20176672\" target=\"_blank\">",
"        20176672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McRorie TI, Lynn AM, Nespeca MK, et al, &ldquo;The Maturation of Morphine Clearance and Metabolism,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1992, 147(8):972-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/1636668/pubmed\" id=\"1636668\" target=\"_blank\">",
"        1636668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miser AW, Davis DM, Hughes CS, et al, &ldquo;Continuous Subcutaneous Infusion of Morphine in Children With Cancer,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1983, 137(4):383-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/ 6187211 /pubmed\" id=\" 6187211 \" target=\"_blank\">",
"        6187211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miser AW, Miser JS, and Clark BS, &ldquo;Continuous Intravenous Infusion of Morphine Sulfate for Control of Severe Pain in Children With Terminal Malignancy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 96(5):930-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/7365606 /pubmed\" id=\"7365606 \" target=\"_blank\">",
"        7365606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/7614777 /pubmed\" id=\"7614777 \" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/30/32233/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,\" 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16024 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32233=[""].join("\n");
var outline_f31_30_32233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775511\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512349\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443893\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512362\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776907\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776646\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776634\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9845085\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512363\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472939\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472938\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776767\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512358\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512350\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775520\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776724\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512355\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512353\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512357\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776699\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776700\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512364\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512359\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512360\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512361\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512365\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512367\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=related_link\">",
"      Morphine sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/33/14870?source=related_link\">",
"      Morphine sulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_30_32234="Phototoxic eruption 2";
var content_f31_30_32234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76399%7EDERM%2F69140%7EDERM%2F86479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76399%7EDERM%2F69140%7EDERM%2F86479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phototoxic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 11-year-old boy taking doxcycline developed a painful, confluent, erythematous eruption in exposed areas after a day of summer sun exposure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Phototoxic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 296px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEoAgQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6W8Sa7p3hrRp9V1mdoLGAoryLE8pBd1RQFQFjlmUcDvXIr8YfBb/cv9Rb6aNen/2jTfj/AP8AJK9Sxz/pVh/6WwV4dpSyFSzsoIOKyqVHF2R34PBxxEW5O1j3f/hbfhD/AJ+tU/8ABLff/GaX/hbXhHk/adVwOv8AxJL7/wCM15FE6qm043EE561IS8mEUn5uv9Kn2r7HV/ZkP5mert8XfBy9bzUx9dFvf/jNMb4xeClOG1DUAfQ6Pe//ABmvIp4pBFtc96oyJvkUkfL3Pc0nWaNYZRTl9pntX/C5PBP/AEEdQyf+oPe//Gaevxd8HMMreamR6jRb3/4zXh8dsGVyfu7sjjmr1vCI42ZySGOMDNL20jX+xKdtJu57GPi54PPS71T/AMEt9/8AGacPiz4ROcXOq8f9QS+/+M15FFDlgsR+cds5q5FZqsiMZCCxwfU0vby7EvJqa3m/uPUv+FseEsZ+0atj/sCX3/xmnf8AC1PCv/PXWP8AwRX3/wAZrzi3SKNflYuwJ6jOKW+ciIqhKEDkZzVe2fVEPKIXspM9Eb4s+ElzuudWAHrol9/8ZqP/AIW94NP/AC+an/4Jb3/4zXkeyTLs8m7d2Uc0rwBEYmPnbgd/xqPrD7GrySmvts9aPxf8GDre6kPro17/APGaYfjJ4IU4Oo34PodHvf8A41XjcsO5jGWOTySBWDfOEZsDkDjPeqVdvoZyyinH7TPoEfGbwOTgalf5/wCwRe//ABqnj4x+Cj01DUT/ANwe9/8AjNfOFv5q7egRhyM8/wD6q2bVGwGQ7iMZB4o9s30IhlMJO3Mz3kfF3wc3S81M/TRb3/4zSj4ueDyMi71Qj/sC33/xmvEjIrMFDgY7k1ajjJGRICPypqs30NnktNLWbPYT8XvBoPN5qY/7gt7/APGaY3xj8FIMtqGoKPfR70f+0a8huGy5LKoB53AVlaiVdGAwwxzjtS9u+xLyen/Mz29vjT4EX72q3o+uk3n/AMap6fGXwRJ9zUb9vpo96f8A2lXzRfxELgHIIzkGpdIuTFcReYQGPGaX1h9jP+yYfzH0wvxb8HsMrd6ofpot9/8AGaePiv4TJwJ9XJ/7Ad9/8ZryjTzHIIzuBUg55xVx4m8pTGSpTknrQsQ+w4ZTCX2melj4reEycCfV8+n9h33/AMZp3/C0vC3I8zWeOv8AxIr7/wCM15KHnjZ5D68gc5q3FqKqcMJGOMjHIxT+sdy5ZKltI9RHxQ8MsQFbWiT2Gg3/AP8AGaH+KHhhMb21pc9M6Dfj/wBo1wDTkQRtFNtY98dfrUZ1ZHYRySPgdcA4+tN17GP9k31TPQG+KnhVc7pdYGOudDvv/jNQyfF7wbFjzLzU0ycDdot6Mn/vzXnF1MqfKrMxY/Mzc4rNu2SRd0gz/EBjOfepeIfRFLKE+rPWf+Fv+DQMm91LH/YGvf8A4zTR8YvBTHC6hqJPto97/wDGa8S1CRiRg7l68daqwFPNzzuboOwpfWH2LlkqUb8x71/wt3wd/wA/ep/+CW9/+M00/F/wYBk3upAf9ga9/wDjNeMxXBKsGIABwCBVCZyTIuOHbkjtT+sPsQsoi95H1F4b13TvEmjQaro07T2M5dUkaJ4iSjsjAq4DAhlYcjtXnv8Aw0F8Mf8AoZv/ACQuv/jdafwD4+F2nj/p7v8A/wBLZ6/PEqyBWYMAeRxXSnoeLKNpNdj7+Hx9+GpBI8RuQOp/s66/+NU1v2gfhkpw3iUg++n3X/xqvg6zuxAWO3IwRn6+vrVeZgcDIIHT1+lJN3BpJH34Pj78NTnHiJzjr/xLrr/41Sn49/DcBc+IZBu5H/Euuufp+6r4IErLbBo26jY4P6fp/KkS9kEYQ5OMYIOOPSi7CyPvQ/tA/DIEg+JTkdf+Jfdf/GqP+GgvhjjP/CTf+SF1/wDGq+A2bLk5Jz69aeEZrdyBlQQSfSncSVz75/4aC+GP/Qzf+SF1/wDGqP8AhoL4Y/8AQzf+SF1/8ar4DQnaQAPy6VJ5aYkBLblwVx0IouKx98f8NA/DL/oZT/4L7r/41Qf2gvhiDg+Jj/4L7r/41XwakY8pmzkjkepB71GfmDB8AqvGPXpSuU4n3r/w0H8Mf+hm/wDJC6/+N1O3x2+HShC2vTKHAKk6ZdjcD0x+671+fQ610llc5tYC8gVoG+VsBuFweh9/60Sdgirn3A3x5+HCHDeIJVPodNux/wC0qF+PPw4YsF8QSkqpZgNNu+AOpP7rpXyWyGe38028LLKoZGGV54x+fWs6eJLKL96xVnTDAIAcEjnOeehqed9inBdz7DPx8+GwOD4hcH0/s66/+NUh+P8A8NFOG8SMD6HT7r/41XxtNJamXfby3JBGNoVRuPXnk8d6xr22Uys0UrYY9ZW6/lT5g9n5n3Av7QPwyYgDxKST6afdf/Gqkf49/DdMb/EMi56Z066H/tKvgwpKGDIMZ5yfmFB8/ndIn6dfpinzE8tj7yT49/DaQfJ4hkb6addH/wBpUknx++GkbYk8Rsh9G066H/tKvg5mERHnw7e4eNgQfp/9Y043EckW15JFHPTO0n3B4ouwsj7s/wCGg/hh/wBDN/5IXX/xul/4aC+GP/Qzf+SF1/8AG6+DFTIAeNM9iMAn/Gm3Fu6DlcY64UjH1p3FY+9P+Gg/hj/0M3/khdf/ABuj/hoP4Yf9DN/5IXX/AMbr4BIxSUxH3/8A8NB/DD/oZv8AyQuv/jda3hb4xeBPFWvWujaDrv2vUrnd5UP2SePdtUu3zMgA+VSeT2r8669U/Zc/5Lt4Z/7ev/SWWgD7/ooooA87/aAOPhVqRHUXVgf/ACcgrwqynbzCDtXvmvdP2gTt+FOpn0urE/8Ak5BXhmmojI5BJZ+dxHeuatuj2srfuSNDzzI4ERB457cZrTMx83amFXHNZ9ugij24BOccDNWV2RpIzZBxk59KzWh6ejJZXXzFBxg8/X2qgVDwyMQAinOTwevaka4GcIN3AJpkl1FJagc5JycdT6DFDasSm1sOjukIZYgCBwTg9av+YPuIuXIHNY1ojQAmUjYACfTntWjpUMlxJI7uSg/iJwAKlNnSaFpCUk/dlVdhjdjJrUt0eNAZSC3QEjnHtVWVD5cQtsELxnqTSSo0Q2yDCsDvbk/gDScktR6yJppmiIWLYD0woyaqNbzSMS8jbQ24ADH61Hbb0dcYSInKoO/4+taNxA1w0aRK3XhWP3vw9qL3NLezdio0f7wEMPLA6DmpJLbfNblhhJCQQT0NadnYHeBLAAwwoGDlj/Srkvm3L7JITb7BnaceuM0culxSmrnO6vElil06sjKp2hl9a871aQuUf+N2ya7PxlctFefZAwO4jeAMYrgNVl/erGhOA5yTVbq5yyle2pfsR5i7mGWzjPYCtMXKoPKi5J6nGKzLMuyKiABT/KtaKyGw78FsZAxx9aV+iN6ULlVWfzGQj5gfWkkubpQFDMF6Ar1FW7O1BlJz06HNWJbcMc7cKOM46mpWu518tnYzbfUJGk8qZ3POcnipbgIpdoyQDwOKbfWgV8betVpgY1wGJ7mo2djGrG+qM66O6MqcsU6motFHnzAMR3PPai7dlOduDVfQ7hUjnBG1g5IA9DWsddzjlJpnovh+2MskKmTbySq9d+a14TLbwswG+MyEdMnA6mqvguNH063nyzSu2ACOg6V0WsK1rAirE7REY3KM49zU+Z0QleXLuZRw5LRxIFYZABwfrVJkaGUEoNrYJYDv7VoP5SwEkrkD5eMZH0rOu7iSJFBG+Ic8etJu25aveyRIZHCAJsdWbKg9VIqu6y/aRKHCAnJC98+lR2s8dyreWp3jIKnq1PgdpDIpypUZA/8A101JMSTVx8kmXcymST0weB9RUcq8gElHbs3NELlLkSB9r45JH3h6GpWmRG3ldw5/3eeuKe43Pl6GJqCfMyyDDdOKqKgCrhOnqeTWnOm6UqpO0dD7VQDGOSQHop5NGgTrJxsKQUzsyVHzGmHaxZwWGecnjFSxTB7djsOcYBB5OOlQySAxgMCDt709EZKVz3b4CHd8L9PPreX/AP6Wz1806d4NsdU8F6W5t7aV3tIXZ4kcupKA87c/yr6W+An/ACS/T8DH+l3/AP6Wz15D4Cs4J/CegyhvIuBYQAHO3d+7X8/pxW1aVlE+YpR5pzPnnxV4XbS3JhimjjJwrODtP/AsY/lXLOkkRIdSM8c96+pvFFhpOovNb36eVKVI2OpVXPqCOo+ua8Q8WaOdBuVAikjtXw6xs/mKB6qeM/z+tVCpfcyq0rHDxPt3AjKsMEU0k7QDjA9q1tXitmiWW0KOSeWUbT/3z/UVk546Ctk7mAlW7bhiAwAdSp3ZqqcYGOtT2rYdTzwe3XniiWw47iFfLkZdwZehKnNLsBiJGQy9uxFKYxuLclc4P0p0IGznqpxx6VNx26FtW34mWPcCuJB7+tU3TZwMcnFWEEixkjJEZwPcU24Qkjnaeuam+paV0UlXPfHauqtbaaeUJbJE6NF5KqpAY7Rz9ckmuehATMpwypyB23dv8a6HSpJYFthEFLjB3gdvWibFFWZs6JLOkXlSwI0qJ5W5yVZMe/rjiq140rAsnluCuTk4LEZNWBeLHK9tFibzV3ht21lYHr3+lJezrdaf8vzvIxDEJlgVHPTrxgVKbNNLHKzyN52/ygqD+73pJLlX4w6oOC0ZOB9VNTXyeS7IER48ZGFIxWc5niBdCVXuUPB+tUtTNuxZEW7L2029hg7H4z/Kqs1yXLLPGBIONwJDColQS8xjbJ1256/SmSSmQAPyR+f51aRDYu8qD5chMZPKt3qN8dRwD27UqA5yh59DTpMZ+YBG7haYiPJ4BJwO1SRzyRgqrHaeqnkVGMZ5GRSUxE7lJh+7TZJ3UHg1CQP/ANdJ0NSMwlHzcOO/976+9AEVeq/suf8AJdvDP/b1/wCksteVkYr1T9lz/ku3hn/t6/8ASWWgD7/ooooA86/aCGfhRqg/6ebH/wBLIa8JiKwYBfjtg17t+0CxT4U6my/eW6sSP/AyCvn+zBmAdwOW3NXNX3R7GWfDLsb9rMcM78kkAD/PejUJWaIqoGQQgJ55qtDPmMNjhc8Hv71HNI3loNwP8Tcd6zPRdr3IJJvLkYvjIGFweKrxhp5F5K/NnApyRpIrKykMp49TT4IJIb0sc7FA+U/0rO51Uoq3maM4edEiU7VHD4HpW7pduZLVOmeTg9hWZbxh4DhsDAPNatpG0MozJhW4xVdTRRSjbZmjGpijAGSDyAuBTZo2RFJdvmBI4OAB1xUsBQHa4Jf75DH34BpZo5DudpMqw4PbjoB9aYk9dSKKxN4sYtYjnGRk5YD1qbTrG5W5YSNGW+6gXIcjvg9h71NY201xKbeASKWALSbto+mf6VtWMR0oAzIjysTgLl8gerfSqjAzq1nFOK37F6zeDT4mE0eXkXcWJJB7da4rWtb8i7LYO4DBA6YNWPEGrmSeUovB4APUD6Vw+uXTBHCMfm5bNTVn0RphcLZOpPdmF4g1B7rUJ7guxdTtUZ9utYltE07jLbiTjFXJ490gIXBJ7VPYQbZSCu3np39qLaWMEtbmvpyCP5Snbr61u29sjjDHCgZI7ms+HBKBWw3c9q17XKY5GCOT7+lSdkFpcEt1ActhOQAAKmktN0QbbjOMnGOK2dDsIb29EUkgRT1Y9BXb32kWrWqxQuXRIjgtz+RH9a0jSclc56+MjRmovdnkF9bAnIA9M54rDvYd0gkU8KAOPSuz1m2EF1JEWDZ44HH5Vz2oxx7CqDdkccVlJWZ28ycTm9Qtc4kUEhuTXPOpguhggA/eB6A12yNtjYbFZRgn2xXNatEs99I0QAyuSPRsVSV9UedV3sem/DbU4Y9CDNtM0AOB35712FneyXDRXHkGZGzhc/MxHt6CvBtDvprC+QbsRyAK2P51654V1VYZVMpZY2BRXHYkURfvalxoWpue7Ny602W8iubk2ywsrEmMHgj09jXK3EB8sfKFLngE16TotrbLZxz3E5jLOVMbtuVs+vr9a5nxJYm1uJXj8sqedoXhx6/WtKlLS5nh8SnN0+2xydtH5VwfMixu+bKdj6+1aMghZCNxL5B3d/8A9VR3dtuCyKWB7YNRPCC5XcyqVzgrjNYpWO2ST1RUlIkkcqF+Q8AjGKry3UYVkI2459VPvV2SHaSyhXB5K46/Sq91BGIWeNRt647in5kvl2ZQVkVQMhiSMMpqG6iJjbYwB3dB3FV7mUp5Z+7tp9r+9k2swKHn3oi+hjVi4u4kMxhhxIBhmIIHYUxJFkLRuFznNRXeBIxOBgEY78VTWUnbIhK54bPNMyl5H0V8Bcf8KwsMdPtl/j/wNnrzLwEqSeAdBEkauRp8A5Hby1r0z4B/8kv0/jH+l3/H/b7PXlXgdiPBPh8A4B0+36n/AKZrWmJV4o8jLoc9Wf8AXU0JbbzA0bNkddsmTj0weorm/F+hveac0eoRpeW3RS68x++4dPxBFdvaxF+RwpPXrV+Sy8xCrAbSOcjrXPG6PWr0Kc1ZnyFZaZfjWJPC8jqI5XMkKShSpfHykE9M9ODVXxV4H8QeGY1m1ey2QM20So4dc+nByPxr0X4weG/7D8WaNeQblFxKVVcdCMHA/P8AWvUL/RLLxV4SSKeV45ZYg4EsCls45A6Z59K641jwK2EcJO239M+QwKmh+WTGQTjgg1Z1zTZdI1a5sZwQ8LlckYyOxqnE5RwRW+60OOzjKz6FxEbYMnKn5j7gf5NLboc7l27Ohz19qshyYIgELqrEq/YA9RTYyLfz1UBmwOSMgg/1rHmudHLrciuCUmPlnYD8jDtTwpMbowyyKRkdx2qSZA8as3LscHPcjpUG1lYnJJfgmnuifhkV2LL5cJHGdxHqTXXaRpDzRPLbSMiDI2SEbSPT/wCvXH3j7rltvRcAfhW1pWtX1lsSJtwHRZFBxTknbQlOKeprW9mS7ureUYmBUSnLe+COcVJejy5EcIsYThHT5uvqPzqquuSGWSO5tI9zZ59c89K6GTW7S509C+loVaIKdiYUkEc8H0z+dRqi9HsczcNcTIjbUL7ezBevoKxb2G7MmJcqW69h+lehaeuiyWu680tPLICrsYphyeOcmq94lhAzRSxSRhSSEZh/Oru+xHKn1OAa1WIoZJVcd/LBJH50SmN1xsfzOm9zgYrsJJNK8oFIFypzvyGBPpj0qg8mmPIpDBTn512jj6GjmYnFLqcvkBNpgTIPL/Nn+eKZuABwMZ7YyK3biCEzM0Z3RPwrDnBqlJZvFKVA3MAcKeMVSdyWrGaFycZA+vFKInKhgp2+vanSl1Yhh3zgihJJI2BRjkdP/wBVUSR445pKkaRWjC7FDA/eGeajpiHs5dPmOWHQ9zXqP7Ln/JdvDP8A29f+ksteV98jrXqv7Ln/ACXbwz/29f8ApLLQB9/UUUUAedftA4/4VTqeTgfarHn/ALfIK8EtxiAhCcE4Xjmvev2hP+STar/182P/AKWQ14FYldgB+p5rnrbnsZb8Mi0jsiOvXjoaru7IBE3Mh+Yj0qe5YlR5ecDqelUsksrEKfm5rHTqep1JrdHjbc/RslSK04mLjMu4OTz71UtmRQd6jk8YrTXYZoiRh8dB+lJo6aer1RetkbytoCljjPHT/wCvVkSDzwSyiRTn8PalXb5MUeSJPvEkcVVaImQy8Fi2MjufSlszeFpbm1Jc5jaNFB3/ADM3TNOss3cRdgVgBA3sMgHsB71RDme2kcFsxgKB3XmtTTkOYlhcrgCRkP3XPT88VS1Zk7QizotMdVhzJtIX5VGRyPXnqar6jevFFLCNyoTwRgY9cD3q04tre3NwZ4lOQdmAWTjoo9a53V57cb3Mnnsw+4eNv1/wrWTaRx0YKpO9tDE1i4RMiGMA42565Pua4/UDK6TSjPyHnit9yZA/IJ7k9vpWpp2hpdaJPGpBlkQnnk1yx96R69WcaNNo4EKXcZHJ6nFPkOLgt0C4HpTZI5LWVopsl4m2t2xViIS3twqW9uzN/e7VrfozgcXHWxcspFJCscY6H1rdjdSVBwFx2Fc7cRTWTKJh8w6Y6Vfs5coBuODyM9KTKp1Des7ghwV4C8fN3rorW58m3O6ZyzDIUNxxXIrLhNwYHrxnGanhuA/DZBUflQnymk4qoizqdwLiXgbVxj5upJ6mubvpCpKKBx+Qq/eSjdkE+5z2rJndFbccE59elJml1CJmSybFZWJ55I9aruix27SEbiwwB6Ci6kVpc54HfPWnNtNvglWJHODVJ9zhm+ZmFdqYIGYAgsQAffOa7rw9eSGGHqcYOa5OS1l1O6gs7ZfmZ/u4rr30+fR7jY6fKehHSspvqejhXG3I9z0zRdWW1tJZG2yRsAGV+cD1FaOty2UunQy2O2SI/IUU5KnvmuI8P3qYEUryID0K9z6V1mi3MEsMttcwxJNnapkx09TjvXTCfMrHnYnDqnP2ivoZ5tVhvQkiq6lQwb0NZl6innlZcn5QfvD1rZ1zZDd8MXiHUnuaydTmXJ45VRtY/qPrUSsrouk3K0u5kRrLBcPJFyH+YLjoOhqG6csMKVDMCM54GPWryTGNwSCV2lVyOfrWNPL5rnyVBVCd+6obsjqUXJmZcp5shU5zjkgYBqqW8pVaMc421r3TGQq2xVyOBisuZcSJjcRn8zSRM9VqNL+aSWXLAZyD0qogG3y1GBnIbHWluD5UzbSSe64zxUcmfLLrlmHvVepzTXY+ivgCc/CzTjnObu/59f8ATZ68t8BA/wDCG+HuAc2Fv1/65rXqH7Phz8KNLPrc33/pZNXl/wAPJwfBWh5HzLY24H/fta3rfCjx8sv7Wdv61OvtJl8wD5dnOSO5rUjdZcBSMemKxGXcgkUYKjpViyEsLKxBK5z71ytM9SpTurpnB/HqxEunaROSCIdRjJyOcEgcfnXZaTo0U8aRTbzGn7xG6Yzzx+dcl8cJzJpmlpEQ268QkdwAQf6V2llfrbWlo8mHkVdjBe/AqG7M5FCbjotdTw39pPw8EmtdTSICdB5ckidJo/4Wx6joa8HXrzX1B+0LcC98NJsVkLSAbT2b1H15r5iliaJsNXdQldWPJxdNwkm9zU05gsZwQcc7fXjkGluYRHKske7y+oJHb0NN0xUcqzYGOemckevpXTyac6w/IFaN14xzj0NZVJ8kjWlT9pD0Oct4hukVRuCDcMnt/wDWok4zkDltxx2qd7KZc/KysDlSeAR0x9c0l5CVSNwWKOuGBGMN6VSlqTKn5GCT+8NbOnxie2T5O2CRyfTpWO4+bgcZro9FleDEZkEeT8rMnCntn25reRydTQsbG2n1A266g1ruGFeVOFYdj6fWtfRpri1uFt7q4tpEUlkdVyrjoclefTisaO5nXURJLIfPX5SeMNnjBHfrVaWW8iDQ+cuFkDNsQb1PqPUdqzuXFX1OiuCZdNEaw2mCpjcRkrkg8NzXOvMpRQ011bunGNodfrzXpHgPwfrniyZWW0tLeOLEhMgI8wEYyB0/+vXSav8ACfxI+nXFpFNYP5R8xPMQMzKewbbkYIPfFQ6qW50LDSkeDXemXV5KZbZ4bgdS0ZCE/hxzWRKksUjLKXVx1B5rudb8J6hoeopBqcTafI/3ZDkRn3BHasu/0y4DzQ3BhedOHVm+YehB/iB9QauFVS2M6mGnDVo5+G4EbgOxKH73y1oxGXzRJBO0oYFGCMMn25/r+dI2gzsm5IyuOTuPA+p7fjVCaCezdfOTYydCRwfTkVpdMwaaNGddOuRteJ7eUdWQnd+KE/yNZd1bwwsBFcLJ/wABIIpwvmZAkyLIvqRzUMs7OoUsWUDA3DOPYGmrkMjcL1DfhimYo49KcpGcHpVCG16r+y5/yXXwz/29f+ksteVupRirDBFeqfsuH/i+vhkf9fP/AKSzUAff1FFFAHnP7Qp2/CbVT6XNif8Aychr5+tnQwq4xjOfSvfv2iv+SQ6x/wBd7L/0shr5z06Usigg9OM1z1t7Hr5alytmxK/ykcc8cGq7sC4i53MQ3FSuR8ox0XOfehIUa6jJIwR1xWNz1Ul1JbYgu/H8WcY6+hrTlXZECwJfr/u1nuvkuSgOD0arTyK0CFy2SR25pNJanbT1tY0Udy6qzcBMhjVmybyd0c5/ds27jr9aqW2wspZtwHar67Nhmckgjao/u+1JaGunwhab2Mx3BUUn5T1xWnaTiIowBzwCowePas+3RlKHCliT1rRgxsy8fzjgEDkUJEVWi9q8j3Ns7xltp+90Uiuavo4Fh+QsvHzfNwf8TW1fXDfZdrSDoQCOf8msH7M0kgAVmC45J4ApTdx4dcq7DbZBcMsYG1QByO9dFuTyPKVwgUfeHH61lwqsHJj246EfzxU08c000bRAgtknPU/SpiralTSqehS8UabbXsMM1nF5Vwq4Zj/y0PvWToupf2XJsnjCueCDXTfZ5I4YzISoV/8Alp9KpXNna6kSZEyTxnoat669TnVoKz1RXuJrK+X5wEfOB3ArJFjOC72480KSce3tUeoafNpt2savvgb7rHqK2tBkaNvLc53nBPeiL1swqQjKHNTZhQ3rFl6bc8KatQTMCxyq/U9RWr4n8LSSM11YKQAMlQOD71xE73UcnktAyuBgk/zq2rbmFPE3VjcubxFOXYEDpisC6upruYJaJuLN97+FavWmkS3ELS3ilYRyF/vVNcsE2LbqqlBtCqP1pPQtNzep0PhvS9IsrRpL0Lc3DLglx39q5fUooI7mRbLJ3EjaADx2+lb2haXPqqu08pijXGFHetW70W1sowkMZ355Pc0ndomkoKo49WR+ENAOmJ9rJRr1xgK3IRfb3roNZ077RYNIX3yrlxgdayJHntZItjOF2AMpHFdHbStLp64G+Pbyev8A9eldP3S6kJU2qiZxFt5qOVQEvnJC8YxXV6GRdKQ8YZiBgyDhT+HNYV/F5F/LhOAMjHeruh30sNwskcgjbG3PZh6Gppvldjsr3qU7xN3X/tCiKGANKEAX52Hyn1wPSuW1CaTzmLIDFEfmycjNdld3gaEid12kYJXncewrlch1KeSg27jk9SDWk9WcuFlaOq2KdyocKPMIIA2DPQGopEjVAq/KR1JqZcBllcYj5wO9Vr1mK4CsOeoqUups22+VFZ9ixiPJGDkHNZ0mMFXyMH8qvMqq5DOGOeD6VSuG/esAcoeDzSM5WM6RAZW6A9z61WZwroqg5b7w96t3asqhdxY98Vns+JJDJ2wR71S0OaR9H/s/Z/4VVpmev2q+/wDSyevHfh7cg+E9Ej3DIsoR/wCQ1r2D9nw7vhPpbDvc3x/8nJq+ePBF4bfRdJ+Y+X9lhz7HYK1xDtFHl5W0qs7/ANansVnIZYDgjKnArQRz5OQArenp9KwdGkVkyCfm6j3rRt5t8zKcYXiudSPUklJtLoeefF2GR4opWc7UdSMepyf6V2Hhl/N0yNiSTIgbd1wMZrF8fRJc6TebCC0WJcduMZ/QmtLwPdRT+FbWYSYKR7SB2xxz+VTyrmNL8sNTk/iei3MSQtyuclf0GPx/nXz14jtdl+gjYMu3JKjgHJzXtPxK1aM6u8dq/wAsYy23sfXPf0/CvPrvTBc3B2kPvjBHplj2ropuzPGxsObU5LTYxHIAMq3DBuoz7/WvQvBl3Bb3hWSCNtowsUp+VlOdwB7e3pzXM6Tb20eo/ZrtW2yoQhXruBq/PstJtgkVby2bML9Gceh7ZFVUjzHJRm4rQua3piQ35t0d3UPgPt++p6H+n5VhX8LRWMpwGDkYJPKkf45rVj1/zZrdrgK7rwOu5lzxj3XnjoRx2p2vvDercyIEQCEMuOAwyOR+f4cisVFxZ0uoqi8zzuVDvwc9a3dJZ2WNTGJD1G7kYA6VnahG0TZK9Wz+ldH4QktxdI9wCFjJPXANdMpXjc4nT5ZWIrmOOcRm3/cMctk8gH39v5V6N8O/DlvcIby7WOS4iJQLkHacfdYejDjNZmtaBazyxz6LPu81dyRt/EQMnaeOfaqPhjXJdGuJ/LiKJKpjnhdfucjlc9DmsZPmVjqpQ9nLmZ9C6FqthpEENvZIRIVHkxZ+76jPoP5cV2NrqH2hEui6JIPlkRf4c/0rwPwxfS6xftfxxxndJhcHpjpx2yOvavRNPvHvHFq0SjCkxOj4PupHt9a54ycdz1FhY1NX8zp/FXh/T9cs5bPUfKmjYEocfNGT/dPrXzh488HXHhi4QRo8pQlo5FXIMY6/Ue3btwa96g1BPtgRw32uAbZEkGGx6j1FWfFGnW2v6SVcqGByjjnacYz9PWqdndx0NPYumoxlqmfKFvqnk6hEl5KvzYHmMoIZD2I9BUkzRXlvLYL5Szqd2Bho5kHTaTyCO4H5U/4i+HptA1mSy1CDYhfdCcZC57A/3T2rm0VrSKPy282Lv/fjPYiumnK8b9TxMTS9nUaWwzUdMiV/3WFfGfLPcHuPX8KyHtH2PJHtZFPTPI/Cum1z7NeW6mGJ01CNQXUcrIuOvse/FcyXEgLZIkHO71+v+NbQbaOOpFJlYgg4IwaSrTXCuu2SCPd3YAg5/Cq7KRg44PTFaGQ6RgyJwQ6jBPqO1eo/suf8l28M/wDb1/6Sy15Z2r1P9lz/AJLt4Z/7ev8A0lloA+/6KKKAPNv2jDt+EGsn0nsj/wCTkNfONg2EUnGTivoz9o//AJI5rf8A12s//SuGvnHTATsB4XGOlc9bc9bLXozTVvMdY+wOeO2elXraIK5D4JPHNUbf95PuV8+ox6f/AKqvll3kqDisD2bO9kWvJ/dDaAx559KYSphwOWzgk+vtVu2ZVgbOckcUxVjBBABDnLY4xTZrTl3LEUWxN6ouT1Ge9W7aR3QkHnptPf3qoJQoCd1/WpYpie3ydORjFZnQk2XZNu5TghRzyc81ds5klgVjkA9Oay/lZl2lWBBO05Aqa0l2LsXciZ+71ouEopxNSZbd5UIKqE6KOf0qCaF3OwLwThsdhU1vH+/3IgP+1nGB7irNwUMMr7N2BzlsAfSqauY83I7FDh7mOPzN6gYHGeBzzV22VIdrNvbqy4P5/wBKpWsyy3TiOQR7R36n1rQJXydjHBPzEk4wCO35URKm7e6RX2ZI9wO7JJz78dqraeixR5kUjqQKsyXEccPzbeR0HYf41HbEyRBcYGOM9hUtu92ckqtk0UdQhNym7aNinI+tJY2UhmRkAG7oelai7HYgchOBiprSPDuZOnbFG5FKrJKyNK1cLaYGHZeCpP8ASqzxWN3Ljy4d/bK8j15xVqFQRtXgMMHNH2ZUQvCNuc7gatEcsbt9TnfEFm8RBXaYj1wO1ctJZCW45BCAdR/Kuz1WGWXlnJXHGD/OsZUMYkXcDtGMe9S372h1r4FYs2zCxtotiEgdTU7XBm2yFf3nbPpWNFeFi1s4JIyRk4yK0rR0kgcnIwMYJ6j1pXbMUlTeu5qEfaokBwMKPmPQn0qPSJJbaeSG4RwV6D+77e9Q6VK2WQ4Uqc7StaUeI0kuJQ0r4xkd6rf1N+dNOBlaraNdyOysRzxjpis6NZoYkRAkTMcFpPun8a6WEpIod8qN3Vhx+FNW1gtrjMp3o2WIJH8qOTqjVVuRcjWxjiKaS3CsqJkFmPUH0AqsyosPLKkuMnnJNdC4jabbZQPu4284SsTVniClIwF2tgkdCfY05RshQnzOxSldWVdzhSBnHrUdyrSKAOA2B0pFKeWXXl1PGRnNOt2aXeZT82OMdqguWnvLoYeppJG+IRtA/HPrVTzxGqbhu3DqKt6k7STrGnyEnLE9BWehMKbZPmfJIFKLuRUbcVcinnPHGABnNXL/AEloBfSfvhCturpOyDy5CcEgH3zwRzwazZt7syQRFnJ+UKMlj9K39YhzprmFLVbdEXaj20gkU4GfmK4znPOa1Rw1Jao9p/Z54+E2lAdPtF9/6WTV8y+GlkTQtN4PNrEwP/ARX01+z3/ySfS/+vm+/wDSyavn7QrdX8KaH1BNnAT7/IKeL+GJ5+WK9ea/rc7fR7wx28Sg42/eOK2Y5/MkJQFR6+tYmkRARjByCOla6kLtjA5x1rFI+hjCKehREP2rU7u1kXdFMpXB9MAEVzvgySTw3rFzomq7o1GWjY9GT+Fh9R1+ldg8Lm5juAcFflwBUni3QbTxBp6qytDdwgmOdPvKT29weMimovddDOrNX5Xszw/xe0762QFBXLHf1+U/Ng/h6VmW2p2keoW0UscOwW6bm9COcj37Vb8b2epaDrlpb6hFlYwYhNHllfI4OK8qutQlklJzjAKgj0rajG54eZT5bWNFLl7q6aS3yHLNwp6Z6Gq99fvJL5jcuThwfUdwarWjPazJ82ASAcc+4NO1CA/aZXTG0ncCAcZ7iujqeVZ2uTpMxhBJJfG6N1GRnuPY/wBa2ba5iv8ATXjeXy5bZcpno2TyuKxNGTzblFQgSf3W5B9q6i40q2YJNbwtG7ben3Sc8hvQ+hHWs6ljai3c5zVULKpJ5Y+vQelSaUzpC8uWLKwG0Hk+v8qu6/a+U6AqcuDhaowMbZIkB+djuJ/Qfy/WohLmgdFeHLVO5sr6aO0jEF0jwiQSBSc7T2YfnjHvW7daPHr8M1zpkYlujE0kiJwTgDcAO7A8jHUV5/Z3KwNu27lBxIinGc9cfzruPCkrrfSyRNs2CM5H3gpydw96xaalc64VFKm49Sn8O9SksNbhgZg8UsgwR1B6fzr2qa28xWa1JV1OSoONrdQa8O8Q2C6V4pK2xzC6i4gYcErn/HNe1+H9ftryKzkyu6ZQjL33j/JrOoj0cDV0sXdTAvBD9pJt9RVRscHqR7+hqzouoSA3Nrc8FYy2ezH+lM8XwSTaUHt0HmxHeCDk/SsfRLo3xmkYNk2zK4zyD6+4rKLtOx6Sjz0W7EHx30e31Pw8l06qJIYwfMIyQp7++DXzXBIYJWViCyfdfHDDuPxFfQnxZubjTvB7285BLxqiknnBI6f4V4Df2yHM0LHaW3jA4GfSurDu6Z83mUVHlS7EN+dgiubVzG2dy8/cI7fSsi7XzWM8Shc8sq9j3/CtYEXEEkRk2kjDRvzz22n1rHbzLeRTGrLIoPzAcMPp/OuyJ489Ss2ehOcDihCAcMSFPXFW3PnwedGgWSNsMqjjae/55qka0Mgr1X9lz/ku3hn/ALev/SWWvK+CBxg16p+y5/yXbwz/ANvX/pLLQB9/UUUUAeZftJ5/4UzruBn97Z/+lcNfN2gjdBH3zyQa+kf2kzj4M66fSWz/APSuGvmXw9OJB83Vl4WsK3c9TLXq0dREgilO04AGRgdKs2w8xmwDwe9RWwVkUgjnIPPSp0YwswI5znOegrnse2n06loJIWJBwc9KIpAsj5Hbk44pwkD9sY6084yAWyB7Urm8exGSpky3Rh+VTxgumOueV+lQTW8k4BDAMBj0zU9qswYLI6bEXt1qJNmrdkO891uY/kA2jn3q5brmVc5TecZFMFvvYlSRgEg/4VLZkhNjEE5+XI61NmPmTWhoxZMLBm8tx0PrT4d4nO07ic8npTQSYMsvDD5go6H6UwTCWMKsYJBzuDda12MHJ2K7OySsrIMrndwMkVMl1FlEuidjYJ3DcF46U4bWDyuhD5wDu5FUr6chVRQBk8n1o2FKV9B9zKJSyCQGMPx6n3q8JcRMm7DbQACOprAhxne7AYPOepqSW5Kwtk5Y8AjsalmXsXLRHRFsHluQBnbxTbZ1a55lURgcKB+dYkRupo0wrD+99K0dPt38ySPcVDDbu7D2qdzSOHVNO7Ny3u4hKF2bkA6jpVl5FkjPzqr47VxTNd2cp2kqAcE5z+lXFvp2jUu3zHjIHSrU1sE8K9HFnTTlJoyruVUDIA6Vzd6SqugAz1BJ/rUUl2xR1Mm0j5lyO9RRJNOqqzDYWyG70m7s0jQ5FqzGu3EUu8jbKOgPT3rWt5UEYkUZYjcQDx+FUdRsgx2lzhCSvamwzxm0jj3FWB7Doaz2ZjWV0mjoNPmEls0wb5lGT/Srq3JVEYGPbj5ifX2rntKxHZXKLuDAg5z2q5BcKWZZWAwAV74FaRl3MqSvJmzE5nVmIzL6EcL7060MYDBpN4GdxYZB+lZl+HMa+U7eU3A25qBTCLfDeYhIACg9T61fMrnRa6NtbuzRZjEz7iPlH1HbuK5S8fc4WWQn0GKmd9kwZUbygMnBxmqd0dxaRwV57dqzlO50UoKDuAkcQpGF2uGyHBxkU5GEkjBuD3P9ajEi7QxDHIwT0xUE0hjIAUbz0HpRuTJOQl5CNxbPyZ5zWNcEGQlc88ZxitO4cMhUnMnWs2+24ByT69s+1UZLsytnE8flM0bjkMDgg/WpLu7u7l3t/tjgEEsJJyFIH1PJqrIGJDnr1Oa6bVmCaUwSyZBLbmRl+T5SAgB4OQF6+pLc1STOWq+Ro9m/Z9/5JRpf/Xzff+lk1eI+Dow/hzQ+AR/Z9vj3PlrXtn7PH/JJNJ/6+L7/ANLJq8U8Hxs3hLRWTqLGD/0Wta4j4YnBlEb1p/11Oo0xYxcGPeuSela9xEqLheq85PesWyj2tuxknqTW2sBlSMudmT/SuaN2tT6CfuyTvoT2nlyqUlO1T909xg9qY7yFGklDEZLBl7jjqO1WIoEEq7Ay7P4scVcKg2YxgSbcgL3rSxy1Jq90cV410221pZFlkQ+fEViYnBSVT8pB/EV8i6lbSWmpXFtcoY5Y5WR1P8JBwRX2gII7iKwknjXCuzNt7k8HI9jXgHx08JXlp4kl1NISba5x+8UcMwHOfQ960pTUXqedjsPKpBcmrRylvpP2ywiVB/pMK7XAPUZypHv/AJ71YgtvtKsLiNVnU8ADqR1B+tN8K3aXCJHKwS5h+QjoXT19yK9Ag0q0ud0l3EGV1+SZOSGA6H2+vPvSlJp2ZzwpRlDmieeLpokYxR/LKuNjL1IrptB1BI4E07VLdnk34icDox7MKfeQ+Uq+Xh415+YfMvsD/jVmMRzPCsqJLtKAFW5TBz+I9u2OKfNcwcLPsVfHGjtb6VYXEmFk3rHjqWOccetcJcMxuZxwfIxz7dCK9i8ZzLfeEJxEXlNrdRsHxkLlGYn8wM145aOI51kdsCVtj5GRgnnNEI8q0HVk5u7HnfujmAD5y7KeNw6Yrf03VjZ3tg6NuYKFfdyCp42n6Y/Wsa/AiuWWIYSMAJkdV7f1P41Xu5RG6NuYgjbkc7ec02r6GalyvmPQvE08c7aZM23aqtFtPBj3MCBnv6fQ10XhmKWTQnurdR9ospghcHqp5FebXt617BCq53eUB7Pjv/OvTfhlPdSw6nYxQ7jcxxur9FU7c5P61lJJLU9DDSftPcPaNAjjv/Di3JB2SRA4Ncpa2v8AZut7gP3Ex2nHvXX6YUtNDWzjPyKgKkehGRUVjpyyqzyLgAEqW/nXK05NWPWpVXCM3J6M4D9oAxf8Ixbxgr50s6KM85HXpXgyH7PtW9iAAzHuB5UH29M16L8WL641zVGs4OU04F32+vAyPoBXmdwkguOiyJJxwfvevB7110ErHiZhJ86XZW/Uy76AxPMoLEwkK5J5KnkGqsk5aMRyll/uNnlW/wDr1q+ILZ4Yba+8v7w2Oem4jIP6VhTFGjUfPleMHH866o6o8maswtN5lZFUAsNmc7cHqOfXIqGRvM3OeHzk4GAaaDzkdRQ+DIcYwTx+NaGY2vVf2XP+S7eGf+3r/wBJZa8qr1T9lz/ku3hn/t6/9JZaAPv+iiigDzL9pQZ+DGuj1ksx/wCTcNfLWgPAqAFwHA4wO9fU37SOP+FN65u+75tnn6fa4a+SNOT7PehSM7v7p7VjV2O/AStI9FsSsMKyBQST3HrUkgInJySCOM1Vs5GltPLxl1A4q+cGPLFQfuiuRn0MHfUIZnWUq5AReBV7zFl8pycEenpVZl8mQEgGM8cc/rVqz2gMzDJPQZ4FL1NeZWuTQ/LJgjenY9MCr0Fsru7IR+JqmsQOwxt8p5NaEHEA+bIY4xj9am5cn7ugBlZmaMgEDHPQ/SmeWXAQKQ4PLKM1aktFi2khgDyVxj8alhj+zKyOmYzyTnHP1pq5m5W1RWmuXEkcTkNIowOPmIHrUQmQECQtG/IIC4xUl3IrTCUqDKvAYHpWLr2oR26sJ23NgEjOTmm7kqa0RZmumRmjD71HR81DJcMCdzZwcjArk73xHKI2FtbSMDgZxioIdcuZsb7SQcEEDA496ST3E5XOpkutkvzYPO72NK1wJSJDlcH7oPWuNn1m4Ybo7SVghwM9Krpr13M202zgjsBQ4yZ00rb9T0tNTjggKqxLZHXnitK08SxLMRIqIn8Ix0rytLy/Y8W8xxzwp4pRqDBsSgqw9QRimoy3BuD0kev299p15uMxDvnGRVq4s9MRcpISTzjt9K8ht9VkhbKHBPrV6bXZzbjc3485os9mhOMbpxnoehTava2sD28UULuy4O4cr6c1TTUoS6uCu9fm215tLrCgPJNIPU5PX2qH+20RFJlALdB60OMtyLw1sehNeRTNz82AfzrHaX7PKjJgru5B75rAt/EMcSjeCQeMjpVqK9huHDl1CDnk8mps3uEpRUWdTHIUtGVUDM+Se2MUzTpmd3EyEPjAYNkCsaPUQkbPIQAy022vlJBjbbg9OoNN7HND3djtIjiBWZ22Y5xUkMcZhYu4ck5VSeazbdxJGDvXDDmrEU0wYIm3cpzj1prsbNuxDcIzBlZvl7YGMVn3bq4MakbR1xzWlel5MoGKluqjjmqeEhQh0y/OPek0b056Ga0zqvPfoP61CJDIy7jhs/mKS6iaRvMG7LUjMY4jvVc57jk0kaT0WgjjBbIPc5NRvEBGrEcAZGe9PfzJom2MB25qO8JAjULnaOMmqWmxyydtGylcqWiYBBk+npXSXaxTxz2El5Al7HAPOkFq+7a+wEZ3YycKCQPWubZiQ3IBPT2rotSntho86W07brdAyS/bCSHAUphfclhjsRVxZx4hu6PZfgBE8Hws02KQAOl1fqwHqL2cGvFvAgA8LaKMkZsYCef+mYr2b9nklvhLpJJyTcXxJPf/AEyavFvBS/8AFKaHk4BsoORz/wAs1rXEfCjlyZXrVP66nX2uM/IpG0ZzWzEAturP2GOOpHrWVptvsG0NkE9K0g3zAMCdrZII4rFaHsVHd2LFrJvZk3AY5XA7e9WJZhHbuqth/uAe/bmqsRVAHwoOcYptxKwkycE8YB6HmqbOdpSeg+O3Z5Y14WKRWBVux9R7026sbbWraTTtRhR9gwVYeg4bmpzIDCpLNhT933qS8dMQ3KkiVDgMOpU9iO/akiHdngPjf4W3FpdyXWixblU7to4DD/ZPY+o96qaDc3loPL1CJ4bkEYjmTakqjjg/3v8AJr6FlkinjMci/f4K87T7g/hXMS6VFPcXNtqEX2i1f5gJRyuOMg+tSxqKd20eYnTYGvxFPGPMfcx4KlD2H05rrW8C281n5wky2wKGHVDj1HNLLpAisRCkkN1bwliGcANEp/hLdfxrr/BEllqGj26z7FuIl8soT1xxketJanNWpWd0fO2oa/K1tqGmMfKEoU/KM5KoVwfrnkVx1w6xefEACzHPXBUjg4+oq94hXyPEU6LkMszfdOcYY/4VTlLifzgpwSykf7JBH8q1i9rnJUp/FbuSyTCe3tHRcyKPLkJ9c5pZVjlmLxcJGQAp47c/1qvazKizRZAVk3A/7Q4/DNSWhDoU2kAoTgdScf44q3e5ho9Bui7vtb2hYYQ5QN2ORkflXuHwWuVQ3aNjeFQYBzwpIx+orxXQIkk1RGlByzdfU16r8IZxH4qeI/cZyCT1wRx+oqKlmzfBe7I9l0G1lWIPcDGxmjC/7OeKn8X6wmh6PPK2DKw2xpnlmJ4FXFb7P57yfLGkgxn0Irh75z4m8YszEPp9gwQDs8pHX8P51ztWVketKa+OWy/pHF6jocllai4usyXlwGllOOhBzwfYH9K841m1EctysyfKSHwB0z0cfpX0LqccU8s1u4ywi8xSe2Dg/mBXkPjKyVbQqV2SRttBPOUPb6VrTdtjxakpTupbnE3LNL4du4spII2EgPU4HXH6Vy4t1V0ZmzA6/f8ATP8Age1dbZvAZWjYHZIrK3HYjpXNMyfYpLeXcQhO091OR+feuuJwTWhmsDDKwz8ykjIppxngcU+fJcFjk4APGOgpg5BHOetamQh616p+y5/yXbwz/wBvX/pLLXljfeNep/suf8l28M/9vX/pLLQB9/0UUUAeV/tQkr8C/EpU4INqQf8At6ir5TsZ2nFtKmZFCrhgvO3vX1X+1H/yQnxN/wBuv/pVFXx54IuWnsWhd8mI4AHXGOM+1Z1FdHRhpcsz1CyZVzIrfKy4BHerU/EUfYntWTor7k8puB/dzWmg85W3n/Vjg+lcc10PpKMrouLI3kxrgEd/896twhXyUPJ6gdqoWq/KzOdxHTjpV2zdkAJGGz1I7VL2OmPkadqzMF2HLDvWhDuMi+aCBjghc81SsZBgtkHGT7VoIclOeM5x61AORo28YmTcx8zPQnjFQzoQm35m9T2NWbVgx4zjHbt702dVDFSzknoD3q7HJJ2djmr23llEmwiBF5JNZ0WhW6qZ5g0jE5VpDXSSKHJa4+ZEPyoOn4+9ZuoT70CuBkcjH8qkI05VbX2OXeBUutpC43dR3qVrOJ5DhR83PTir0tsJSJGBJ/ug0lr5kMx3KOeM56VUWzovbQjh0dJNoTClux6CtSDwumxBEmJurM3etfShCSnmDnbxWhczQxldkrAnC/hWqknqZqpPm5YmPc6ettZLHDHm4IwB2NV18PrIn+lQKGx2rpdMiRiweRT8+ASeMetW9QW2Vox9tjK9cg9/Q1cdrsUptS5DjrnSLARrDHDHubKsccj6Vj6hodsAyRISyjHXg1102nxTKWRo2Zvnzu/Soo7BYbuQCWPzAMqC4I7/AOFTc0jGO99Thm8NRuFZIVTJGCRwabL4bhjZknjyqjOAOhr0G8imFuCyRHb0OfbNZ97afbFLBlViPl+bv15pc1i07ryPOZvDdtEZlcHAwwAP6VBLo9sjfuBMmB1DV2dzYyiQSsqknrioreFGXylUZ5J3ckCo9pfQOVJXuceuh3jbG+0yFT2PNa+meHpHDslw7Sgggk/0rdKDYCAc7sDitLSLVo9pKjdnJH1qOa/Qynrs7MxIp7izYRXa/KOFYDg1saYNsxdJN0eBwfWtXUbOK5VecShgVI61RjhELuhUK4ODt7+9GxnGtNLlZehtfNkEwOZD1FNvbQR5bO5z/DjGK1rKUwwjGM/3h1rE1eR5ZflOTnPXiqlojWlzVJ+Rj3ICRnHyHNZ7B5XJ2jrgEcYrWYKFKyA57c8VlSTqsoVVJPoO/vWd2db0RHLI0DHagLdP/r0yNi24kYyOc9s1Kg2yEyDarZxk9aglfLbeNx9KtHLN3epVmwWztPvj+dbXigXEVhIqjUhCYkOUhUW/3R36gfrms2IlLiPbCJjuB8ogkP7cc1W1qaR7CdG0SO3Df8tAkoKe/Jx7VpE5az1Vj6C/Z2O74RaOfWe9P/k5NXjngpUbwnoIyQPsMAOP9wV7F+zn/wAkg0b/AK73v/pZNXj/AIBRv+EU0VcgMbGBl/79ita/wo5cn/i1H/W51entHEqJ1AJ6itOZigUMRtPUdazLAieLIA3DhgwxUsxVIVUuSq/xeprnWx681ediQ3ChOuccE0vnhYiAeW9eaoNI6yoqDCEcAjvT0hllVmym3tilc0UY21NJJw8HBBcjbuAxT7N3yFlUkcgE9KpRh4pQXQ7GHY4GfWrJG84KZQ8gg8A0XM3FbItAuWeBmyCvCn+L3+tIVaYeWD8yLlN/UGozCUwMnfnKsOufT6U63uDFIsknO37+BmmZyjpoK2nwX0TPLCu9chlC4Jz2NYnh7SoxDfIkzKIrg+WBwOcZrXv7+L980EhVwvbjOayo7iW2vXm4NvcsFdR1BxnP86m6uCoya1PljxUskXjbUIeQVu3UgnJ+8etdb4Y0y2ur4R3UXmQncrBR90FcA/gTVDxjYlvizdIiYDTGfAHbBbOK7T4cxG38QRSlPvRjP4gE/wBKc9o2OKPuzqJ92eTXiC2ldAQrb2Dc9hkY/MGmW8jQNG4AKjK4PuK2/HdqbTxZqcIj2CO4fC9MBsMP5ms0WZk0+Z1JZkwx/wB0EDit1sjz5K0mMtx5VxAzEAGQD0zxg16R8OWSDxZbNPLtV5xnuCSrAfrivPp4t5tVQt8sjBc4/iNdBb3DWckcgJkjiYMykcjI9fqKieqNqTcKiPfvF+tHfdWduwNzcCNYE/2u5+nGaseHdK/srSZIWYF9x3yY5Zj3/WuX0Cy+0WcGq37iS9nVGQA/cTsB9a6WKWZ7Z0RmLeaSe5HGawk9bs6a0uZJJ6IravLDp8trduQ2QyN+YNee+OcyxM8IEtuSVIHVfTH8667xZA0Ngm5y7NICPqOtcLfTu8Up3EBwCUHPI44/Cqg7GVWEWuZanmM08qXasuMqwyAMg9sGmSwh7u6PyYdA5R1zjOKs65CPN8yM8A7Tt71Tefa8cmdgMeMHr78V1xZ5M1a6M+7snCZaLn1XnjtWasbKwO0kAjNdVbMjxTP9pCZG1gTg4+lZ89spBcTxSDO3KNyTzzitU7GVrmJcKVmcH1zXqH7Ln/JdvDP/AG9f+kstecXsbfudwJO3aT64r0n9l5Svx28M5GP+Pr/0llqkSfftFFFMDyr9qP8A5IT4m/7df/SqKviDwVc+TrCxMxCzDb9SOR/Wvt/9qP8A5IT4m/7df/SqKvga0ne1uop4zh42DCk9UOLs0z3HTz9nkXJBWT5utbkBDozbwWx9wd65jTJnvLSGRVIbG5QeOK3rOLzUWQrhkboPyrkkj3sLVurF+F2KHll2/rV6IGRF3LyepzVJ2+baAME/KKsxyJHtHIOcZboKxkrHpQaexr2qeSdz9xwPatO2kSXhQQUHU9PpWTG6sgDHpznNTwskaAn5V6jBzmp3Kk313Nv7SiKjKf3gGOD1qQXB8lnUrvbuewrD8/CszDocU+O48lC28nJwQad9TJ0r6jL2ch5I1BYD5j2rCuLmR5MRrgD14q7eS75CQAhYE7qzsZmZjIGUD86i/Y76MEl7xbeQssWBkt6dRTEdhKsiDPU4J60xN0UoA5GMKc1YgRmldGPGPlz2q4ydzOpFGhbXD3BO5NuVycHvUF1K6Pz06j60xDNAxURmRMdVpt3OJMCX5AOg9TTb0MYS5ZaCG5l+Z85AGQO+agN2xUCIFmY5/GhENxJtKYU/rVy20w7l25Ue1Tyqw51+XQoy30qpteKQHA596fbtdSsz+WwDdMnk1rXH7ryxjzMnAb1I60CUgDcihCT8w9KLJmX1idrJEUTSkAXAPtkVPDIVhZcAL/CenFD3briM4dc8H0qwXj8rb5Y3euc4ptIUqj2ZQuSWkjMmFVegplhATdyuAAMYB7ECrs8fmSAHa3OTVmJ4ocRDbtI4OeaLWJbctEZ1tAPPIJwCep6e1XoJvJnZd3yggg1S1K7RZ1WBQoJ4z71VuZTG7EEnjn3oOqFG6u+poT3zLcHKKOeCD1FWkliupl+UeaBgf7VcxLOzqWcYPTFaFjKGjDoQJOOe4qLsmvQvG50Em8QmMIrEcrzjNZtxI4QK6hPb0rS8yU2YkYDzCMEelY92HUAsBg9xVtkYfszMuyQ+PvIeSM1TCjLEkcHp3ArRuMLtyMknj3qlOuED4B/vCkkkdE3dWKrTM0u91JUEdR2qu22WZ3bgdAcdasTEtuILeXxgGq+VMZP3XU5G3+tWcraRBeXDQmMwlkZRhGBwQfqK2NVns59CvNkwYCLarvdSMzEhSp2E4JJ3gjHGKxJUEjRqzAStkkMQAPxNaWvywx6Xd3SSqJri2SJoDcxlEAxyq53EjHAxxk1pA4q8k7HuP7Oox8IdHwcjz73/ANLJq8q8AoknhHQGUbWFhAGOOv7tcV6n+zic/B3RT6zXv/pXNXmfgRQvgfQcONzWFuee37ta1rbI58plarP+upvLG0ZJjKiN+xOMUydFkJCsyleCBjipkkTyiHBBHTikaPcm0ZXPYHGa5j21dO7K6pxhSxXvzU9rtGAAVIHQ9qXau0CQfdJ+lPiDocnkY7c0kVe+5OQTCFIycdeuaikyuArYUnJwfu/h6VMgRoyW4OOCKMrHHkIP971NInYXeAcghgwyMHtVeKZgZcsQwO36j1qOEM28fdOeF7YoYMBgYBPoOlS5FqK2ZJHErAq6hjuBB7j0pi2pkuS4wqIclfT3qxBH5Ucbg8KefTFWkK+aXkI2Fct24FCZjOo1ex5H4s0ZY/iVHdxYEk1kyuD0XOUyD/wIVS8N3NuniHUFadoreJ2RZY4xITgEDCkjP8Ndl4ymt/7Rtp4AHmMcgIB5CjnH8653wd4QuJvCj61fxsiTXgSJcfM4YgZH48Z9q0SukjzqkuVyb3dkvU8v8TJLP4iv5LiRpJCyl2kGWLbBkn8qn0qANZ3iCMtIYTJkjjZlcmr2sQxya7qDbg4zIpOOTgEH/PvTdGdUsIxFtfdBLubOcptBx9BxWsVdI5KrUZteZhPAFkszH+8DMJmHTAU4x+hrbkVJYG4VVmiU5GTzz+mcVTsdhkkkGCBCVQMMcAbs/rS6ndhLeySNsgp1GBgZA/w/KhrQnn/eKx694SVpdAs8tmXYgAPQLk4J9q2ba5aO+kiL/ekUEYxtHr9MYrM8Ez27aBZncBIIVOc8sVOcfSrekj7Xd3nmHO8qxfqR04FcjZ3XUk7knjJw4QjaUwVTn7x9P1FcQ9sIryO3dlDtDmKTsrjOQf5V1HjF5lWFo1BiRyAc8qDjtXM6ncRSwuyuUSF+cevWqj5nJJycbLY4HxBaIkaM0ZIZdw55z3BH5VzVwCNPjklXDrKY8nvwCB/OuzvponieJsmUDIOMbvr+FchqcQWCdWGTncuPXof6V005dDkmrlSCGFFaSaFvLzwU649CaqSIFjlERzuOR8uTVVXHKlirgkB+RircSI7QxO2Gzzlcg5roscpMEZ4Q8sQ2qw5Jxx9BXpn7OBH/AAu/wuBEsfz3OPlwT/os3esHQ9Et7zQrqe1iuL28t3jC28KANgsdxIPJAAxwOrDPFdv8Ho0i/aM8PRRTyTJGZlG8JlP9Cl+QlPlJX7pI7ihbjex9pUUUVoQeV/tQjd8DPEq+ptR/5NQ18Jwaey3KBgSCeuK+9v2jIhP8H9Zib7sk9kp/G8hFfLdv4dFxBLZlFE8Y3xP/AHl7f4VhWqOLsjoo0lJOT6FXw5PcCJLdwFEQyg9AffvXTabKFI3MQC2M5rm4VksRDdwQPJDwrqeqn+7WxA3nIzICFK7kHAIz2rGnLmO1PkZ1EUWCVJACn86njRTOSRuRvWqWk3QeGNJn/eDr61oGU+YFI4zxj0onA7aVZlrzY5EIVcEccUzJRFVWzzyPSo5gIDk4G7nHcfWpIVM5V4ycdOaxmuh6NOV/eHmVwihgAADUQnTZMWdm44A55pJDs3K7Bj0xmqsMJcnc20N1AqdUbpLqy7NgptyCB0qlEU87+LOOuKsPCI2WNjwetTeTE2Edl8w8gD0oTL51GNtytKu0pIqHB696uWjmXK7dpJ4PfNTWeUDo+wr79qv2lrFdIGCgEEnIHWi7Zg6l09CiI7i2kGclTxyK0o4I5oNxVVc9VIzzU0yRMFwwBVeSelZctx9mb5X3N0GRwPeqvYxUfa7bmgsars4APOdgxj8KmitztcrwW/PFZJu2aLDOAMdu/vTo9VkwDwBjr3PvU37miwcmtDQkgXy1BJco+VUjt/k1NLYoUVA4Abr9azYLm5bljtEmcA9MetLDfSwSE3Lq4Xj5sEE0XFLCy6MkXTlV93XBx14NLcQk8BWJ6naOtW4L9X+XYFVuQy8n8qtrKkrsu4cDI96druxzyjOD1OWdZRcZUNtzgDOKVIZ23PIfmHAFbs0SRsmEBPU/41Vdk3suD83oKNUbRqPdIwZ22ShpAODj1qndSkuVDdR0HYVvSaem7eW4BJ2jmq09rCSjNw2c/hS1Z0qvG5lxRSTRvhSVA+UntVnRx5coDfMwIyO1XW5GyAAJ054qKB0tQWIIZjgijQTqOaaNh7tkGzaAMZHOap3UoZQOAO4zVae73nMZGT3qrJKM7SeO4pvUxjC2pI+JGYZAOeCT2qpeIFyC2WPb+tWTjyFwB161TuC3nqWPPUChIiU9SvKGS3J+VnyBknp+FVY1XLEde5x0/GrTMDJujIyfbpQqKBksQvoBWsYs5qlRWsZ94iLEWkcM7ZwR29q29VvpYbI3Ukk4tjFGDaeTGxt0+XLnnJBAPUDO7msK+/d8FGYnjAHQkdBXL+LNckntdSWCzjt9Qe1ZZ7s7yzoNoIAztUkYya2irHm1qjaPqz9naaK5+EWkT20flQS3F68af3VN5MQPyryzwICvhHQNwIB0632+/wC7WvR/2XePgV4Zz1/0r/0qlrzjwC4m8HaCj8FLCDa3/bMU6+yNMn+Ob8jrLJY2TBALdieAfrRImBl5cR9gM9TUUBRlLLySOoNL5pMmGHyHgjPX8K5j3FF3Ywg7Rs2lMdjViNERcs2dw4FRuSoRQAEz3HSpIo84Eq4x8wJ7UtCuhOdnXhSBwPWmNIBHskJYHn7tMDlWG4HJ6Ec4pSTxwNwGcHpWbeonG25XkcKRjJJGcUsql8AHr271MEVdmEy2Tn6VHISJB8xx0FG40+xYSQZROcEYb0xULxi4ieIgv5rbQo4AUdOfeqUzxo7ZG5m447CtqF44FicgAkfKOnIH+FK99jkqpxd0eS+PbtbC9v40YiWO2ZAF7F+P0BzWVZ/Ee6l+GTaPMN7wSAQSZwwXJKjjqB+mKwvGWqHUfE+pmI5UyiNSO4UYJrIntV0nQZJZ8rI7ZXH93t/hVwlf3UYYily2qSIZZv3zFmJATaw9Sef5ipNTuxb744UaPyYfKUqMfwgHP41k2dw3kqHzveUSOG/iHBx/n1qTUb4SO4wHl2OXA9WYcY9s/pXTHR2PJk7q462kkt0kYMCTbuhJ91qk0+23tVkXOFAAPpT7+Urasdy/dA6dyMVlW7NM0K5ZvmCjPpT+yC0qJHuPh9THo9qRlAIuGXqQfvD9K66OT7DZzk/eIHzZ6kgf41h+FIBdWVhAEXy0xHzzk4Jb9K7BtPW4jDj5o4i3BHX/ACa4WepKqk9TmNVJljUPgRqvIz2OCB+lc/qQQaPcSoB5hkbeo6jvmt7VXU3MiyFE2kfIOcqO/wClcvrmYjM7MDCw8xGXgD++P5VcTkauzhtRkEkpmyE3Zb8M9DWFNJ5/mKSfmVjnPpXR6gEkjV0AY5ywI4Ydv51gXdrEhkdW2dDtzyD7VvBnLNNHOPEyykgNtPcA0kUrglSRtY8gjiprgPFIQucbR+JqEujEbyeejYzXWtTkasdx4P0+Q6TdzfZz5krJ9nnm02S6Qr829VwpA52847Yrs/gQZY/2g9At32hFkuThLf7OufskvSMgFfyryC3uJdkUdvfyQkZ+QyMq/wCAr0z9m9XX49eGPMniuGYXLF0cuR/osvBJoS1Jex95UUUVYjz34+rv+F2oJ/eu7Af+TsFeMnRDLbkq7pMg3ROOx969q+Ooz8NbwZx/pun8+n+mwV5sWj8uNlPLYBYd/c1x4ndHZhvhZ5bdWxiguTghl/1sZGCpOefpmsS2u5LedBcKVb1J4IPeu88U2TXE6zQEJIPkXJ4lXsGHp6V5vrkU8+oKGtZV8vj1Ax2HqK5ovlldHXyprU7G2KSPHKjBXA6E9a2IL0BMSKxXP3iOa5nS5WWxt7jCnJ2n29K6JFivIgYsAdSM967FJSRCUou6NANG5A+9/UfWnxybVaNAePbFZyyiFgrErzjZn+tW4bhXQkFzIOgHb8ahwOunX6MbLhncPlXx909arWG9D5rOTjhQKsxjzHkkndg6rnPf8aYFMKEsQ3GOPWsnFI9GliVsiSWfzHXaD6NSXUqRv+64k7tnnHpUHyMoIcrzyG7n2pJW5xwzHkVPLbU6YSUtuhZhuZCSV+Yjk46VtaRdhDu2t5X3SAetc9aoyMe+Rk7TWhAXUkRHMaYyD3oVzSSjKOhq31ypbJOAThPQe1Y19KWk+VssBnFSXjPNIBz94A544qq7qdRQMQsbEKT070puyCjGxc0+0uJmDxRSPuOOOQvHSrpiKuiMqAHqQp/OuwtbH+yYI2e4iQsAQIzyQeB9TVVot900RCxsRtJAzuOOAa09lpqZLGqcm+hzccJfIMj+X1IHf6U+W1YHyxtcg46flWvNHHC+1yWCjJAGOfeleMSYlDJleRkd+1LlG8RfVGEN9s53MQAPvDse9WIbguE2AsTg7uw+tTTHDl3QHA+Xd0981lvJPbtGuAUcMqle4zSsV/ERoXEzyHcX+U9v60ySRI7YtvGSefr2rOjdsYOeD931FVb+63BFViQ3BA9qG+pKp3aVx7ag7uXBYAHpTHuW8ssMHJ79qokMvABAIzhvWo2eRSV3YH0qLNGkoRvoXo7xvP8Anxg8nnrS300kzkjb8vAFZ8Z3EjJ+XuKmExCHEedo5agxklF8yRMNwhYqudvBx3qBpWdgAhLD+IVLFM/lHI60RcI0hXgHJwOcVXKQ5uKbZIxMaKE+YgdDUDq8z/NgjPHFI0wUGWRG9AtMjlebAKgR44OcH6VcYanHVrWHHBck4WMHBK9TUUs4D7xlUGdo7mmPIRb7S2Bu+Z+30rN1O6WBGeYBY1HHc1vy2POlU5m0tynqOoXMF4r2Ujm7JPklWwxf1z+dcXd2/iTWJXW41h7y1xumiivxNhAepUNyM45qzEbvUtZtZopo7ZFcLHJLwmenze3ODkV0+kWiWWq3kXm+H7d0iaKVLYSea3PKDdwOnbGal1LJtGMoXtc+l/2bYvJ+DWhxD+CW8X8ruYV5V8PnU+FNDUnrYwAjP/TNa9c/Z8x/wqjS9vT7TfY/8DJq8a8CgL4Q0YEZJsYMY/65inW+GJ2ZMr1Ki8v1OtTanybThTjB4yKlD75Cw+6pxjvUCTDA2H5sck96kR8AHkZ9OK5b9Ee47rVkrFfMT5mBI6GppSwRRyRnkr6VQ+dbjLAYYcNVpdztgFs+3epuOStYlLpIpQEnb1J6/QVAnmA8bic4+Yc0E9QV2kde1OgcDeTw/XNSJuy0HwPIzkrkkDGMVFMtwUICgdenX86u2jIVeTocdfU1BJMTKdi+wGetFu5zKTcmrDbayIgRifmzzjk0zxNcLZaRc3W9Q0EbOrf7RGAKa11PGi4hIIbqGyK4P4t6rcR6HHbRgqlw+ZCp/hUZ70XsjSNOTd2eVaawe9a4ds4LOSevJwPxrO8U6h9sZUyoXPXPPHXj0qnfXbW4FujMsjBQSp6e351mmN7q92qCccNk/dA6nNdFCFveZ5mY4hN+yRo2E9wsiOmzIVm3Nz26/gKozzA3i8AFo8n69f51evJEt1McWCSuxW+uCf6CsUFmuyDnIOK3jrqeZJNWRoamxGmg9AzD8z/+ql0BTNeQRrgksOfyqPxA2yOCJQcbQx+tWfBqlrpX54JIxUydqVzWH+8Jdj3/AOH0bPBbqmQuHmY+x+UfoK78OIV4C+V1wfTNc38PrXy7QsVwPs6KMc4zXRax5kNn5cXzSOhUcfh/jXEtjqqSTk7nmQkSTxFctKj79zbASMFD0+tO8Vaak1ssUsHliTBUKcEH6fnXS6dpaXF5LfXgGV+WPnAUAYAx/Ws67mM0+bmKRYFOVcHIAHTk+tOJlO7d0ee6r4We2sQVuY1YDKBg3zH8OK4/UbaVLcmVJRt4BZeD9K9u1uVr/SVRLZnOCFJODx3zXnGtrdTWpL28hg4BPBG6tYysYuLktTz7UVYwxFB8p/THFZMlu42qc89O/Wukv42TT4dwcxncAdvfJrElCxRLJGCx2857GuunLQ46kbM3/BgeKPUHjs0mmt9s0U7SIih0VyoO7k/38LyfL9Onc/Ah5JP2lNCeWNkdhOSWYMX/ANCk/eEjglvvZH96uC8F3QsrPUru5lX7KrRxtEbQ3G9nV1B4dduF3jOec4r034K6Y9r+0D4XvDc/aI5muoh/o/kbNtkxChMnACMgHpgg9K2Rkfa9FFFMRwPx0G74bXi4BzfaeMH/AK/YK8xtbcBGaZwuwZRD6V6Z8eJFh+GV9JI21EvNPZj6AXsGa8qt0hvk+0Q3EjDGFIbp79K4sVujtwq91szZ3DRyFERjuJCqDnisufTCiO0x+d1LE966WwtYobJ1jDYYHLEYJqjeLEJIkU79yngHOK5UdjON8JRLcafLbooZiSVLdaNPmltrkxhiDnG3tS+GX+z6nNEny4kIxjOOa1vE+nCKU3EQO4AMNvcGtobkybT5kXciVGiliBBPBHODVNswsS8btF0YqMGqOj6kGVs8MTyCeldHazQvGTIMlutbLQtxVRXW5SinaUycrl1AUlqdE4kXbIoU9ie1PFqkcjM5wpBOPU03ZNHEinauf4WXn65qtGjFTnTehXdo97K+GA+UAdj61FDlUcu24DoafPE4LMgPA6ev402SPMKNggHgn1NZOHY78Ni1sx8ErbtoI2gDr3rRLiO2AOMMcnb1rIRgoAwWPStCJwd0bABccZ9aysewpXJt7ufusQv60tjCkk++44KtnkZB9KfEVC/Mu7bzwehqdVUJkfLxnd70rdxqe6N8XDLBDLDcNCCu7jkZ6Y5qZ7h/OWUOzEjMmByT2Nc4t5JlQSPlXaDjPP0q1FqUwADqpfIGenA6CrU0ZexaV0atzPJHKqEbXZskHrjtVbzlDvgqzBixG4+lZk880rsJWwcH5iOR9Pao4bnyIIYt43HI+Xv9e9DkmNU7rzNK4f8A0VvmOZBnGM9OcZqo8okMKREK4XuepNQSzMXCgtuxwh5GTUcT7JmkZAJNuOegPepctSuWyFuDGJWXJDkdCeKzL2VfMB2kbQOnerDSIEGMkg9ew5qldlXmPV27DPWh6k35XqJNLvBZMA1SMwkdUDYOOvY1MC7sY+NmMg570kSZBRRyOtNJsmVVJDTMqxjKuRnr61Yty7KwjO1W4IzzVa4iMa+WzHrgDPFWbb93GoY5PbIP51cabb1PPqYtLYsyK6K0Sc4xhgeM1BDIY45Y5MlHYd+mKkad4W/d8nPLGosNP5r5AZfuY/iPtWip2OaeKurCSSSSAkDagOMmoZmkaYxg/uwv3u1WGiclgw5Dc84BqtdypFEfNkKkfrVaIwlzT1ZDqN2ltbq8hCLnseBj+tcjqBn126CRlhax/MxzgH3q9cCXWJhDGTsLbdo7+9Sa/Zz6fZJbW2wlRgyLwT7Gs6k7rQ0pQcmc9b6hCdUgtLjy0s9+1yAVwPqM/iashYkh1Ca9stLt5BH+4a0vjI7vkYXbvbK9ck4x69qk0Owe0voL+/2LbxPuOFDE59AeOOuD6Vr6JLa3mmalJfRSXN7JHJbw3aoF85SRjzAO4xkH3xzxWakkrCmryufS/wCzWxb4MaEzDDGS8JH/AG9zV474IJHhTRio+b7FAOf+ua17L+zmgj+EGjIOAs96Mf8Ab5NXjfgrJ8HaKynGLKEHPGPkFbYj4UaZM7VZ/wBdToYptz+WwOAMe1Wkd9wVdpxwT3rLVS8qbgQpPXOMVfyWbLMpTGM5xXJ6H0clEvMVZOV+Ycgnnmn2kmfmyOO44zVVHyuSvPTg1JDgFl+7jA4pMwtZNSJ5txUHnd3HcVXDqsRD8MRT5pcqcNjsSaYyx7Rn6g55pBeyL+m7UgKED1xSCAiXzN33+APSo4n8tVAJJ7k9TVrqACMHqM00jls+ZvuJGqbiH+515rw74t6qZtYmtkYG3txtA9D1Y/qBXrniG+XTNLmnJBfHyAj7zdq+XfGepNJcOm4mWTgknoM5J/E0KLnJRQ51FRhKozLh3XN885YFjwoxk1PJKlpCbW3IkMhDOw/qfasaN2A8tHOW4wtaVtAsTjccZ4znsOtd0o2Pn4zc5X6k0Zaad5CfljXg49qo2CNLefL1LcE1qTKLbSnwPnZdze248fpTfDFk0syjad5yR7HtU81otmvJecY/Mq+JJCJFBJye3pxWz4FQrNEOhbJ/WsHxSy/23OikFI8IMewrvPhlYfaL2MEZGFU56AtUVdKSRWHs8RKT6H0V4Th+yaJbAgZfDH8BxUN3K775Nrb1b5FPA/Ctq0iWK2j7KidP6Vg6uZJIomUhZC20Y9M1yPQ2pxU22ygtzKLFECLHKfkxnd3yc1dttPL3DGVi8Qwx3Due/pSSReTZ+Y6bpEO856t9Pzq7p6s6h3DN5ihsk8CmjOotLozNSto7iMo0bY5CFeD6Zz2Fcj4jtVtY1gkMSxTuNzsoJznpjtXo08Sl9oUYYc55/wA9K5/V9JhJMUu6RC+SwGSP/rVRimeCXdlJ/Y+W+aHMmzJ4yGNctqMDQwL8gO/oen/669NlhRtGuIJYiwSWbYRySu4/lWTNoEtxbQwlUOVB+XsPUmtYVLMVWncwPh3PaWdxcy3DN9qdkjX/AEp4AqMGy2VIJw2wH0BJ9x6H8E0Rf2iPD4hY+Sr3G1BOZVjZrOVnUMSd3zZy3frWB4M0y5tLfV4rUag8qyw/8g5lSQj5+dzfw+qjvg9q7r4TWEkHxx8OzzrcpM1zOrLdMGl/48psFiOD07V1KrdqxyOm0nc+vqKKK3MDzv8AaBGfhVqYLBQbqx+Y9B/pkHNeXaLa3dtpzSwTxtGV6IBx9K+gfE2g6b4n0S40jW7c3On3BQyRCR4ySjh1+ZCGGGUHg9q5KL4PeC4oykVhqKJ/dXWb0D8vOrnrUXUaaN6VZQjY8vniRoVV5JXbAJ3NwKrXaKt02wKQEwFHcV64PhF4OAwLTVMf9hq9/wDj1IPhD4NHSz1P/wAHV7/8erH6pK+5v9bXY+aLLMevzLIACzE8fnXbj99p4dxvCcN7qetetH4L+BjJ5h0y+Mn97+17zP5+bU6fCPwfGCI7TVFB4IGtXw/9rVf1d9xvFxas0fMuq2cllevsQlM5Vugwa1LC5JiQMew6HNfQUvwc8EyjEun6g46YbWL0/wDtWmp8GPAyY2aZfLj01e8H/tWtFRa6kxxfK9EeMwhZoDh8SbeajVWYFmLl14YAjP8A+qvbl+D/AIMXlbHUgfbWb3/49R/wp/wYetjqX/g5vf8A49R7J9y3jIvdHiEJyHVmyD2PUCqlzGIkVVdnTqSOcV71/wAKf8GDpY6l/wCDm9/+PUH4P+CyMGx1LHp/bN7/APHqaptbsh4qN7pHgUiYcFGA7YBzVoEMxBTy854xXuI+DngkdNP1Af8AcYvf/j1O/wCFP+C/+fHUf/Bze/8Ax6plQudcM05d0eGRvJAo7Aj+LvU1s4uVJ79MH+Ve2H4PeCyoBsdRIHQf2ze8f+RqF+D3gtTlbDUQfbWb3/49UfVn0Z1LO4W+DU8dkK4+ZfLCjsODTFnXapBwV4Y56/SvaP8AhUXg7/nz1P8A8HV7/wDHqZ/wp7wX/wA+Oo/+Dm9/+PUfVne9xLOofys8fSdTHIY5AXUdWPb0FRwXisJIHiQqcncV+YHHY17GPg54KHTT9RH01i9/+PU4fB/wYOljqWf+wze//Hqf1d9yXm9N391niUcKWqQhHZhGMZPJLdakuFR5FkU5Zj8yZ/Wvav8AhUPg3Ofsep59f7avf/j1J/wp/wAGZB+w6lkdP+Jze/8Ax6j6u+43nUf5WeD7XSSRJhtHJGOoqqckBh9889a+gX+D3gtyS9hqLE9SdZvT/wC1qaPg34IAAGnagAP+oxe//HaFh7dSJZwpL4T5/bJKZPvmkluVjmJIQbhgBe34V9A/8Ka8EYx/Z1//AODi9/8AjtNX4L+BVYsul3wY8kjV7zJ/8i1oqVjjqY/n6Hz9ZzO5BCbiucFqmgTMvz7mVv4s8j2r37/hTfgn/oHah/4OL3/47QPg54JAwNP1DH/YYvf/AI9VcjMPbx6o8F8pS8YdQD97KkkkdhVp4hbovlqdzHgg9BXuK/BzwUv3bDUR9NYvf/j1KPg/4LBBFjqWR0P9s3vH/kapdNvqXHExjsjwK8uBAgLcOBgLjofauVvp31CUKuQmME4r6jk+DHgaT/WaZfN9dXvD/wC1aavwV8CLjbpV6MHIxq15wf8Av7SdF9xvGJ9D5+0qz/s218wjL4wOOUFZt6Jb68RNrNGeZNnOB619Mf8ACnfBXP8AoGo89f8Aic3vP/kamR/BjwNES0WmXyMepXV7wZ/8i1Dw7fU3jmEIxsonzPqEsCXlvauoeFeBkYDHB2hvqcCtOO4C+HryO8WFIYiWgZuWTPTgAbTnjb7njjNfQU3wT8BTBhNpN5IG67tWvDn/AMi0+T4MeB5EVJNNv3RRhVbV7wgD2/e0lh5JbmUsZFu9iL9nZg/wh0dgcgz3pBxj/l8mrxHwTPjwvo6M4KfYoePQ+WtfUfhnQdN8MaJb6RolubbT7cuY4jI8hBdy7fM5LHLMTye9fKngtgPDOknP/LlCDgZz8g4p4hWjFHTlM0qk3/W51dqgkfdIQWHAAHAq5CY4lKM3XoCOlZtsSmWLseON3erwYcEqSGrlSPcdW7sX7eRRHkJz29verNswJ+YDJ7nuayVlxjJyMdPapEnVSDuOPek0Zys72NC6iDqWGB6g1WCbsZBx1HHSmiVyWABwT3qwrYwWP59KXLcFK2gR/uUO4HJPB7mllmMUOWOPU+lRyzArluMnjFcv4zv1s9PeQrMz4+UDGAfU0npsVFPqcp8TvFEalonmwka5KDuey/U14PLJJd3DTSHOSSSewrW8T3jX1+0SNlVY5z1J96rWlo0uYVX92pzIw7+1dVGKpx5pbs8nHVXiKnsofDH8WRWEBd94HOfl4/Wuj1rR3tbCC5CsBs5yOOP685/GtjwXoMl7dhli3IvXjOPp6mui8eRNKIbCOMEREZCjhcdV+vrWcq15XNKWDtTae55tqfyWMMW4HzsMcegre8IWo84TtnbErP8AkOK565Xz9TmeD/VIcLjv9K7fSl+waFczsozFESCTjPHX65xSm7RSRNKHNUcu2h5jqmZNXuB/01I/Wvc/g7ZCWGRxwVO/GPTAFeF6epuL/Lckksfevqf4O6UINHMgXBcAAkdsZ/mavE7xicmH1jOo+rPQ13GDgrnHIrMjg864LuAFjJxx1zV2CVUjKsepJPtUaSojgMwB+7j361ym9mk0iK4t42duOMdx7VFE37hFYMjgcH1q/O29DtGQcAVBLtMfHbgGmZ7oiiZ5JGGQQo+hJrMvSwfHJJ4OO1TQyGO8IK4Vzndu60y4iaaCeUH5myR6gUr3Hy6nmc2nyPoMVxGsnnSGQNnG0KXNbcWiM6MJFCKEG5gMnp+lbGmxpH4Tsdy8uAxB6ksf/r1tvbtGskTjIbBHc+2aaCerOA/sN0t3aPw9b3SKMJK9q7s/uSDzzVz4ZJInxd8Iedbx2knn3GbdIygQ/Y5+gJyPX8a6XRpo7j7QbtWMgYbVkZgoViRnAPrjr2qLw7p6w/GjwvcxIqRm7ljwrEqD9guM4zyRkHmtaTvJGVb4Xc+jqKKK9M8wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+OvCU+PDGkIAv8Ax5xbiPTYK+xa+LfDEYHh3SduSzWkTdf9gVjWtZXO3BKTk+U6i3uFjXCnj+6auxXDMDwWUY4rERvKZMhuOQSKvW043E72G0c8dvpXK2kequdl8TgnI3Yzyo7VLuMwUAY5yAe5qpGPOkHlsQF7kY/WrcO4DgrISfxpbmsXKOjL9s4wq5fI6kirLEKAW6dcHmqW/cBtHHThuRU8b7W2MSfcjrU+Rdm3cf5fmOrFAFGCK5/4gSR2vhm+uvKEknllU35xk966u1UOOSSPSrV1ptvfWZt7iLdE4wysM8UNClXtufHthpc13e7Lcb5pDycdM+legXHhb+ztOtreRUFxLhyq84HfPv8A416W3gu30XUPtukorMpKiNl6enWr+gaC81zPf6p5TXBPyKvRBngD6VM5uWhlS5Ka5kYegaa2kaUPJHly7Tklh8reprhfGtylhGzib/SWLKuOSR0z9ck17NqJsdPWQXJgkllHG5ctnHpmvArzT5td1mUwFpItxEY65GazVr6nSqt4u25Q8H6RJdzo0sbGMnccdTnoK674kQWWl+CpUtmxOxSBs55PUn6dRXceAvCTWVmxv5ljD8+Wq57evr/KvJPjVqsdzrB0yxn8+1sTsMnXc/fnvj1+ta07zmmcNZ+zg1HojlvBFgb3U40UHLOE496+xPDenRabpcNtEDlIwvXv6182fBy1ji1eCeZfufOBjqTwK+nrWYC2UgqXC84NFWXNNsmNF06UPvEKjz1U8x+vvTZYYln8wqCf881atoiYSWb5jz071BclSD5vUcVn0JvroQuf3pA6deO1RyRYUtkDvkUo2JGGYYB/Wjq4IJK+9BDKT2zZLhs4XbyOTSXtu0Wn3BDncY2A9iRxWiw2IVxznJx9ahvVVrWUMpK4I+tFgUncx2gb+zNHRVjCgJnPcgVtXYk2hTHkYOSDmqd5g3VlaxopaJd2ccADitpBiIDHTr70Ico2UWcxp7KLy8tbspEkmyTInCtgE4HPbv8AlV2wfzfij4QcMhUX8y5U7s/6Bc4+bv05rWgtvM+0+XI0LNtzIpAxjPHOKZgH4g+Ci6MJV1KcEtjp9gucDj6Z/GtqPxI56z91nsVFFFekecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfHPh20ubLw1ojzQsqy2UEiMfuupRT19a+xq8O8DWSXfw08NQXIjeJ9Mtcowz1iXGKmdP2isaU8S8PLmRxUYV4VIAP8JX+tNeBomWRRlCeM9feum1vwpNp58yyZprcjoeHX/EVhxmQSeXIMFePmGMGuKdOUNz2KGLp1VeLHRyoHwpVsnp6Vahj2AtKAvHrVGKKOOZZJcCUd+xrSgChSxJwxyQTwKg67pbEgTDZ2HnnOOKtQQiUZYBSeOtOtxEcMrZA9DVoxrIA238M0yXUtoXrO3EcXJAA6e9T5AGT34qmpLKOTgfpTllIG3FDRzKLb1FkRpFIRQVbqT0FV7ewSNHXaDIx+8RirsZdxgsQKtR4CAYJ96zaKnLl0R5/qGjXU9xNZQwSHzMiSY8KF9FNWdE8LrpJZ4j5ko9FAx2wM127KM9N2fb+tYPiaC4lt1t7FJVlfIMgcgIPXIqbFKs29TgviVq9+kP2G0uFF1/G8a8xg9Bx3IrxHXNJkgNuHUl5ZOSRjp1r6EtfD/2ZB9v3TZ+8S3Q+rHqxrznxTZrqniq2t7ZG8uJTnjuT1/LFKMnB3N5KM1yWOi+FGghbH7RIjIWwEZRz+tevIslpaYCrIMdOhqr4asodOsIbdVG5FANasoUjAHWi1iKs+d7aEFvcSFBmFh2HTiorrzZXXb8pz0xVqIFV27gB7CiVBsJOcHig5nL3r2Ksahl2sAx9SKk4RQTwc0oTcoKfLjjnvUM53pzkHP40ENdGNkYuoGQD/EfQZpbgiVkjBwpcYHcgcmq0SSruRRtQck5zmnRW0n2lpHfhvljUHoMdadhSilrcdbxKbmS4/wCAD35q+5PJUcgfhRFEI4mHGAaWUkrjo2PSkHNzMbaGRA4aLzUY5IZTjjuCKGDDx94L3YydSkOBxj/iX3XGKsWsUtvBHvuzGpHyhmPTPoKqqHHjzwX5h3N/acuTnOf9AusHNa0fiRjXs02j2CiiivTPOCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvFfhxL5XgDwuzHdt0y1OP+2K4r2qvGfhmhf4f+GJWXESaZa4PqfKWqiY1tjcMD3LF7iRjvU8D+GsxtJg1WQ/a4/wB4G2mQcEGursod253APoKzdZixc7oiVRuGC8fN61vTafuy6nK+Ze9FnnevaZ/Z92YfMFxH2bHP0+tUHV1J8pyD3U9DXoy6ZDPAFkhD5HOa5HWNLlsrx4zwfvRs3Rh6H3FceKwyh7y2PUwWYzb5JblGwlVNu5eSedp4rS+0jdtyM9R71kRgxMPMVlbHIq7BKpGOvpkVw2seuq8Zamgsj4BwT61btwGbc2QPQ1nrOQRtHFWY5iD0OaQSqNo0FYDoOCe1TK22qCydeMU6SQtghsKOo9aRCSbLqyDGMn06UxpD05we9V4rhH3DOCPWpcrjI6DvSSK+F6ogktA8T7dzFvvZrktF0IJrNxqF0qgFyV9ugH9a6y5MksYSGQpnqMZp0MIjiMRGS3UnvUSsaJuO7JU2ElgAfepo9xG5xgjpiiMIi/IABS9QdoI9OaQ5TurDFnG8Lg59anLg4wRgdPeqyDlt3PoadK6kDoWFCMppX0EnmEKsWG7HOFqq0ouCrMyoP1xUqwBxlgD6gVP5SKpGBx1p2M3JbdSHG793Gp2kYyOwqxFEFYO3JUYA7Cn25JBGAN36CpHICmjQnW9iqSkquhB4OSBUpQsuOnpTiqryOD1wKdCDu4AA9KRT02LMQYQIfPjCgkBXTcVP5VmEk+PfBZLl/wDiZy5fGM/6Bd9q2IgBAmPJU9HMi5Oc9jWTIEXx/wCDBEpCf2nLjggf8eF1nFbUvjRhN3gz12iiivSOAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8j+FMj3Pw48OxFV8tdMtVyB/0xT9a9cryz4aQhPhn4UMeVLaVaFsd8wrVRMqqvY30mWO3eJ2KsvB/xqjPEZYygf5W7+hqa6QO+3+9wxHrRCmAVY554JqjDyMZprq0m2tJlM4Unr9Kku5P7ShaGeL5QOGzyp7EVbvrTe+H5U8ZrPZZbOTaRkZ+U9jXTGamrSMHFp3R594mWa2kjbeVaJ9kmOhB6VFb3MqDLAMpxyBXX+I9Nj1a1le3wJ9vzIT94e3vXEaPIZIDE/wAssZ2kH1zXj4ijKhLyPfwlWNeOu5s2t0JPukdevpWirsTlT9azJLdJEU42sO4OKdaySwyBHO5T0PrWKaZ0yUomyJisfzLikEgckY5FNRtwyFGaVU3Dk4btgdaTLp2ZJCIkIJOTnOO1LPcBl4YYA4AprRMzevt2qBYJFf8A1eeelQzqpqC957liyd3DZJFXlk4AqGIbFGePUU5DuYkACoZE5c7uSmUeZsH0p4cKc5PP5VEEA+cjn9aN+8Y2nHvQQ7W0HSSAPgZOaa6jBA478d6U/dAXGRTFY7sdDina5DlpoTxcHA7dak+8NxpgIQ8jk1KgBOTyO1VY5+bUI/kXJxk1KGEjDHUcZHaoFQPJn5gAMCpFwvCfiak1BIwjsxbJPan4wQBmmOSSCBk9akTBO5iBntSHLa5YF0UjjXHCghkP3WH+NZskgm8eeC3TIU6nKAD7afdCtmJN0ERjOMnDEdT7VkzxrF488FJGAB/acucdj9gus1tSvzowqcvI7bnrNFFFekeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcXa/DPw5aWsVta/25DbwoI44o9fv1RFAwFAE2AAOAKKKAH/APCt/D/9/Xv/AAoL/wD+PUf8K38P5zv17/woNQ/+PUUUCsg/4Vx4fI5k1/8A8KDUP/j1Nf4a+HXGHOusPQ6/fn/2tRRRcLIj/wCFXeF852azn/sO3/8A8eqv/wAKh8G+Y0n2LU97HJb+2r3JPufOoooeu41psSf8Kn8JYx9n1bH/AGG77/49R/wqfwl/z76t/wCDu+/+PUUUuVdiuaXcUfCrwoOkOrj6a5ff/Hqd/wAKs8Lf88tY/wDB7ff/AB6iijlXYXM+4f8ACrPC2f8AVaz/AOD2+/8Aj1L/AMKu8Mf3Na/8Ht//APHqKKOVdh80u4f8Ku8MHqmtf+D2/wD/AI9R/wAKu8Mf3Na/8Ht//wDHqKKOVdg5pdwPwu8MHqmtH/uPX/8A8eo/4Vd4YHRNa/8AB7f/APx6iijlXYOZ9w/4Vd4X/uaz/wCD2/8A/j1H/CrvDHHya1x/1Hb/AP8Aj1FFHKuwuZ9xf+FX+GM5261/4Pr/AP8Aj1A+GHhkdF1of9x6/wD/AI9RRRyrsF2KPhl4aAwBreP+w9f/APx6j/hWPhr01v8A8H1//wDHqKKOVdg5n3D/AIVl4b/6jn/g/v8A/wCPUf8ACsvDX/Uc/wDB9f8A/wAeoopcq7BzPuOX4aeHFztOujPXGv3/AP8AHqsaX8P/AA/pmrWepW0WpPeWjM8DXOq3dwqMyMhISSVlztdhnHc0UU+Vdguzq6KKKYj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, sunburn-like erythema is present on the face and ears. Note the relative sparing of shaded areas under the nose and lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Phototoxic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDjR168elA7565pBknkfrS549s4rrMwz6Z9/SkJ+U4P4U1s8FQDzghu1K3B5pNAPHUDsPajcSBzjsD1zSdzk9P0pT1P8vegBS3NA7Y78fWm4pxOB6460gDGOmPwpOCQMfX3p3Hc84pMkHrz1zQA3IyASefXpTsdxkUu07gSSQQMDHf2oaOTH7sYY9BjJNY1K8Ke50UsPOrshpO1mDDcwGcA/wA6ZEGlKg4L5yEByF/xp7xOCFwvzc5XrmrVvEIpECqNucMMgE++a86riJVNOh6tHBRp6vVlGaPEgO3DrhjuHBNPgVpIMsSWbq3Tcfb2FXfKLTIZATBu+XHamTxGSMDHIO3K8Lx14rnep3KCWgBVhi+QHKDaTjO5j71ExkWaEBAS2VOSOAOc1bUtJES33V6cccDHT1pyHy8MudgGclcfgaW5VkhudoQSZUeYDt/vD1qyjLHHIM/OrZY9xz1qHJkmLB9zZxhuSD1wKkKgl1ZSVbktjr9aBEm3dK4VjxgHJ7DnpT4gP3i8FcLkH09ajjfahx024GOrnNTwsEuNxUAMcEdgK0QncUqwiCCMsFHIHJA/wqtch1jbYVDnjB43fQ1fmj2sgUOSpwvOMexqCcqJE3oOQR83RiP609ilIYHA+dQykbSARnHOD+FLKuW3RgrtbHIxj2BqSJhE+8xqybSpIOT+HtUZiG4qZZImGWAIyrA9BQS2NaUTIw+86HoBhgOvX2pZCnlLshVosA5HBUd856mmiIMi/JtGOdp5B7kHv9KSMK6xRM2z5SEb+9xxj8KQDwNnz4aMKco4G7H19RUsbLMAfMkXuAowPqBUUCxpjDMh6FGX73qAaemGIAdQCOF3/ng/0poAnG4K7ST5ODk8be3401ITHIqOjzOrHq/y4P0qxErlWFud+7j5jkY9alYM8ZOwxrzkFMEe3HaqsSpWI40aNQJSwdScHJUvweOPSpwZ2jUosYHJ+Yjn0A9ahVIY5C0WWY/MNh/QE1Kdj3JTY2c/Lg5IP0prQrcez+WWeBEE275xIOuT/CKd58MqzQGYlTn93ECOPrTUtMLGs0jM2PvZAZe4571OC2BHtCRngsrYIP8AX60a7laWG7ljjd5crHt3c9h7nr+FQ3sx8nMcannJzxt/CnSl12kbeB0H3c/1qrEwZ2ETsygkAnj6/lSuFupKxTylwcrkqVHWkAwNrguApZyoO32xQCHd2JYoMY7YGKRGAJbY/wAvAGeWJHQ0CtqOfZHH8o5PGFXJx1qNmyADhT/CO4BqVpCScKsTE8ewxzVWNfJGdplc/dyaRoloGQr9CGyCFOCOO9QyDZJu3YVslm28DFMLBZZAvU/LuB4+tBJ3IQwACEY6ggnn60F8o6QeYokY4xyqgdM8cH0p1lMqs6klypHI6sMYxUMrMYMLwS+QpPbPFMhCzXTKFC8lOD37GgjlJorgQztCC2087gMg89BUcsRLZGVVHV0YdQe/FSQvG4GEDbWJwO3PPPrTBkpIBtXDblYdCP8AGkZv3WSTKzzSF3Vg22RhngE9x/UVBDIiTyW8yKJFGBsztbPOMU/DtM8cyMYSflK8kEY5q0sGIhLMGJSMqxXHzjPf3AprUrYgghcn5sMhJYKF5I9DTXuEJZQNscZCyJjrnkGrRaOKWNN4CbsL83DccAn19qj8gx3W/IKbOgHOO+fpTTsJxUtxbcF3RVBZGXIwuDx7f0qO5jjYxnmRcnKsT8ozyP8A61K9ttXHBjPBD5IJ9eOlWLZknbEzCQn5chsHj37kVcajWhlUpxZi3ekOrO9o5ZBzsk6ge3rWY6lHKMMPnJXGP0rt4TIoZSCIww8sg54PUdPWm3drDcxHz4I2UAZDnBVvYjmuuniP5jyq2CT+A4kdxj600c1v3vh2WNmNlJ5mP+WcjYPthu9YUsbwyGK4R45e6MMGuuNSMtjz505Q0khrkHGMfSlBGOaaQD0oH+eaozFJ4JHDHr3ph6cUHH0PtSgnHI4oATOc+npSDpTsg8HqaTpigAPAwKD1oAz2FJtHrQApxjrzTNue5H0pxGO9MLEd/wBaBGgAMnjvx7j1pT9ePT1pCc9u3Wk796XUoFHPP0pcf4c0nYZ6UvQD6UwFPJGetHA+tNydwHelAB5/KpAXnjpzQOoByffFOSB3YlRz057fhVuO22kbgWOMgA9aynWhDdm1PDzqbIqhd3PG3PU9KlhjyGZlIA5DZyKu7I2B2qxIG0Ff6dqd5ILriNRtO7gk5/DpmuGripS0joejRwUYay1K5SNgPlPzYJbOBioJIZY3BTheRudc8e2K0GwsoGwhc5O49Py70s7xholUGQNnBwf8iuTc9KELIrRxl3UbSSjAlEHCDtUzRIytKZFzGQFVcjb6ikWOVNzONsR5z3IqdVXJXChwAZMk4HpzSKI5pUIIJw+Pup+g96i3om/ziBt+TanAz3+p96bNbyGSRgfmJAA7KP8AGn/ZVEkajLKASSewotY1UUupE84aJWJzGCqqpHJIpkx3OiytukAO1On4CpljLKoJKKQNpAz09/SoWgL3SNGBtxnBOOPWkCSuWIlDFWYbUCDH19akSQu21WO9l65yMA1XZMSRjO6Q5XAPp1qyqsPLVF5B3qM4BzQkZsfHK7BGhHyj75PHY9KnZtsW5nCngngELj0qK3KXCIZDtOShUDp7EVIpGyTMITGV2n0/wrRIgmhfdCrNuCuGj+voaJEZVViynjO7r83rT7EAs4b+AgrgcEkVAzhVVVCKjnB+tU9Fca3sNj2qfLCMrHJwo++OufzpJMJwFJZmI9ge30qYTrEjSSgYAB9cn2qKM74wSQTj5zjBPPT/AOvRoIrOfLk4BLFeQeme/wBKmiVZVWLdH5nVRjg47EetIsWZTESGBQlZFI+b2xSxpC0wyyhiASNuMH/IqbDUuhcVnQiKdAzDg7RjP40mY4yd9sysCeAAfxxUbOyRkCAuAMg8lW9s1LE7uFyu1gNwOQenXHrVJicR5WA4bHlttOW25J+mKA7kKXnky3tjPHQU90fcWXYxznjkDj0qMkMVVmJUKQY9wxjsfaqYokLQzNKBGqNCP4s7ePxq3BLCD5auNoGCckN781G/kmJgW2GP5f3nIOOn1prSbwXVyVQD5Tgbjnr9DSvYvcuRWsaI7CPOBhVkz09ajVi5Yvg7RknGMjsKh8w+bulUv8vyjeafJKpAjk3KSASQ/tSbKsyOaYOdyjywBg4JAIxycVHGAqlxuy4JAIxxjqadLKieY5LDb97vn0FLIhMBldm3BRjcc4x2/GktReRGhHluWwzy5Jzxj8Klwz8264bBwg6DgDJ96qqVclVG0Y3M5OcZ7ZomDymFxNyCCNg+96DnrTLsWJTvdkHOzGWY+g7UwhyFIGeN4B6dcc1JEQ8rpujJA+baOCfSm30y/Z2UbAE7Y4yew/8Ar00NaOxnpEXQheUjyRt6nJ/pTGJWduFIjyqZ+nb8amtHVA5boSQD6nuabLyzMm4yjOMAZOR/jUmvUrzM8duN5HmIQmR79aSVpIpmAIkL/NyMDaPSpCFidA6+YA+9gv3en61BOxbzDvOQAdw6f/WzRcfKT26bpZEU7ckhR2PGSPrU0qEjyXffkBhkYLD8O4NV4mHmF+CjYK7h0b1prSI7zQMWYswC4OCAeTg9qOhlKDuWhGjRmPe2UJUgcANj19Kmt2LREdGI6gYwM5/SpwLcqroQ5+6yEdfrTYXWCZ2kUAdCTyAew+lPUcdVaw9YoyCQwdZMNhgMHHf609IlEa+WZNr5BDHlMUsMaF2hJMhRdyxgdR1zmgO0WFaPBlI2knviqfciYhWcP+5JcqclAMcHsarPDJbyP+6VUYgsG5ye+PT0zVt8gxS+YyZBYBTkOB1FMimM8z+aFCEnDLxn0XFTYldyTLmISBhEGxt443f4UsjuJvnxnGGVTjqOT707zfItiQE8p8E8EBR3/wAioCzyM0XSEJtLZG5CD6+4qrmLje5dgLuio6kxBc7Tgn8D3ptxbW9xAFuUR88fvUOD6U2JgWRCN+OBk4wP8ae9wShBj/dj0zk+1WpmUqd9GYl14ct5JWWGV7Zx/A4Lqfp3xWPc6Ff243CETx/34jn9OtdirqzFUZgS3yAZyPbntTBGzOrbdi5wEU9fqa2jiZI454OEtlY4B12EB1KN6EEfzpCc9cE565rubq0MhAeRDEOikhgfesi40u28whhHvcZBQ7Aef881vHFLqc8sBP7LOdBx7mk5wR6/yral0Mlm+y3McjLjdG33l/Edqo3Gn3UC7nhbaOrKNw//AFVvGrGWzOaeHqQ+JFNTx6UhHc9aUHnC/iKRenPBHXBzmtDEG+br17UYPfGfrSZ/HmkZsHBpAXhySfxpepzkZFDdyMDb19qfDGzkiNeR3JwKyqVY0/iZtSoTqu0UNHXgVIImJJICnHBJ/pUyLtl2DcT1LHgfhVqVY4NpLdRksTk/TFcc8bf4Ud9PLv52Ukt2MmwqDnsxwpHrxU4gIyNqMAeqnFXIVdipZ1QMM7UXkj61biQ/I5RVjHONmR9a5ZV5z3Z2wwkI7Izfs22P5uCw6L3qyiKqffC7RyEU4J+tXBGsrMWHz524/Xt3qaK22F0zvB5wT+dZp3NfZ2K27d5caZC9weScjn8aqyAspZYyqgcLyDj1/wDrVfiUqq7PMXnPK9aiIaaeRAM4wwQEA/Wh3KSsUpZRlUjSQtkDdnHb9TTNzQeWVifd1zgngHvitNoVhiCyMpkJDhAPU1BIqyS4R2bjH3uFA/rS5bGqa0IobkTnLFQrnAx3B6/lUwVX/wBUV27jtBPB+vvTE3RDyliAKsd27gVFIWuFWaOMLErhRt4/T+tPRILdgaQm6dV2godq5OQM9aawVEeVmYAuVyT1B7/SpxGM7WDNlc7tmB15+tEpVJljRVkYZJ54HFK2pSXciRi8alFZY1AwT3HsKdIEO5ZN0ak7SQOtAnmSEbYx5bfcVuMCltIyQ4k3EZByO+exNFinBrVCrbmJD8x4yVAH5/pUqPGqgAMVUcEL6fypqoxkKlUCjPO7J6Yp6hxFJG3LA4TnbzimZtDI9u1GfOZCxDKv65pYMPtHmsVVMEE5JI7ZqRuYSWBxKvzLnO1scjNJFCsVuI4gF+f5R/EOP1qkiJEO8PdvBHKRL5e5ge4p8gDw+ZnbKrDLMuc8ckVYW1SYxzBV85QQGzjk9aToAXxk5XDHAKn09KqxCkRSxtCOr4xztHHX73/1qDH5wdA+3ZkCWM4JH0pQcEBizN1QHncvp9aW4ZjOmEzEM52jJzjv3FSy0VHADABlG3ALjt7GlDJt3HiVTjrgEfhRua4RY9oCk4ZiucEdPzp06RFR5WQysWDgdCPX3qfQBvnzKx8xzjggI2Q3v/8AWpfMaTLweXIQxIw3XtRK5KlioMmQxcc/kB096kIzIAVQZ75GOe9CKXcYXlG3zywAGevBNTedhwEAKA8MxB/CnSRMPlLoQq9Qm7dVYQqHDfIqByd7AgN+FVZoOa5OxYYLsEYHo65zz2HanBt0nmFgG6qVGeKjJLIZFcDLYIY5OSetTxwlGYIUTqFYdG96FuO5LASSnzP1JOF7/wCFNmAiZMRblZvlVcFz6/TNSbthCIxds52sep+vpTZWmLMQrCRmwVRgAg+tDDUbIJGnIxEuwkM+SeOv/wBaofLVZkZXwFjIJY/LjORxRNIjkHzNqtyPpQi+YyHau3dkAHgkDvRcErBnEikkKR8wwCA3HX+lKwZ0DS/IqfdbPT2qa4YR4Uo7tnIz0+me1V5/9cdwVwqHCqvC+5PenYpdx6fLtAAy3VQcYHqajngLMglJBYkZ9PrSp+8YO5dC3KkDH1zVlEBb53LHPPGBmgL21RViSMrsjQKY/XjNTtHs2hFH2gk9edoPr6U2Vig8xVUuxx65qW3jC3DoEYjhj1I98n1poL6lK6s1aJog7bDks+OenQVXe3LKYwExgHpwQOnFaOGkBUEbASQSemf68VXt0WWSSN0IJBZnzww7H8BSL52kVIyY0iJQBofmyehbOMCku4XU28+BmQM5XI7cHipXkLbv+eUfAfGTke1LjYm4YwQGkbPOT3FTuaWd7hIwDRFQuGAAbHHsasSxE2zK5/eFSDgcnvUS7duxkGCSMt19uDUqOnnFecAAEAjJHsKaB+RPaELcRsj/AGdXAXdu74HXPr3qy85hiLsh27uTxjPr6iocx7i4iJYn7rjOKkWR5LfOwbGARgRnJzVGM9dbEU772EaIyiUcAnG0D+f1qW3ETENCBgg4GeoqG4QSQlZCFEY+UJ+tNhE9pL5EsQZW+6Qc7Tngg/zp+bJUU1oPlgMAeSSUOQpVRnBAPanwx7kTa27djEYOM+v+TQm1rjE0ryrkqQ3AQ9vrWoIEiGSfvY5JweBSVnsZS0KcaCFVRVG9Qclh9znrzUtwk7tsDnbjIdT8wx6jvTjNHdTkeWhBXDMD09OPWpd/2d1jYZbBCsWwWFK5FmUvLaVAMvtJ3YJxj8qkEcZWTzDICowdjZ3e1WiuVJ8zenYnGDntUJgZN3mknaAV2HA4oQJXKSvbS7RCyhyNzDGAcdvY0l0uUCmKIpxn5cbxjn6Yq/tCsoO0sDuDFR83tVW6KuQGIbLHb6BvrRzMuMUymN8VkrwhTs+TLjbkfWrCW2797E4WRxgKxOz8h3pnnLErKUkVmz8q8oT3z25p8L4uTuXy5D911PX2I7elaRnYJU7lO60y3li3XJO8/dOcfhnFc9qGjzRHNsDNH2A5I9ge9dhIIpVwZAmV2kHJBbvgf4VNHaGQyMt25lwZODklhwMj6V0U6rWxxVcLCotVqeZk4ODnI4OR0o+fA2ius1DTorlCpyjp0GPnH09a5q7sp7acx+WzAchlBII9a6oVlM8yvhZUn3ReWNioAXduOAM/qe+KtokauBkgZwSQOfU4qG6g8xJEV9m4bCUJG0HripYLaJAiciKMAbcnhe4zXjuTk7s+ihRUdEtCZrefYZMMkZI2sy/eJ6YxU0YRkKuV3Hg7iM02zUFyyY+XoQc7R7VeW2ExfAy+MFhwc/8A6qSV9jpUEkJbhkGJ2G1cso24yKvxysZVLMAQvA7470JAwjZTh8D5GHOajt0nEbrI42hssyrg/hRaxnKz2Fs5EdJmSOQqW+8xwR9BVpolwGXaM9c8EcUsInkUeewRnOQpPJGMDjsadtUmRflAPyls5/L3quVGc2r6DIozsGWbk5OOMjHY1U+yFJw8PQ8ksv8AOtKKMK6lzkMeEDFcjHenSRhnCkFYs53J29qdjPmaZkPFFu3jaWdSoOTjjofwppjVC4LL8o5bb94+1X5YioARS8cmMHAGM0yaJEjMYLHAG0bckj1FRylrUzZQot9rn5iCQD6DtSQxgxDZ2bcYx06dM+tTIZjuFw21BxwcN16Gp/NVwoyxZfmzjrzxTsU/d0M2KOYJl5j85K5buD1HsfenRqkMZmZiFQkMvGSPr3qdwZvMDYZWBbIGA5z+lR3iGQbcbNo4yOpI6A0mn0NldixRedConKuEcnGCcZ6A+tSMwjAQlWj6Fd2MUyNNsikKFYDBzzuA/wA9acEV34AfzB8rP/CaES+xDKpDOrYUBR+8A6c9MVJJhx5kIGcDfnkgU8Nu8mUKitjHJ7imNA3HlMHdy3GcA/WmifMNqQxkdQ2WHU54qGI+eTFGm+RTkKrVZWF3iVPMypGFQDgYHX3qqLaXzUeInzUO1mwflGOlULRp3Lnmb4EdUdACQuRg9cY/+vTFRkEiyMZBkHleinqKWAybjHIwVw+Nw+YFf5VZlcF3EYGT1QDIdcdfwqtznasyqsccj7f4kOQc/KcdvY091UoTGPMO3lwc8f40w7IpCka7GOWyehbHWl2FY0aJRvPJKNjd7Ui9xsKqWZrcopHJXrk+uKcIixVyAoDElduecdPpTFDSuS67ZDxnvjvQFVCygNuIwoOcA5qSrXKd0VjMQfdHL/BkcZParEMTxx/OjbWI+XqMUTW4ZlyrYRhg9dh9adHFuZ9jNgk/KCTu9SBS6htoS20Uih1VDtOcZbDE+/pSrExiUNMwK45LDGaZHCEAK4QscgFvTr+FK0fnDauQyfeH8JprYN2JMqxOMMGkHGSMjinozS524Azxnj8qhAEX7xwTgHnOfxPrU8TmRThiwz98HA/CgbQsTB9pZgqPwxJySR2pXU/ZpAYN7NyT3+pP0qnevKLdfs6I5LfN/sjPUDuasQmR7hlcuFPRm4AGO1K4wS3kdV8hOmA24DofU09WEQTykOB8vBztPftUjMY2VUJZgmP3hyq+9QEzRmM8NIBnC989x7c09thq43bI7AhByxyzHqfb3p1wsXEiP+6HDRnsR/Ol8sReVGrfMDndIc4U9xRCiSRqiAll6Ow49yBTXYGx1sBtPyscf3u59eamnVECRBsndgoGxg9eTS7ydkaNulPc9vrT3XcGaUh9uOnGTVpENlIL5WD80jKTs2g857CrEn+rRMtlsM+GwQOuD/jTRFcq87ySBjxx2A70sZVnkBXYOTn1GOlFhjoohCsYSPIxkLnPf39qrTusQAY7ZJDhSVA6nrjpjtV0jcVb5um3HqKqyRma4KSOpiUEI3cf5NJji9dSssWHC8vLk52gEY9alvGWFE3LnPfHA5qy+4wSJB/rGGN2MEY75qsscnnGNFEpU5yuTkdODSNovmeo0KzCWUqXlByCwwEFOigdf3qDBJ2s/XaP65qxb27b0KSNLkkOegz04FSrbspdpD8pGCASam45TSKsyiQRmJsFctknK47jPrViKVkjEkcg3kEhM9T6CmbWjjQQhDu+YhuB70kJ3/dGHXGHIyMew7UJmTTaBJEYjyguc8qewx0HpUdzI6zh40UAgfMTg47nFXP3UchdS5QjBJA/nULSOIlaS3baTnAwc4H6UntuCSWpet2REQSDeOMZHX3qVI3RyEKSICGDtknB6j61Vt2DhmBPOGKgdOO3+FackohjVi2IyBkAg7vp6U07mU7kMVo0bBkw5U5ALY7dzU0sDKi7nA+Xdl/m4Hp6GpViCKZQGwPmZm6KCKaC8iJkSOCu4EjgfWqsrGetyKOQAtEwPmHD7Quevf2qaVVVEYsX5+YqAfrgU6Mx/ZUMJMbFvmGQCffNN3ByFQEgHAwMkn3oFe7M6cpuzOvRiqhSM4z3FU5NuAsL8hidzDlgO2P61qXgVvkkKlFO88dx2/Osm9dItqohLMcZPak0b09diFp0nRggBI5Kg9aSWWNI1nUsZc/dHp0P1qrBIUuX2qVQJgtgZHNWh+9DAAq65GCMg96SZ0SikR2uoDgSbApYrluoGM96syTwYV7ln2SE7Sq457HjpWQsEhnWQB0G7knoB7e1WFlmKBSXRWJyV6cH/PFOM3Yzq04rVGgyKJnYsJmVRhnfOR6Z9aY4jRsRzogPO2VQSp7iqtu8Rijd3DqxKtgY2NjGCKspEbdFX7MsykblYOeB6cVpGXYxlDXUxLeEROxYckggdj71K8TM7tyqjrgc8+lTJI7L5ayCMAAgnnJPfFWmDjajDzJJO+eD/wDXrnSudUVZla1jEj4QEZwMHBOPXFakLwxyAyHncBlDyM/0qnFsCqpUcgt8/t64p9ky7yLiPCKPlKc5+o7GtFoaNm15WRsYqiE5znk+1RoHDsMnC/MuzuAeV56Gkt9skaO8eWIOFNPYuvmJsAiJG0K+cA/4U3Y5G7kkux4llYYZjwC2AD6H3oWFwUDIQhbcoGBx3zmkcJ5CRpA2MADJyAfX61NCqF9gkBkDc8/dOOOaN2Q9EDNy7EZiCjKn+L6UyPIdymBtJIy2PpinKqqpdsI5fae/41JKSYvmUMMBFUHrnv8AWixm9Cu0KJcO5Tc6jON3b2/xqqArswT7u3kMSCPbPvU20tCUYN1JKsOT27VXRikjcENgLk8ipZoiNYkRZPO3bj1LnO76fSmvbrFPIQDGhAGS2eP/AK9LPxKsZ5285B9+v41JcMWiJnfDgckfxYPpTLe9yBrfzJtyRtsUYPPGD2omkiTeAuJU6AcjPpilMiMFEbOmDjleWqKzhdLhmfh2B3c5wP8AGkUvMYqCMEvyWBIw3Q+9U2PmPELgMI1GcAY561ozhUXckYKA4c88VBJCuUXqqLkHGSPrSt0Ki1sxixRMwaEkRE4/2S//ANelRRc3ETYkSVPm8oPjA6dKsSR/vOV3LGoAUDr3qAfu3+0IGVwQH54J7Uhb6IsTFTKFVx+7booyvvinKGeZm2/u+Pn5GT71XW4jeUxXOVd1yGIxz9fSn/aVtzFE77WfhMjn3BNVGSIcdB0kbI+Q2V5IHTJ9vanKpZQc7OxBGSD7YpSoKrHuXPP6+lHmOu1ZepYp7H2+lXsZ7jmw8eHGZRwO5qOO2bYuFPH3ivDYHtUquoKqpCA5yBnj6GpVYpt3/MTxvTgtxT0YlcpNGVnThGxzjGCQT3NOaWFEcTKFBIwQcladcos+BFLt3AZwM5HpSqjxTO5wWVRnK9Kl3Ra1WpFmEAGN84JLq+QB2qOJIk2kfcU/KvPDHvn0qeRI2iZlj2yg5VxyOe5p3ks/McjGTacqVwVP1qRECo77lCI2G5fn68AdqmeDKs0Y3ANwDxkY796a6vBEWkZwFG0EMMn/ABqaVSFBcu7L1bqPpQMozF/nBCxow2gt94+1V4oWUy7FA3Yw4Pt6etaBt2ku0nC/KQFRsZ4PYjvT7qGRbbYvzck4B29O3rRy9Sr20IYQflG0ANyC39KeVUmN2OWC4ULzge5phlZIwFeM4bhuPT1psgiYkEkM3JAP9KAtqKhYyoiAIfvMcZz/APWqwgUR71J+Vs4PQ+x9qYE8xwsjMqKd20dNp9cVLcuIEVgP3OTg46+9PzHa+hAIVaQyTSAPwRjGB9PSpLh1MahlBTP3t3Q//XoWN44N4w5Y5LsuAc+lPiUuplcMeM4b5V56Cq2FJa6kcDr5+UxyMkrwCPb1piyObllkO1iQygDnd3BqafL+VFCu0gHgHp6k1WhtpEmkuZDuI5GO/wD9ensVGzTuSpEyxFmyNrA4L5dyepHalhGU2owIPzMzcYI7VYUgENFkMASQQefb3NViYmCOqsBtO4ZyfoRS0W5naxJNIiW6Llvm+VXHJznPNVpHWcCUFtpBGDnPXrSQ3O5UEXKHcCUGcgd8UjS7kYhuTgAA4OMVLlc0UbbizDeoYPt2kYOCCBUsjlnRVnEJxknGMpngHHeqaPNJEgtV2hWB8zq3sasQSEyhTEWLH7zHHTnmoNVHqXyUYeWcEIM9cDn0qKdxGsaqMyKfmPUY9KimKrfs5V1IH+t/hwfbqaskfaflMgd1OSAdu4Y/lVg421IIp41RI0UeYGwQe30qxaxOjkN88hJyE5wvpVeZDvO5yFUAFQRhDnORRbv5kbtGzlHb5iPlJHcj8qLA4qxciCywgxjCS8uGPAwehHY027tllBVWWOVTkEdPce9IsapF5rBVy2Ny8/nRBJJLKfIC5GMA+nqff2qfIz5bu5YSHyYreGU7XYlQSeGBPOavRLIrTx7YsJkKAKXIY48xWDABlx3xkGpefOffiMAfKQ3+sBFP0MZNsdH+7zHIiMGOAQRgd6JtjY3ZIOSDjrUcAPlhXO4owIwOg96nZA5dkEfOAzAdDmquZSsmRlGRm+XdnH8OABngA1XdgAFWJkySWznjnrV2dvkKMADxuGcAn2qnt2u/mEDJGCrclT600Sl1KjokcWCQH5J+Y4+nvWNdeZLJulkAgwMlR0rXvVVOXORGMqAc4z9KxTK7NKcYz2HU/Sk9ztodxwULghozxhuRgn29qpTNskWOFgg/iHpStcmYkRpnZx83A9/wqqr+ZI6F8DOCByR+NZvU3jFt3ZZt5mZlUnaCgYErnPPRj2NRStMWKhsAkEHPBGaasb71bJWPheQTzjoBVsDyrcodg8vPIz07cUeQNJMQRbkeSUBjyRt5HWnPYxyEO8qKzDJAUgD9aA0m3zFjG09cnGB9KmVI1HMiZ6/MNxNSmZNu5WRVKl25YH7oGT9KZLgsxRsycEAnp7U60aNgQ7Y3LhQOTRnehUJnacqxGCPStLqxq5cr0Hu2bQiQLg4zj16fyqxYSwxKiW+z/dIwC3Qk1TB3qDguU4yvf159aUF3kSWeMeY4BDYxn3xTT6iautTeiQ+ZlAoVsAA9se/9asEm6IUQ7IoztbKnJA71m28iM5Fy3PHOcFh9PStZp0O2Nt5AxlsnA+lM5ppxY9YcuhTDvuIOGwPyqUQIE3KCmAA4XAzzznNV432u3l4jDHc3GRn2q2jl2y4O1c53HHP+FCSMZ3Im2/eaNQRyo74+tRFsqzhiMEFtyHDVPOoZflUquRncMfkabAHU7D8y5HI5zQSRxxfvA0RCliNxDYP056iq1yvlK7KwwCMbRk/T9a0riLhGCkLgkY4A+lZs3SaNHIkUHbu+6fSkzSm7lVVVQQoy0Y+ULyeexNVJpnaFMcOCdxJzg+lSRLM0SySgSKVC4jOPqc026UzAqclQeo7kdOtJM6IpX1IoX8qNN4k2Mcjn7vbAq15O1Mb2Emc+YB0B68UisWaOIPl9u5c8DjuaRGkCFlUkD5sg5G7Pb2ouTLcXB2hYsF+Azenpwe9V98WyQBZGxn5l659vanzxs1m7RCTc3zAhud3XmqcClclQ0RIAYk8HjpRuVFXuTzeawUI5iIIbCgDd7ZoLnzSORvGeQCPpTbm6ZFGShnI5x025/nUJkM0xOTHhcZYDB9s0rIX2bk0NvCZV3SAuoGSTwD7US7BuQ7MMSS5/h9Me/FQJaot80mT5o4UMcDPt7Vat5VWU7iUO4YBTgkd/pQhOzH2oDIrAnCDnJzg08XCfL5xSQhh8yn8gRVSV1AM6p5eXJyrdPQVHAHKsO2dx+UZ6d6Oa2guS+ppMUkLlAPMLYAP8Pfmn+dhFMrlgf4lAIA7/AEqgssvkopdQHOcZxjHepZJVCK0bKpVSSp6detUpXFyF2TZGu5WTb8qlQenp9DUTxqQpUtu+7gk4PPr61HCyKpG0LGxB3O3DHtipdmwqpYsC28euc9BTvcSVmRhGLosa+Wmflbv+NOVAN+wuxL4ILGnFQZC4O1SATkYOf8KZHCwmX5yyspz8vT6etIpInikiSNPvPxtXI7elOXy0lDAbOTwckYPORSBm2FPl/dkfQjtipJQ7kSRIMNnPIO3HemiGiAyGTfkeXuU8J39Kr3K3JjCkAnIAbdnI960BEHUK6gucsDnB9qYV8ny2Khjuwf8AZoKTKj7fs+0xqQQGUYxTQI5GV4vmJOSScDjtipZELyHIBYHqeMj6VFOu4IsKFVbJYbe4NJhckicGQpHIrYOORs4PXmpwWUSCYR7sBio578HFQxTCHd824bioXb69QRU0coSdi4JYLgjHbHQUXKWw12WdUDkSEjPy5HTpj2qS5ba4jL4DYO3qQPb6UReWpYpLk9gR0bjpn0qrNdLA7kO29jy2M4GeQPrRzW1FrJ6EkcojdNod0Z/X5mPrQr7jhSDF/dJKn6DPWs6a6kadfJfbkbVDcEfnVu3bCtFNglOGyR0PQCi7LdPlVx0kxikk8tnYIduM5Jbvz6YqnCz+bcO5X95wm3GAP89qhvrowzxvFEWkU/cb5Qfcn1FStb+dGs24CfO7Zu3A/l0qG77BZLUamPMWJAeFyWQhR696aIblpd8jKYHUkkrhn/wFWDAd2JSJC4O4AcL6c0shSC2hVCTuGApPX0GfSlYHK7LFvbRMxjjXgZZm6EcdBT0iGPMkhGXxgvnC/wCR3qRFKqSgQydcIeWPfmp2nEluX2iXZgnbn72eBjuBVoXMVXhSUGWLiRuNxOMHp37VHa2xZiWYKQMoy55z1zVpZo23swIXopxwo749qVYss6jDFxwcgD1FO6L59LDI38oxI43OynOVwq9fzIp6xBHVCMvsJPYcn+H8O1QyXHkBJXH75vmZU5H0x6VaWSSbbIW2scqMrnnt9KVxO49YleOSBSAjKCBjBz2yPWkso3hjxcR7drZZTwBnjPvUoDogdcMUHBJ64P69acEcylXchW5JYdeeRTI3VgGx8LbYEhXAyeo9CP61biWMuscyP8q9TyOOgFNgiij2yE5IJXIPA/wqWIowPmM3ltypPXn1pIykSl98wjD43EZYjG72/CnNsji2ZGwHYOxPv70/y1WRZFXIxg8ZPSnzxeZAUZSjAbQxHQHpVI5pPUoyM6SoH2NgkD1AxxSsq53ccDa+FyAccH6UnlK0POAUALHPJIHb0qujTeUASFQklAy4PvTWhWjKWoyEIoVc4IG0HGPQgist4nk3t3GcqBjnPJya1ruHy2ZmAwAPmPGOOgqtKwiwww8gBOAc5HpSZ1Qdo2Rh38TQhYgFAJ6jng9s9qitY0fkReY54Gw4xnoavXBh5beQxUBiRtLAdsVFI6ROGgRnMhIOey8HGfWoZ0RqNKw1ppCyqmSvKlmGcn0/CpkYpEyoQZB8q7xyfr7VKkSp8gViQcZY4/AVJcP91UO0EbXLDk0npqS5rYTbgLxvIAwT0I7iqKjzFDt5qMeqddvtWpDEN8nmAqHb5Tu+UjH8qpF7VHdWiaQhj8wB5qGmJa7ET27Dc0r7GPA2jG3H+NLmN8DbkbeGYYIJNTNDuQxqg5PIBPA+pqgsBkkBLgFcko/O09APrVsvR7lyUCO2LKgVB93PB+tQqu8LtcszHOSPu+pH+FRTSOkuxWyzYVgwyAemKntEKh9gjYbyO/H1qh7LUfCmZE8sEY+7uGC31Nblurx7s/LKEO3d2zWVHG0K8Ksk7HC5bgGtOBGZY5bjLSd2XjafT6Va7GNWZPbGJpM4zldxB43N3xmp7fzFMgfb85JC9selQsA/3ipkOcHuMds9qdNAYY1MyttY8sP0PBoSOdyTL/mlss0bKSpyW7jHp6VXYYg4i3A9F/u+vFWZczRKTMuWA24PQfT+lMcTSzKkn3CcgZ2kjvQzJWI7neeEyFJxjPbFUF3owCorZ5IY5IX1rRngVEePdtUA52nPB9O+axbKNlYLBvMW7774wxqG+hrC1iScrGpY427jjg9Owqo6sfMyY2IXIYHjGa05422kuybgPmVR1NZpYQEIgbc3RTgbRQ1qbR1G7Vkhxkbsnh+hPfBpBjIUh1Hcddx9Ppio5FZWBK+cwbAYdD64qMRS75N5kdkycgjgc80FJX3L07pCjkgZAJ+Uk5GcDNRS7pCVeLBZcplcHj0qveJcJ8s77mQ7sqR0x0qyk+9UMW1XIwxHPy47e9PcOVpXRRu7dlbecK7EAYHzKO5+hpsMTSqI508wM2/eAPl7ZI9qvt+9tpUVlDjsO3HNZsE/7+WRjuUqAxII2gegobKTbRauoky0ZKuEGd3VSaz5HkkKwiJos4UDr3649KvGFHilTewBG7bwMnviojOjlFjVmYkFmbgk8cVLd9xRVhz2wEEscw2sFIZI15bnqB/WobcbZF2ygmIEDnaCo7EdzVuYuy7JSYjuPPr7fSqsVuuFjkcHBBQdCT7en41D8iktBHmKL5mV5wfu8A1HcyfaHcMgw642g8/TParc0McmxljbkbFyOp75p1ykfyAFlc8hR246GjUVipau8eI5CjwqVCoP4CO9aDyGRgyMUb+AEZz6VSQsBjyAS5ydp9uM1IpIhdgS0zYOwf7J/pQpBy9Syqo6lXJEmPlLHAGe350lnbtvYSMD2xknH40qzgoFZFkK/dJXp3wT3p8MyySxkQkRPjJHc+opp3FrYtQxmXzGXBYY5Dc9e9OWN4llkBDlmwFwBx3FMtzveX5SSRjIOGznofams2CULKGbkqSMitL2JsyZHZiUL5Vvl3ngtSYZGQs4Jfg8dfTNRIQy7n3BSo5X0Ham3UgWdZECMu3LAE5UEdqBW1FZ1eUs20yxfKd3II/xqCZmkxtVgoyGYMBgelPhjWV99u64KZBUZBI6io5opJI0hDlWzuODyR0/KgLK9gtJorhmMTneeVHrnqKmjw5TfL80p+4nITHcetVYdxdo4wFbOBkfdHepBiPMqqPkyqkeuPSouaJEzPiR2QsqkEqzHk/T3NQTFG2RygGTblB059z61BPErQI0ssgdiCMDIBPoKhaS5a4VQ4SIEBQT1yeKd+g1HsAaRLokqskDDhSRnOOf8aiN0ZbiVjG+0HaSB8o+pqW4to2uOZAZoxuIBOM+wpYxboChZlkA2uueCx6gCp30HB9WWyA8KqU3Q4Db26nPTNMt90KNDlVDHOc5x6HFOjYFEWcgoBhEPy5/GlaJy/lbSHwNpfHT0yOtBm0mPAcxsSNiccv3p08e2BnWEfJ8oUjO055qJ1KARybmkXA2ryoB7H8qdJdESN5SFd5G0kdvUCq3K5G9ixJfJEyp8zupB2J/Avf/APVTLWYkGZ1kQgbUWRsAg+3vVK1wrSyAIEyN2cqxJ4zyK0I7RbsxPIDAiAZUnO4jnNNJtlOCjuTSTIITI0aBVHUfeAqgl2VZERNsTnv94ep9q07qP5SGjaQMO4wRVSWzDZKgocAD1PPQ1TiKKihqXHmTyblHGFyTzgVfkVS7SJKcKMk9A4A5FUIoWSTzVjwMbtq/dAx0NXVJ3vhwrMuUyDnHoKl6jlboSEl4kCBo1Py56nPtV7yvkLRnI2E5A6H69qqQttBEAYFfkCsAfm6mrplXO2MSDHVPTP8ASkjJt7Ifaok1uCOcYBB9f61bMbp5Z2ht2SRjGT9KqxtIEXCoUcfITwCfQfSrUQ8tXQLvXcOegXPUmmjGZKjFmZmHCj7hGM/T2ApzxJFZ5LNKD93Bzmo/lVw20knn8+gFSSAuBH0k2/KD3Pp9apMwkiq0QjjLZYb12gY61WuyEdZDsLj+Hr0PNXpN2zaWAAA28ngf/XrPnI2ukG4N2OAQvrmquOKuzNuWJDssZ2yYHzcHr1ArGmkklZ4mPyZJXyzyoHvW9cMsynYmUyBu9fXFZs6FGOxgsWOUxyecZFJ2Oum7GTl/N27Gjj4O9v5fjUzhXdljJPIzknCnpj3qzEico74YggP6jPU065CwbIoiXkz91vT1qbG/NqkFujELgsEwFO8YBOegq2fmzKTsckAkjgDHI+vFMSMK5ZW3wIobDH5iQecU875EZMklsttOPm9KVjGTuxqqjKHICQlQRs67gagVVky+9U3HOCMZ96tSKfLh8sqxT5QVJ+QAUyApHGFkQB+p7/lSBOxSVi8L7ywbBHGcA+1V5rUrMSd2FYFgvJ/OroG+EksFZwWMYbOQDzTjsQAkbYM7lUdTx0NMfNZkMQIZTKY3kJICkcqT0zTgWLoYFKSYyDtwCPTP60Eo0qPG45wrkj5vXBqdmjViq+ZuGBg8k+4A6UhsmXfDGA252B+YAfw9hn0q3GgJRgQyj+IdB+FV0WKYxnapDfcJP3e3SrSjyIg7IgL4HA4T3qk7GMrFghcNtARhg8Dof/r1I8fnQLtyJMZIz09aZsGcKuXcbstwOnHFLbx+UAZNucbQpz9TVGEvIka1flnyo/2W5H4U9S0katGp3YIUScHNLM3b+E8s2evtilkRZJDhsgNgj+f0zSb7Cj5kN/LtAZ14GCCCMdOf1qpK24hljZeB90DAJ9u9WbiMSLGhBA+6AePpUe1omY7dpxuJHOKTNI7FOdXUK4zuYjg/3fb0qhcx7WVhGdzt0bv3JP0rYJQyrIqjytvJ6nJ71mXRQKVb5d79253d/pQbU33KUckkl9gu23djGMBgR6Uu5muDDsKowIyGxio5YpFYBN24nkZyeOgz2FSsRLEUbO9Pm3KMYqWjaSvsQmMm8/fEiJR/rOOD2zSW4YTzJhDGp6dOPUVJbyvL5sLlXVSfvrzj6/TtTUi8hFIZpY3YZyOn/wBancTbWhJKYnbY+/IJ8wk449R61DHGu5AsiorKHxn7wzzx2qwHBVI1B2jOc8DH1NRCIJKFlSNJAThlOQR60riiyK3kWWMFhtVMgSAYPX/CpjbOzeVGNm7kyDqhPf3qsJoo2+fYRnOwA/L6cVbWTYo2zBlJJCrzj1pITfKUZ7eK381ZZGMzMGP+2exHt6037VDb2zTXTMNh4OT82e3HWrmoCGVkjkkcFcliB0B6DNUtVWSRBbl0ZCQyBucAdMfWk0O91oSQ5kdHRkZyu45Hb/8AVTik2yWUqGKYyS2M+nH9aqqfLuLe2yBuXeSmeB3GfWtGOMARKPlIywVl7Z79amw0xjptYMjYf+6vOP8AGoVld5X2pFuU5Yk4JI6Y/rUjmchNkak7/vY+YL1qeOBCp+TYg4IA56dTnrRa5exAXcyhnVlixkBW5Zj/ACqWKVyrvcPgE4KKentTYvLlWUldgU9cfeI9KdLGzxbog4facN0wcdxVJdQ02LquOdjN0BJHp6VXNubi4LGM7mJx8uMj2qCyt5FKZ3ZGRu9z1q6zhihYlVBG5yegz+lUvMTXK9CIOsMpAaVh1Cn7p9fpUGoRSXFsPs0hWMAkoRkZ/wAatsq7XaN2feOVbA4FRrJ5ca7wI0IJULxtx0PvTfYm9yO1Ty5NsCIsIXdgHA/CnbSrZV3ZOrewH/16YPMjmIj+dtuMryCDzn2xQSGCuI9rKNx4JDe+anoK2pIDnMaFVGeD03j/AAphzLGXfaUXIWPs31PajygYN4lw7rkD+6SeTTDiPozEqMNnjPp9aB2HsI5CFALrtBXGePX8qnuMorTLtVwPLzjnnuKhV3hAkk8sMeqDq1LcMNsJG5Wx9wkHA96ExtWIRG4dMqzeWdybuq8dz9ahNukD5YL5ij5iW6E85/8ArVMrtCWjkUquN+9nyQe1RRt9ouYsqqSscjpgjHU+9IcUyaWMuoe5QiNOWIHPTtUengHEyvL5WPl80DIOcYxUtyvngwh3eTk5YEcevtSw2wW1VoSS0pUox43Huop2sJJWuTXDeW8ZZUjZm6nJDAevvmowVknIaEsRxndyB6CnLFIDsd1DRsGbnIHPb6+lWoZsSFFZmVwQgP8ABz0otqGz0BY1cYUKXPDMTwPr6mnwHdahSWKsNwGO/TOD2qENHKrtCQVU5AfgZHX8athvlImZmzxgEfz9KpMlspqsjQSbQ5ZWGd7ZAz7U65WRdiqM+Wm4kHpz0HrUqsUuW/ds0YGMZwBnoPemJdBNpEYKyctH0IGOqim3crVsJlaJWJG92w3zDA//AF1dh8s7dzZbaA0e4cD1NZsMwmlMjKykrtZmP3RnjitO3SGCZ2zy7DK5BJIH8qkJxcVZj2mzG4CnKEMAox8ueo96sQgAHGGYDJxxuHrVYwpF5kbK7K3UZztP+FXxiCDJZTGg+RicHBoMm10JM5EZYsMcqVHT1Bq47qNyDadnUL2zjmoY/m8sqfkcBVZu/rVu2ihCkuqsRnkdxTMJNLcgYA7EBMewjBbOOtPdkj3OzA4OMkcdew/GpZ1aMM+QQANygdMioiAzPx5it8u3rjjrj0pkXTGMEkCiLLAfKfRuOwqhK24K2Qu0bVC8c9s1pecECjYSF5XHA/CqN7slcSEhcYViVxuPtTvoEVqULuRVChSJCh5Kj7v0/Gsq/G6NhFtZ3IZWz0yP51ZvppLeRgDw4BzvGP8A6+KzxuQksyh9wBVh39/eg7aULajIYcyFlLBlO0EnkjjP4c09dxmmdiFHAbA7f3j7YpnnKZ2EYCrjO4Dcfw9hVmAmdWYhFwduTxnj+tIud1qNgldftKM6qm75VwduMcf1qzbuUVApBfPBxgHpwapug/eqrMhOcBudw9jUax+UCjBy5PysT1x0/DrQYtpli5Esdinlrvds5RWxn8fx6U2JiIwfs8jk8llcAVIz+ZEEUIMD5vp6804yOTwi7Rwo9BSEQQJ5L7CsbbhwWPPP8sU0lFBf7qodpdTu/EVahdE+Vx8p43luRxk8+lVJsgKWJLhsFcDDZFNiSuRxRztIPMdWRSWLDjOeh96RlVHLRI0bA5BI5cn3qzEz4wyblc4EkZGAcZ59BR5Ym2n5yoGI2K/mKlWNVJxd2SWE0iKiogCq3p071pPcK53ncAwO5fvEnj8qzoXEQXzF25/5ZkAjH/1qeAbgq7E+X/EBxnnjPrVozmk9TRLecCsrhDgDJ5xg+vv6VdAAKAEOoXOQenv9e1Z0CwWZaJnwSd2CcknHb2q9a/vWyVjC9FXP+c02YSSTuh0Sgna65YE8LyFP+NTJbbd+Ryx3HDZyfrTM7lJVMLuwCDz/AL1PXYjOImCmQDaG5PfNSJjXieSRyx2KCCoHf3qqm5xNGIpIGVyiE8+YOm76c1akgRHDBH2kcYHB9qZCWMYU7UKnAABJHtTGnoQRwvuK7hhflCghWIz6f1rPu4QcouGyN/b5RnpzV4sWZiPvhsMc8jPr6VQvYla583ajMTndyMA0mjSN7mVdzg4iiLlUHrwB7+tLbqWVAoLSPxgnao/GpLu2ERKoN5POGPQetRzB4FUQrlVA59fpSsddly2RVvMicoJi0fVMH+Idcmlu3b7HBDaBiQeQRznuSakEDyxyO6lFLAt5fT6YqVlfaqzY3uvGRt/Eii2g7LQpQXQ+0KkjMucAoATn8asSNK00ryxPt4CgDLIB25oUwxW7TsMSA4LFcbgO4qszSS7yxdgcgu7YyewHqanyFy8z0Fup441SJlbDfM7k5bPQZPel08eUCBIkh5cp/ETnAwPT2qNJ4pNvAJj67eoFTwRQi482NULAn94T1PYUlpqLlstSSWWMJHGHG9jgnOAuaC2FSU7cHpleV7H+XehZoyJVuEDRKwGQATnvTXuFe3ZkXZzxjnB9MU7IIryJCU+8zAxnjb0z70PLCFZmB/e5CMR94DtVcs80ah8ho8j7uCfWpo0MjlpDI5QjZzgH0GKAce5Ve78pHSEN5ZOVQ9cip4vNng8yQyNuJDcdB6Y9O1SXyJcTRkJ5cp+Zgx6D/wCvRzAiCPaoLZKk807F8ysrbk8EcMMMIYbwB26YPY+9VhF5UMrB5J4jyVK9Dnr71HHeCRZFZjj+8F6c5q+iNFbKYnYDoWPHU0JXIlpuNIQ2qlnlC5CsiHHNEm8IS2SFIQg9D9alnVYgp9GAYjjae1JCJEkdXZmZlOznhgf/AK9CViSvCkilfldGbOAcY4xReSM6LukKzICCu3nn9Kcpm8sNKypJj7vpjimIHCnZIGKja+772PrQNt3uENvt8xRKc7FbptIz1UetNiaNryXEspbBbyWXC47H60vmo+I0lZmXBUsAd3qKZJseRRANysN28cbscEewFHoN6loQK0XmcxrjPGAQfx7VHJINyqjqQF+VQM9fWmRXalisiE7eM9m9cnvT2eKOESCISPztxx+vtS9AV1uSvAepdom2kbiuSM+1QWts0XmglXeMg73bGaBIpCM8jCR+QpJ+b8ajePfJiSVEbPHcnHXNJg+wsnzFN6AyO+3bngHrk+vFOHli8CRoQiKWZsZLH1Bqs8JklIjCsSRjLZ4/xqdZzDJGpkZowCrKMDAp20HbTQsWex/OlXPLZcE7cD0zU0iiSQOjgKRhN3QHrkHtTYz8rqdu1+UTgkj3pgkyio5VkIKqOg4689jTJ13HwxTIrxzbWkKEbogSQe2fpT5JGt1ErjEb8Myr1OfSpX88oI4Gi8rbu3sSCD06elZ5lbzCIdy8YKqpxkEcgUgXvO47VFhhBJBQyH5Sew64xUsTYQyKwbK7g+ASeeePaq95cxysoeN3cnAyMcD1NWLUOibio+/jDN2/u0+ppa0dUU5XmR2O2RmJ3IDwPxq0UZXRSUYqBuBIBDHsB1qf5pFD+SI9wKbsZINVVMat5sbjcCd20ZOfqefxpNakJXJYI3DhGBWJjnOAccn8quwKI2jZ1OFxn5Rkc+veqMz+W3mhztOBuXBJPbr2q2WF0AHUhgMsVfGMelU9i5ptXL7zfZ4d2GEmcE46j3FXIE3QorqMMDtJbKqKiRwUUjDc+x7d/arScfJOu1s5BQcD0wKNDlk1axP5f+jKo+6WyxzjjHapWdrdACkapgBdx6dse/NV3Q7WiXYjsSynPGR1OO1WpJAwxnIHDfLnHrTMGgkkLopGGRyFbP8AnpS87/3a8qcbh+oBpXVAVTOBj5Oeo96hiLl3GFyBuAHb1oJsMmVfLKuRzn6Yz1qrPbtPaybNyu/Azzuz3FXLl0YhSpyFA4xgA9vpVAsqbSuWU5zxyAOlBcbspXVsoccKSgIIccDI6isV4yThCHjwWzjqfUj2rZ1ED7u5lUDkt3Pas2Mbd+5XOGALBsYz3FM6qd7FJUdJEDuuU4DD3/nzVy3QLAzO3u2B7dMGk3BUVpCqM2cZ68HI4qRpFlVcEM8iDaCvX1pFTbaKdwEEwBLqzAFO5U+oFTzR7kDl1JU/MW4z9KZKVcq7Fd0Z3JjnB9KkWJbm5ZQEQQklXZsAdMn3zSW5gyBp9kr/AC/vSoyzDOD6CpIlkKZgIZPVs1BsLEuHOzB6HqQaRZGlRT5cvAxlflz74zRa5SVy27sPMJZQey/wgdDTIJG8xi4MahsB2OQ4xxike3QJwVXcTtDHLE9v5VJbjEOSgD8YXGQO3PvRuwHmRBkRiMoCdvHB9eKjK7ZYXBZV8vkZ65OfwpSRJudkZf8AlnyORUkT7ll3r8kbhVPUflSGNQtIP3KqoU5yoJ+UnkVPahyfl2rGPuknvnvSqFRBIEKKflx3P1x0qd84UgLGuCcEcgiqFKWlkK8G2bzGYea2cEjoR61ftSslvIfmCAbAcYzUayLuUnOCpcHGcD/9dTRbt/mIu7gbQ3Q+tU2c7k3uTQsDt2Ic7MjPanFT5gcncGIwvqcfypmS+9921cgg45xn+VPV2baXHHIPr+FSJjJpCkMu4HjhOeBzUYXYihiGP8XOTzSzhLmR1iLIYsZI43ev1pGVYQuxxtIOO+P/AK9MatYI7eLyywJLDJPHftmsq9iGY5Wnbaxxg9f/ANVaVzHKEAGQCoDbeDyOtU7qE+SqbV5PKqeRj0oLpP3tTKmVmVicgcK7NzwOmKbGAtsGwcJlgpXJ+tSNDI3lM8nCjOScbuKrr5ifMq7iDgLnAweppHYpXVif7sks0cZBO3tyWx1qnPIxINwwZFYknnv/AA1bMgmWQOSkxHy4/u54qCOJURxIyjBHyt/OptcEu5HJs2lP3ig4K5GTj0x0FVZLZkfeiM0RPzDnGT3/ACq19qDbEXcAo+Y5+U+gqbhgm394CNpIJyPTAprXYFJx0KMkBh3eYjqP4PlwSvvSJAzK0is235RkjGaukSFDAZHJYHKjGQO5z2qFp3tkTa+MHdtfB3Dt0o0KU21ZDJVRIlaSaQwx52LsABPrTobYGLzpSVRuir3H0pwmjmcOoyR95RyG9f8APtT4lMYASTcAcH0XsAD60iHJ2sSCy/fytFIqIRvJJzimOzMQN6hHUYO3p9KeyNJOoZwVHDYHHPY+tN2GOIrI+2MnCkHr/hT0ITvuM3xGWMLDjZwmTzgdc+tQTThrhcD5V5LKM5GeKb8qKZd+GByXByc+1MZ45gwYlw/zcHOQOORQ9EacvVE/2aG3Lyk5LAg88f55pvnkttjmd4VK5VhyPfimRSPcS4niCxbsIAvGPerdxDGqO2XAzyynHFIaVviGhiIsByGUFgW6H1+tQfaZR+7DRkfxEDIGBnA7ipfN3lht/cquBsII5HrTWKW6sMZkJAXvn1HtUt9hW1sW4oVNuDvKqQG249agk09dzOcy+uDw3P55pTN5VoJZXd5GI3J/d9OaW7aaXY37sZG0n+Lir06hFMiiEcUpcRYf5gofqKrxGaNwUVii8FNvfocU+6NwzQsBtDHHzEY/GowMnLK4Ccnac5Pv+NTYuO1zRAClkIUsF456H3zSxw7Yzt2EkjLA5AX2qtBGSrtJJ5e7AyRn61O00e7ylJZUxgY4b1HtTvoZeSEUNHHvhh83Pybj0H0p0qQtP5DbhgArhPbpmnXd28cgARgDghV6H2qsjsN7oU3DB3uvUg9Bmlbog1epG1nEfM8xlRC+5TnG70qKS3mj8ySVH2DlMdf/ANVW7mXDbdpkkbjKjp9KLUsYfNmd2DLtkAx68fQijS9irtasgMZSMeWxbcvz9iO+KsRTrBFhVkIJHXuTRKdih2wMnAJ5PX9acq4EscbBVX5l3cbvoP6VRcnoOlnwAyOAWXKgdevTNVy8q73kLYPOWJwR7U51ZkUOvlw8c9z705YGjIjWUhcM4Q8/r6+1SJNKI1VjllTZMVlAxyMDP+FSXV7JbW4lWDduUDcccfh7U1It8YCgqCeGPJx6fnVjULdmhjAmUAj7jng4Hf2p9NAbWnYisryeaKMOhZGUYduo5rUS3hijbO3zdpJIAARu1Z9ttgiUiNY3OSiLkE+x/OnqskpZiyvIw+ZC39PWnHQbSe2gSIk23yclFJPykbT9fxq3aLskAmJEYPIbgE/4Uw7UgjT5thY4YL3HrTraF47gMrARsNo3jdnPWmK7asabQMA0MUe5BnAHAU9uavxgLujZmZiqtn0qFVxcLlyD0KgYBFPiaKRhIWG0qeHBxig43qT/ACGEmSEtt+Zs9iPSpBK1xbIx3KrqSQOCB70kbbFLdUbkjHU06ZZChSMD7uSOxHr7UjLqQtISy7i0ZUbdjd++c/SrCgtjC4B5JBHPuKWUERlWwAv3s/wg+9MaMrsclWGcow7e1MlvQY6MwO1mKkDCrjiqTnZvllY8EAqOcCrMjhPLC43HoT0zUckYC4QDcQQe4YUFRdtzJvz5hHkujMSM4GCOOhql9njaKQh9rqDgqPQ8VqTAK5hRtrqQSCMDb7GqcyrskaLI44O3LA+/rQdEZe7oUZojKzkI5ZhsKj7xHYiq8JdBC27JJ/TB6+9TXmVYmFitwMAqTkkE9PrTmiMSskq7QCRHxnbgev6UjTVRHtvG2Rx+8GAvQcEdc+tNW0mawuJkVpY4Ww0nQKSevufagshIVh8p5HPTjGKuwCG50FdPW8jtZoZC6NPkJIpHIJ7EUzCTsV/s09jpUkrIj285A83AYx4PQemf1qiLtFztVpRn74AGe3etS6SGy0a6s0vIJ7mcxgpCSUQKclifXtxWHdFJJSblXaQcZUgDFJuwR11J4YiHyPnYHhiOQB2z6VL5yi4LeaoBXDbuR1z+dIoXb93naMDPOe34UshSJ1VFzhT1XPIpFrUese9Udg5Vju54GM9jT2QBXkw5DHfsWq/mMYDwoLMARz7dqnUlOThJHUKFB7D1PahW6jsWFSIeWPMEeSWK9Nx7GrLZmhCMN24ctyQMdqzFmLSxkEMW5Hf8T/SrwZWuB52SRzjJAPsAKdyZIn8xoYF+zxMw+58x4A65q/CUKKu/chG49jk+lRRSEkDkAk7VJ4P19KsgCNHCDcQBgDk5NMyk9BxfaYyi7k6YPAFLO5UuIgNudvTJA9aVQyB/OAAwBuzzn6UkrLIoMj454zxkduKCLECrIEA3tuOck9QDUkACmRsZk5O3Hb1NSb0BQSBTgcr/AHR6Y7UshAlLIMtypAPAA7UDeu5C+6XzSM7QACf7v0NUmKxhmOQT1Y9WzWh5v8bscdPUdPSqF66uHYkjKbeV/SmVF6mLqTv/AKuMiMAYOehPf6VQiYrvZAw4JXP8Qx71PqPm+c6EEoAGXHAbPeqoiDgDczs2RuJwoFT6noU1aNx8UvlOvzDeFBG4Y59M/wBaR4ne6ViRJnjc53YH0p1zExBdkLccnPA9KZAQQEB2dAxzwMUrA+8QFix2tFGA2cMf7wx6etP814FVTK248shAJH09Kla8RCybST1QIO3oDVWMB7htpZof7zLx+fcUX1Fa/wARNFPl38xNoYcoeuOop1vmTdIFjebqoYBcnt1qpdjzLuRsqZSAoI4AApqyvLDscs4AwGUYzijVPUnkTVx+nxZd2uo5IRklQnOfX681cW4iMsYPByAYyOW46D0+tJa70hK+YrohwBnnPapJh50yGEB48EFyOan0ItqTPko6BcEnI74ps0JVWMUbFCfnXI4+tR4jCBRJtJwRt6ilZpfNAaPYxGWKv9761V0CjYpXMGyaaIuuwYO3bjjvzVdOX2pEm0fMobqanvIpTM7SAFwN6hTknPrUEcGHVpiSccgNgZxk596d7nTGziQCd1mLSFn3Zzg8qK0oZxMit5gQDB2vn5vQVnxIq71jkCD723GQT6USbyw2yYYH5ewHtU7C5Lmm8axRAOgI/u5wCCen4VEioWGWCyEZHbb/AI8U17keQYn3MOAeM8+57/hVZEafLw4l55Vs8egFNrsSoPqWnZobdrfzCwYbicdfTmgMJYo28tg8YwMjdvb61G2ZIVXBReM5HI+lNW7jMQhlkfJyA2cHHp7GlfoxpaE3mbpI1fdtcBSSOBz2qS4aO2UBJAFQ53MMk8/rTY5dm054Xp8ufpx60sSmedoyqIU53sAQ2e4P9KXQmasMjuHJUmNQoYBZG4z6n6092iAkZJSpwQzj+I06bcboRzEGJVIyjZ69KZp8UT7xw53EoCT9M46U9bCt7o0FXRPLLSYxgEfd/H1pqBllkXLOy8guc5HeicOq4VlXC/MiOOO1CmJ1EYXfISWYDr06igtE8O6YKNvyg5G7gineYiBEcLHIeDg5LVGN37po1K7SVyxz+YpzRKXMxJyRjCcYPbFN3Ymr7kkG1iwILHdnaTgjtnFPuJFaQEyIjqCdx/h/wzVed1iQSbGbf82P4iR6mmxyx3EZCjJyDtfnii/Qi2t+hMbli6vKmMMAGwOAetEDjzfughmwWJ4z6/lUBPzsSEWFDhQ2dzNjuO9TGQNGzCNgTtwuM7gf5UXRXKrEX2l/NeNCGJbBZRyDU7PIAfMLEKCCq8Aev51SncbonjDq7DLAnjNSukrwPI7AFWAOTjcT6etJamiScdCdZZXuWEb8KoITIGBjjNXY90mwws2/70hI/lWQIZAzBVVmHzFh/KtDTpmLguRt4wM5Jz2xTXYicbKyL++RJFZt55wVxnIot0KzZkIeA84OSV5pmCJt6u6r/dB64PQ1Zi8xJN/LJJ1JbGeeTTMk2tDSTPmqznlgQOOff8Kmt3AnZFAdgoJz6e3uKpoCEUMS7gnaA2PoM+tXlAkCYwoA+cd8gdfegwlYsbijEBFVQCd3cgen0pSyAP5YDPt3DB5wfWoYGlZV2ry2edwx0HT0zT1QqFccInzYUZOO9MyatuLbTbvkIXazYAOT+dOjAVSEQ4YsWyfu1XkkVZvJCukjZJfouewHvUjSbmRk3OMfO6t19sUiWhrkiFMp84woYccf1pk0reXkBULZUg9j2x7GpvO+cKAfmY/e520yaMNBtAAY8emaYl5mbdKURGbGQuXI5yvPIHtWRPO7S7cKxCnAI9T+la/3oI/MXy3GRwfunPIrJu2C7vOzu+6No4I9DUs6qVupCJJnETuqPH9xt3XJq1DbrOMrlQD0fvxyMiqrf61vL27CuF/3euPrmlmkJDqrOjj5iVXbx3HuKdy5a7BE4l+UAYUnczenQD+RrVtpLe10n7TFZwzzGYxyvKu4RgL12+9ZVsplKrI4iD8FnPCHsTXQWols1Mdnr1jHGWJZMZyx9CRRExq2SMO+1OS4haCTTrK3LOMPFEQSMZ69s1mSFY22y7HOPlJGSB6V02rXc76ZKtxrNndjcgWONcOTntxXPJKjKCYsk9cjpSluENtCIR7laWTvlV8s8nPTIqWOTDLkDg4BVvpkUQFY4thyN/zHLfMB/T3pmSZBkAqqEICNoZv68Uti0Ojd1lIU72eQkAjhfT8KtCPEhBIb+HB7t9apjcke1cLuOQexqzEpdgSXIOR0yMgd6LltE9r5rxZgOws/BI4Uf1qRX2XEMYI8z+6OenGc/rS2+6ORRvZXcfKCAAPWpUVMtKpIZsrk85qrENvqXYyTBnKkH14Jx2x7062MuWcjYh5VT6Dt+dNiYHjLZ3ANgdsda0fPUEAjKBQRk53D/GmYt2I4WWWISs4cjrtORxSSANEHDDYBhRjnGevtTZgsaFUA+QqVVT2zyKV3Ku0yBztI4bGfrQK3UYwj82WKTO3OGGT3pcsHw4HUjj9KdLwTu+fHPsxNPDjK7FYncWPHFAyGTnawJ+UEKDwPzqO6hjcq7jDKv3VHOaJdsRU+UWU5Oc+tV3Lz7o2jKHIIbsaY1HUp3ECTFHIICKwwB1/wFUEj3bnJ2AZQjGQB9K3GiJZuPlYdSOh9ciqTrtLONzkYY84BJ7mkbwn0KHlkooEQVEbqQcnjvVFtqoUZflYd+Bn+9n+lbCkzKVBy+DnHQD1qpPat50e/AJ5HYAetI3pu25W8rz7XBA8qN8qOmT6+wpY1QKhCKzZJynp6VPGgVQyD5ycbt2fxqlKHLLIWbkk7TwAKT1ElzaX0JAftDFpFUgYGMfN9ackcaQBGaRgGztPXg9T9apoDllCFxnqpxmmW119okcMRJJxgd1AoVkV7MuW0vlu7KUjjB4DLz+dSi4iLYD7EY4yjYwf8KilLleRtQsCCx6+lRxRFZCUVlAxuORx70WE0nqy/uhVIxboh2gqQvTmq6yPC7JvR8nHoQcdDSICyqIwOpG4dTVZwZmXezMg5CqvOPb3oYRWpaFwRGp2usqKc46kVWj4TJIIIO4EdT7ipbY+VKXXzAeMHPAx60y7VSoAJwfnY5wSeo/GlayC1nZCEWqrG0SCNiM4IwfYmqzRmR9sg3op4YDHHUj/69G5vK3uhKMcbRgkVEJwkhKKm7OSpzn0pX01NYxsSyyGVYzGirGMqvJIP+NJblWf92HXIHKngfWntKpVhsB5zv7n60ss8ZTEKKrgjp16dKFvuFwJlJB4THBZ+hpzKvlNiPGDn7uMn1qFCGCtICjkHh/8ACpYS5cNLnCgn5SP5U0tR7IerFWRY2RfUseWqyiRx8IQgJBK4xz3qokhkhxt/dsDt9afbtHtX7QWAU43kgHHapepDjdFqUqIt7nhgQGHRPSq0UqRRKY0Ux/3wx2gnt+lJLKcDY8rEAgHGdv8ASniJ3IV2TyjyxHTPsKer2CMWlqDSZKOUVxkHJHJ4qqVeCLzCfmBOAO/096khTbPhFTYRt3HOVA7VbeBfIWPGCxJBBp2E7RIYp4ig84mQg5bHX8KmmmmaQGNR5WB8p64FVhatGQqqwbOVQ8tjuc1JYK6RyNMQIATlRk7TQr9Qaja6IklM7lkbeG5wRjinEeZcB/LI2qFxyvQURxNIw2JyGBXnBOc8U+dGjViGVu4HJAHTOapIptJBNOku4ojLHnKxscleP71OglKFljAc4GMtgKapRynzdrR43Lj1x7Vc3M6qUbhRltxHriluKURJJY57oPsaOVhyM52j3pQqsQkm1WVf+WnPfsKbFArTEu65HzAZ6/j/AEqcKsbu7NvDgcY6fTNNIastCzJDEkSM86FjnhV/eAdunGfaoldGuCS24gcSx8qx7ZHrSvGqOrYUBAOR0Bxn/JoWNYT5jMFXG8DIxVu7EkX/ADUYq/lK24kMiryB+NW4IQ7QLGHRVkJXJPT2zWdbyGOAM5Ub+ctzz2rVsxIwj3jcXHUnhSD2qTGouUtvI+9WIVWHOCeD7fWpYiEjxI37xh/CvIXtUUy+YdhJXJ3ZC/oPrTmikjdXiVWdgc5P8I9qDFrQsjKIyxOCAQAQOencU552KMka4DJjcvUdjmmxhoplYFCNmSw4z6D8qlh2lmjO4YHfqAaDJ9wh3BY1BUqcH5sE57nNRi3hjkdygw5IkOcbsdKbhEdw2MgYYYwMdjSXHGwFiQhORjjBpEtakmxSqAgkhi2c5pJMLCfMYqpbdnrj3xRGgZXdMDKgc5zn0/KolLBVyAqnGQQf0oCxDcIskMhlBVtuc47juR71l3ancQ4LYw2Om32xWk674zHlC3zEsc5H09RWdeLNMjuh3IOnHb1oNoLUz7rcYwI9hcDd8vGOepqPduQsSABuPTJ/E1FcGTPzfLu+Xd/Dkcc02FWVpEYHzBkEjo4HQgVLXU6XHQnjdlRjwyldnK4OfXNCFULOwfByGOPukDjA75pG2xxgI2QTgDPTjuKcttMbdrrY3kxkJI56DPQfX6UGMnYqMiRO3mbMAghhg4PbinSSMG/d4j9Rgda3Db6jpVuzMsSRyupkVdrMg6gN/dJ/WsQujSSHc6fOeI48r68U2rGalzDJnU3rEOTIp5dh1p68xrhgCMjGO9NQBlkXna3JJYEcdxTyoC7g20lQACMg571JaBsbVJJKE4GVqeBWDYjIAZQBt65zySKi2sXXO/7mQo/hPrU6KQMozKVA3ENjJoHdE8Gz5QihpCCsZ5O4d8+9TWaymMuYeThcDrke5pltI6wlokYfLlj35ParKxh1dmYrhcnB596pESdixbyI7ZJYsRhR0B7fnVxHVGieQBmyQgB5zVOD/XlF4AA4ODgjn8KtysBCm8I0hAIAH3feqMna4SSEsGO3e7YxnnjrxUpljw6s+ZeMgjoPTFQybTtfHzgkDC5wtDvGs5kkXZsYgc8ew+tIdiQ/ejZn3KuDk+vvSJjezMfmIwAT1bNRRgplmyhB+7nn6gVZkVJGLnARTk7P5mnYNtBiBmLOeC3Gw9Mn+VR3pOHQ7gV5Xd/CPf2qWXZjAZmbgAn17VXnlG7bIjn5SCx7nNAlvcrvtllcEKgBC55A96zdQm2AyW2NhO0qB0x2+lbE0TFSFILdSCe1UPLEKvkbDgDcO+OpPtRY2pySdzIN2Y4kjkYhhwp54PfkU24Xz5EkWR9nGMVeuYU/eEgtkAx88Fs8n0xVG4URh/KmJOBlenHrilayOpNPWJLCzqrLPgNy2cYBPY1HIVZCCyvJ6KMfTioPtKuhB2kHg4GQppFMuRKQrl12BumPb3oTDldxsCCPzMxsZAwdgT+mKkS3IlaQxrtZs9MZ9vpVmJVQF5In+7vJY889Ke7edbOqRrIgA3HpTVthOdtCkEQIxkjAXJ2gNnB75prM6/NHJuC/LvK428dSatLFGIEG0qO2V2tn6elRTuFZPNdcD5Rnvn1FIi5Wt0EUeX2YcckZyff2+tPaYQQEhWwOgU+3So5EiS1JyWfcfm9B6UzBk2ljlR/Kg1tfUkLOwQIHELdUPOG9R7VKo8zKsu13yevQ+uf6U11OzEfmFR7ZPT0oWaNYWZnZJiMAP0B9TQrLcJbWRXeKI8CQ4P8AEvfjt70gjeNHAjG4sCGLcqPT8aktNuGXy4wwGCpPDE9x/OoJnBnLSABgQgwCRj1NLbVlLXQjlDFl3MI/76/1zToo2icuSAMBjGB1HYmrFxb7QjMgwBy45xntT0RWcxMgBUDcp647A+tPl11Fe5XaZFkKFFZlOACf0FJdIZkdpEIQEFUQnP4/4U66iQzKwyAAEZY8EDHP51KFZFRQhKs3GDycdcetJ3GlfULaRSXQhwqj+7yvvTo4VacO6BoyfvScjOOoFTWq+TO7qoGRgZPB9vwqvcyHzsDIOR1HfvQJN82gu6OKOEOxJO7ewzgLn5R/M1YE0CERsDJuXI9W/GqUDtLy7HIJAzng9hVwW3nJz8+Dk+h96d9NBSG2+6TLYCSAgkeoHariL/dAKc7hnHGKqrGzThCrRkZ+bqSB6VahuEZUDIN3Uv1x25NJGT0LHFwjOMBgBkMeT/gKqyIzEoMByQPapIklaUPHLlAQAfWmzSvEgRTjjHTnrT3FFdCstqxi87dvDNuIU46e1StCnlOAdr7SQR0zkdahFwwIdlGzGDnHPsKld4pkjkjby9z4AB+UDuPc0LcqV76lcwbYBcRoSWOXCjO1fVj257UEAblBdnIXDEjGOpyPpilREVmWMM6hsMoQgdf1qZoUEuA0nl+YCu8YZuOlM2UkOt4WEP2kKArNjA5wabGS0bSSE7UPlh8cBsZ21I8TKzMwMc20k7hgDt8vuariN4w5eQNGzqNvXb9ab00C9yxCVaHYyBVJG0njJq0Y0kklWB38rdtXzOy9vx60iRJFGQXLIqnZnnHvV+y8p4dqu2Nu4FxwT3o2M5NLVEFhDJHhtm+HAIIHT/PpWhMDNGInnMMmQQ+OoPb60xGCQ71wh4zgE5PtVqZf3S79pGQAMcg9fwpGEpNu5ZgjMUADjfKF4LHOfYVGquY/NnKeYFBTtj3odhHLj7RwewGQRjvUhNtMrRRKFZk6Nzj0we1Bnr1FieGWNo5FCzYAJzgP7irJdoiGZSBgKC2Dk9+nrVa1iIR1ZDIo+ZQeePUGrKM6pyAsrAEKeee1C1JklfQjwWnmZ4lBIC8HIYe+adOrbNzsSrcr3+X0NLb+ZsJZRycY7565+lIW3O23AIfAAHb+tBPUi8pQrs2A7Ac5PGe9NDnyS4dGwRh2Hf8A+vQVMYJxvSMHawP5inshbEecD7ygj5TjoKQys5Z0YbQjrn5cj8xVGdQH8px824spPABHQfQ1fny7x+agVz06fh+FV5FBG1EUBV+6WySaRUWYVySSUkBLMMse2D3FIE25A3mRQSGz2q9d26Odw+WRQMkDGOOn/wBaqswOB5Zwg+Uk9cZ70mdLldaFdwfmVdqr1K+h9a19Ku7L7BbwahI0S28/2gKqF/Ox2Pocis6cK2VbABHUc1t6EzW9jbTWoX7RLeCKZ9uSqcYA9M88047nNWehnXeoQrbapJ52+91CUN5RTAjQHue5rFikniUrEgkGeWLdTXRTxltO1fz4h5MN3ut3dcEuzYYA9xiuYfcDiOQgDsDjFEhU7a2Jo9oPOAMcgLj26etPXJALKM9eB0x2NMJXfnrluOcDPrTo227ssCF4OOPrUF3JY2LoduAwH1+v86nibJ+fDEsNzAY259arxLh08vPU4Xucip4o2VnIBLYyQTx7D8KaHa5PBGfMCkr3Kp7564H9auxOqTBQCeR2/QiqkCRyS71ZugIye/cGr8Lcl8oqkgNk9f8A9VUKSQsKIGmYqVkdjuVRnf8AjVwHcFlGAUbAGcjHvUEYYWwMZJfJCgdSO3HpVlS43LtzjHBxye+PYU0ZNdUNXCvt3yZGG46tnsKDEksqsEHkEFuuSGPtTljUqwDAS7eSDgjPT6UzHmZZSyEtgbD26UDT7A4YM5nClgOGHp/jSouS0YBbo5HqadJGsaHzJA7ocBWGASPSpIpQygtjKLux7HtjvTsK+mhGrbnIYqGHX/Z9qjn3TwjMgUyOTjGcDpU0kiNlgdrYyVA6j1+tRSJuCHrsHCHoR600Td3IHVSWBJMm7aT65qF4ghCMWJPBB4NWVCSKwc7MtlcHqx70s6BiBtBcH5iT6dSaLdTRStoZt6QsJWMcK20BemcVhyRtKjkAmQD73oBXVOImBUncVO4AHGfes6aOJ4zv2qrjJHQ/SkdFOokjn4YVGRkIqLj8KkyzmMFzge+AoPap5YAI5MkbjyVbkjnsP61XEHlouXOQMhQeuf5fWjXodPNzEs8rKJEjkc8gJgZpbcyR+ZHNF80gB2g8gDpmp7NUCR7gpYA55yM+/vTbhArBV3D5snuDx69qVupi7PRojmZsM4KAZB568dfpiq7jd5sjRY3j5CzZA+gHap7htqLv3InBGB+mfeq0QbzS2QoA2j1xQmWloMi2u7bcqiLhVxgM3rUoMSMGlIQA4x2/Crjw4Rt2F+XGOCR9PSqjKBKAo4zhEC5P4D1qgUkwicgPiRwuMAk4LH/Co55SYxld7ZGTt9KfLGCAWRuB25P0NRMxJaEEBhnK9fyqXcaXUdCGTOQWYHBx0zUisyvu8lI0VSSTl9zdcD39KNqwxKNwZRnaO5Oec0tq8QbYzjeeYzyfzFVsGupVdZLp5XRT5jNuxu2g8dNtWgouXbhyxAYnGDnHJ/Sn/ZgiJNIcksFyOAcelQNdQ2yRxEEuThhGCS3fI+goQlK6FLJb5MEa4POcZyf/ANVPK8eYi7ty7gAfmXnrxz2pY2OQWJC4+dTHwPw+mKrwxn7TtAPchwcfjQ30HELadkc7fuFyXycEkjOfpTprdrgO24opwxBHb1FLHbFnySzBzwo5A5q5KdjEP0Iwe56/ypINE7oqXlszFpU+UE9j/SprUyRptIKpt4x1/D2p8jADejJwcc8cd6rvydpLLgjg/pinpuQ5N6MfFbpbO0pRllcHaTk5z15qzBAyIB9xSc/dwDSWpkEOZN6tnAHU5HarbTG4RvLyQwHOcc+vrmpsS2+hUuEeW4jZtxhH/LMHCntmo5SIV3bj8y42v259atIgiTDBxu5GAePp9aW7IZl+Rm2HgkDPTrTHu7FGeMCE7IVeNjuGOGBPUZpPszCIRsijg42nIPr+VWFJTYWQlCOcnA+p9KgM4R1WMAKpwOOvPXNFluzRImWQQE5mLFV2jdxgHvUbGN4lDD5/NBDxsR25BHfNTifFzbzKFfypMhWAw2PfFSKoWQmIOwJ3vI+3knqOOpHqKdhfC7sgaUySBJWZjjhicEAVLFEiyFm2vK3IIOcD6VDOBA5Z1JLN0PGB7mpAC13GhKopPJHGM9PwpFpaaFtIlWVdpwRneoOAB1/OrWlKHRmTPlB/lB4IGTTUR1jKtkoW+VguRwetXYAiheQpUbWKD+VLqYSbWhLHCMLE4fc5BBzxgdKllilEqhVLbgCWBAzz09QaTO6BCh8onjduyB+PrVyRhI8iqQM4GGAyCB1B700c8m7mZdxutpIIm34yDxh8k9KkSIxJAQhDLkZUj5sdj71eiIByFYtnbyMFvepfkkjLDCkDkf7WeKBupZWsRqG2+cGYMqgAe56ilgYopcknjAHcY64p00TY85SyqPmODgf/AF6bExllZyo8srznHzHvx2oMt0STBy+8bjG/JFQFQYVWNvnc5GeAcenpVmP95CEXK7OuTkY/nVcjM44LBQQCSOB6UCiOxt3GPjK/gexqMgbSNzE4Chu3vUwURBQxLODgEADIPemEFMAtwX2gj1pFIpuWMQcopeNsc55A7Yplx8kgOW2sDuGMge49PQVbSYkgyrxnCke471TvIUEB5Zo2z8o+Ynn+VIrqV3IJIly25QT3xx/OqDoeMAklOo54z1q+y+XEQkhZR/EcZx7VWnwA4KnAbkhegpM1RSmBUDj5gcnJxyf5itXRYRHaS3jap9hIk8s/KTuI6Y7E1mXQRlXJ4DDBHUDPFT6Zc29xZfY7+Of5ZGmSWBN5UkdCO/anHRmNTVF/UrRNTtPtFz4hWWJG2BjEdqMemQDx9awryza0uXgkUeZGcMR0J9R+GK05/sVvYPbQJefZZ5ENzcSRbfkB6Ae57mqOqX/2u/mmi3QoSAEJ5AAwP5U5WIp326GdtG48gAnaST0FSRLuC7lGRz2yR61CuVZmK5IxkDndU9vtBCArwMDHb2rM0uWgp2qFcKT0O3J/A1NAG67jEQMBcZP1NMGSAQhCZyRnAAHp61YiXYygALuO7B5AB/rTKTLEKlYlDKpRVO0Adz6+9SW6yC6yykqEC7ivyj1/nUVuuw75G3MFxjJOTk9qsruBGCFyoAA5yO+c96olsmYkFkDoMoQHPf6kU/IkIMRYxg4544xzTYkeWMttJYnCrnH1NSBx5WH7njbx+H/16ZDGKhMY3ja0gwPcg01VdcAygv8AcIPAyPpUwZ2G7GSo+638Jz0pkvlyys0nyoDuHcZ7dKYJO4NK8hQrsAXOTjJPtUsOY4OEyQdxjXqR6mmoFZTuPllxh+MBqRT5ThIlBVTgbeSaBWuPQHY+3O3PzZHPNVJYSt2WfcF2jJP8dXCTu+RtxYYZc9MdKV97EheZB0UnGKYKVmQDy/LBwoXkc9SfUUxcKJGkDZY4Jxx15GadG8ZDHBUDg5PJ+g+tK0IyWJDqeSoyce9CHYjfarDYqAgfeI4FVDh5CqqwKEBht7detW5XxvAD/JyFBA6duaqnEzM2wxEjO5mOMn/CgtJmNfMxdWRcpu7Y3NVKdjGVYuM909vSt+SIYjGwb93UDg+pqD7NH9qj3ybiAfm74NI7ITSWpTEbNCzouJOpDABTnjNUI4ZQhJC7s45JGT/WtiTI3YKBs8hhjjPaq80Lh1yR0Dsc9KLCg9SrNLzvVfMYfLlh91sYBqOOE/akIySfmYZ4Bx1HtUpVXVjGRknIHQe5qCWHbL80pyOp74NBa2sWZbiNxmNGcjK9etM0+WS3k3EfMD8oHOfY0OwQhkCjAGFIJIpsBZApOC7H7x6Zp3syeUS4dAjtIehGQAAMVEwAKMrEscEn+gqQKXc4G5s5Lrg8VKkSq8YMfml8HD/Lx3/pRuO1hkIyo3wuJA3Ut2NSzWsRJO4bweMHgDPen26jezHrjlSflpZIgJWYEgDOMn5T7CmkTzO+hKzxuk/n72fO1I0HBz1IPoMVm3EogWIyABs/w5P1NWIplJKqrF9u0uDwhJ6AfhUbxSCNmm2l85wG60PVBomFxNFGw8riJgNwxyAPT3pgH7piN3y/MBnkj3qGMOZlUsoXOA4GcA9qsu7fKjrsz8pKdvXrUl2toiuLhphvQfu2HDdFx/jxVoOJYC5ZVZGCkH+76mo9rvGVXYAozgjtSrtMm8rmJmzIF4Dj6dqYm+w2NEdnMwJ7Ajnj8atQhftCszoMDKjuDj1qtOpgwm07SgKDOSuecH3qRbhRI6IQ7qScgYH60WSIkupaliGyN45NzPk7R2I65NNgbasPKKGYliX+77r7/Whi6iQgFUb7xzgt9PQ0ttNGc70JZOcydSaAWxa3qSwGfMx8p/zxikwZkbzUQYQAMByee1I8kYyI41YA4AHXmm3P72IOikBegAPFJISWtiK5aOGFlRQSMEAnsfWqsqja5bGG4IH86V5sOSwEmOQcEce1SkFUZ/LyvVh14+lBvy2RDYs8oMZidgoxwfvD/CrUUiFGEZyeQu3tSQ8RqwBCY4JPXNMt7MLOEK4U8gnuaOhLtJjpUnuEUryp+Qkj7o7fU0sEYjby3IYA7jn72O+atyRB1VUkKsACUzgdexqxJHiFm2LMG2qSR1NMXP0H2krtFGUiI3EbCOe/SrwtA13I3mFUB3Ag5+qmobQB4EQZUoByhyAfetAB4IlwvmfP91utIwnKzHW8YQklf3QyGUtwv4Um8squFUEN91hkj/Ip0cTLFKVzzhnHcnNPiQTI/mktuwP930zQYt9RwZZPn+6wBJOMZ+lLnMbGUAIV4zwQfQ0rxo/7uR1XZ83FMALr5c3z+qvyCAOtBJYUowQZB+U59uMAUgCsBuARlOdvvUPyxsysY8Aep64AxUsTqQFZyRjrjqaCWrbDMMFZl79v4jz/AIU1SS+9WDDG3DcYPWpSWDkhdxIOFxgZ/pUaxjcQhUYyeec0BclLp5jxgquVBC4yB9KhZf3oAHOA3P06e9PKx4d9xEiqApOOnenMjKDI23Kt8p9SB/8AXoC9ilkedjcMp0PqDTEBG1cAdmCnG3vxViRJA+EwA3A45AqB1Vm+XAbAGc4JIPWkXuVSqs4ZQQAN4YdB6iqc5+cEAE8MDnmrs42KwYEHO5c+vc4qhJkkbgTnhj0B4pFogdCFYn59vO7gfyq3o93cWWhQ3Fg4CreH7W4GTt4C59s1Xx+5YYXjtjqf6VW0+Oxi0OS8vvtLia6e3CW7bB8vPzE/yppW1MKjT0Zva/Jevp2qx3jSfZop0a3duBIrN09xjkVyTeXuPzxoDyAwJOKv3WoafNa+Raf2h5gI8sSzBkXHXj6VRgLFDgoSDgk85pTd2OlFpFfaET/aJ5PbirEZCyiRgN+3PPNVTISAwOOd2R09xUV7NiB+hbBCjOOQRj9DULUbdjpVQkIcgDAII7U9VCOSMBwMgsevrT1G0EAEkDr7+tCqdhkOPMbqQ3B9Kuw0x4YD5gBuIB+ntVpizqA6qXK43Eeg6e1V4Qf3SS8n26Kcc89+asxRjAJ5+b8D70x3JU+X5QFII9O1PIVCAFG3gD8PalEcbKAQpQDueMUsagQ5I4Axkf3c5pk3GGVTvAzhuM4xlaJBHsXcMAMAAByT9fQdaRA4RRLjLNyqc4/H6VPGgG/gkHIOGxkehoC9gCqd7AsExgYHBpMLLEFVWwzBSBwfzpAGV8Y3DggA449anTghwMyMc7RjimQ3YjuY2ChVHzMOeew7ZprKreWhbG373q/oKm+byogRgbsBRg5PuaBCAAzlmKnO4+tNCvbciVEVm4JCcZ7mklQyzKzE4QcgcAinzeWEGBuOQeRnn1pAXlkDcgYIJHJwO9FhqXUhnCs+zo5BxnqAO9RlVeMqApRRtYHqamMYdQqhlTHzHqSc+tNkYcMCNo4bcPvketI0RTlURglV3ISCct936VFInyI4CqXbaCOoq2YgzKoViM724yCccCnPaMY0eaRSwzhdv3T6CkaKWpz7TqHeOFRlWOS4P+TmoTIzFlJYq5GGA5B9q0mtAcuVZZSchGyaqParC27cQCc7ieQfanY6LxZlsEimCyxsz5IKh+p+tSW8bzS7o1RCRg9OR+NLIHEuWMig5yx/jNMcs4dNgJY4zxk8UlZGtxsweOQhgSjH5SD8xHuKVjEpDbQodvlVeTilMSLgZZpMbQM54A7VZQAxA4wgXDHFP0IbK42ynncCTxs7fjU8VoihSp3kn5gTgGo4mYEqoZeeTjj6Yqw7OwCH5B329xjpQS2yKeQoGRFy393PA+hog8w/LIAMjJGMD86jeMyuWOCW4+gHao2mRph5YdQvGQcnFFy2rImu3XevloRjB29M5pGjYpulZWGAQM4/DNV90fllg5zI3AzzxxVq2kjWCeJwWO3PThGPp6076k2siG6ZXjVkGcdQp5J+vqKa0xLGRjnzDlixzyepIqcxhFUoVRc4AAyB7496VY/JmCg5GcDJzj396NSk0isko88jJUHq4bilUq6eWwHXgqelK0SrM3zEsODxwaWaUBUBhVyGz84ADDHPzdaQb7DFQxSAMSUbOcnkZ6U9VeKZyh5ZeQex+tPKKQB13KTg4Ocf4VHbpuQhGLAEscDIotqK99y1JMFtd0wCb8DLcjNVwSjbyRtzn5W6U65kYqPN27ujDGAfQ4oQDzSF2kY4XP65o3CHmTsRFnyWyjAZIIOe+D6USpKw3EljjABboKoyEouVAV2bg+v1q3BAdmZOWYYBDE89wPajctrl1KL3iWjIszlgvIwOorZjiaOZzJnOFyAcgggHINUhaqiIzoHKEv0BA9hmr9mN8Z8tcCPDBfUU0DatoPt7QIcYB+YHjgAVLJZGNQqbMqcFW53LVid1UeYsfmbh0LcfWorqRi5WNdmVyCDnPr+FDOdNtlq2t0IOI1I7DORx6elSQ2pmAb5txGB/dX8Peq9pGHi3EnaST6D8fxrRgUxqsaLlYzjnsO/1pMiTtdXCC2wkrR7QM/OMY+pqxH+9t3kdGXb0Geo7ZqaBivtk8DHQdvwpq4ldow+13JcAjA4FOxi5XvcdEjeWowvzE85zgcHio9skX7xMsrnJyuenQAfWrJKbVjBClwQ5HVT6j2PpRIjNhCwUjDZBwMevFKxNyGFT5hBXLucMOw9vpT4UEcrFtvQBeCSMelPO/GzjAGCTwW9KcXZlbylDEg4yP0x2pWFqyAIhkKn5mzuGOOD1zT2C4+Viy5OV6ZHqKJEy4bBZgBjaeQMdfwNOJJQbQVfGTz9/6UwbIW8wTAR4AUFSjclh9al8t3AGeoyAPX3pvlmSIbSyNtBVh94fX1qUcIoXcMYHP8QpCuQ+WMFXRwpwODwT3/Oopm278Lhg23I547D61IWxISWYDaSqkYGT2qRQXjCjnaMgse3ekUipsCMokG5zkkZxzUT4Dk5AAI/4D7VPIAJUU/Lzwfw55pkojK8plQvHvzQO6KUr5+ZtpGc7SOlUXCOApwQcE5P8XtWhdJvBTcAwOc46g1QKsByBu9uh5oLiyhqUgg06e6ZtqRkM56YAIzTPC072/hUy2+nrdTzXDNcJIpcID8wO38cZpfE1v9q8OXkMkwh80xp5rnCr845PtTtItL2ytvKg8R2MUZfcqRzHGPy71RzTd5EN5fT3FtJGdLt7RCQxdIGRgM/3jwM1SeUpjEZXIzhAMVt6kL8WDfaNft7uIkAwLLnd/wDqrFinjjXDFueRt5ArOW5vSSsUnkypcDJXgjrwe1ZOrTFbfCYZcpyDnB3ABs1pDlztCjGD1/UetYmsCQ27FecqcY9Rz0qU7Mmauj0xkzK2SQ2SM54NLGFX5SN2cLjotQ2k6zwwzZGZYkcN9cGrSLsJ5yAOtbMmL0HxJuI3EqVySduPrirSKDgllwFbGOf0qGNiCiBSWK5GenNShCCwKge5OA1IdyTl1UBXCrw+O1SSrI7jyvLGeMMSOPw/lTYYyybjlduTk/1p6srx8nCo27pkk47UxPUjhX5McO3PGNo//VSyElWHJ3H5eOSfSpVXa5Vch9ueRkYp6xoAME7FwQxPOaQXsRB1LjaASoIOf4T6ipQDCOCuSM57fhS7cgkKMc7iCMn8aWMFVABPKnORnmmS3cUKiRrnaAf4iMDnvUi5EoQAcA9+tCDhEcAyH5BkcfTFG1XjKqNrJ9049+1O5LGKdwY/Kq89evvUEWHUiAHZtOOxIq5tIVgzADOBxjPrUKJ84jwAFGTg9qGNMryKyySSMGA25YjgHHYUzPzqXyCASAP4frVnyw6fLwjHd1zx6ZphAzMCeq+x2/40jRSI4ztkIRVZDnJHr3p04CRqqIHY5AGfuj1qIcoA6qsgOAD0x/hTpBhhsUkhsHJ56dqCkrO5SYvhRMRkdhwaw7lA0rgsxUE4T610jJs3uQMyE5C5IFZctqGP7wEruy3OOO3FB00pJamazbigVgQBt69aVLYvcM0jFUQDYw7n3q/JDhVcuqhe4XkL71HcBUwARGmfujn8aCua+iMuaJYUZVTliO/QHrx60WkIWAox+UDG3nnHr61ae0cOspbcpOFIOT9R61DLEbSEZ3q27GT2/GmU3dWC5jRZyqtnapBcHIJpUi2wqGPI5HeqaygyjaxPqSpFW4zuUSE43dCDznt+dIHGyRTuGYB3GHYdBn/OKWBSwLhiJGHPbH1p7oYJVhYhi7fdRupPc+wp8dsGjOJFKYGWXkDJwaEi76FfZsYs+fMRQuM8A59altw8sMhVchf73Q+uD3qd9rINqrsUEemMcZ96ryCKDYh3zbhu8sErgn0zx703ZApXRImUBJAABCsqsN3Hr6VFuCcsp2gkgse/1pbbzN0kbEiHd684HYmmBFAcqzHHA4yCOhHtRcLak0kZkb92Y1dmyCRgHjrTTI8Yj81UkZADzGCrfn3oBbanzgx8lWGOnTpUyDz0eMybJAPlJAI9OlGjBqxDEnmMVlwYg3yj0/DtTnZGfZK5MLdGTjbUjhIkIJOAdxCHg0sUPVtpRMnbn0PWkyOYrxo6xPhmbAxjHX6mnhFkto2kjDJk/Ohwfy7ipovKjYhmLqzY3IcgZ6Zq0IlZR5S4CcNzwKLDbsZw2suBg4Gd3qKtrteMBlZBgk+WcCkNumGVgMk4YAZwOtRJFKpVtq4Y7cN0NDGmpFhELHJY8qQAfSrFrHtdQn+rxgkd29KdFbbwPNwuMgKrd8VctQIjHhzsRgi5HXj1o2IcrbDYbY+QDGpaZMsN3OMnoKuLCIlE8cefLGHjzwSferaxFk3bVAKnO3sO1Q2zPG537XhJzwOQO2BTOZzd7j4cxyJgsFIxgcgY55qyImjdZuCGG8fN69wadLIFMan5m3YLAfoaf5Z2sroOoG30x9KbVzNtvVlS7lnMLzK6rszuIX+Huat2csZiYhgoK/Jh8/Q0+OIqJV2Bhg8Edv8AAim/Z40kRUVRsXZtxkBfTHpSByTVhE5l4KtJ/CxP5LVhxhchRhfm/wAc/wAsUkcccQO4A5Ocseoz0/CnxRZ43kjOcHqMc80ESlroNdWITCuPQnrjt1qTapR1Gd3BJI4H09aJcsCfmKgDacZ47ZpUwhbcB8zfwc80Mi5ER5knyrwrZAXj/PNNYBpYzLneXG3BxgjsKk3FGV36sWAPYfWiZVDo4ZsEYwehP1pDuQyhjM7HPs3SnOzclGAwceyj3pzBWUjGUIHft9KYsfG5vv8AsOv1FILjcF2G3ezBch2xSIGB27iGA+Zc+tSlgyEoSD0VgMDHpUckfCBmyeQD05oKT7kbqu5xKCRnqW7VA4QMZOQu47sehqcqx2kgqw4z61WIUs5IA3gEEnOcUDTuRSEbcDoBwM9az5wDlWOcjIxxir0vdlBLr3Hv3qoVZWByBn2+Wgd7GF4xBk8MzxgbzJJGFA6n5un6VzdtBMI1QQvxySYz6/StrxfePbW9gbdnWYXKsrA8rtBOf1q9oF1rWo2iXNzr7Wkcswhh8zkyv1wAPrSktbEqTV5GGkMiKu6AryGyyn6dccU9QxH3JMj+4ua6LWxdDR7gza81/GsgjaFUwAw7N6Y5+tc9as6xARorL65I7VlJWOiD5lcoyOGCt04ycdie1Z98qlMsFALcEGrXmEBiB0A47f55qtdFWXGBg8qcdOKRLOw8IzCTw9p5x84jMfJ7qSK2FALDjg9c8iuS8DXH+g3Vrn54JvMXI6Bx/iDXWxsfmCDj34NdK1Rzx0J8YYAEgMQCc/1qdDhR1Jz8q9frTU2kFCFDAfMW+lLwzqB2xtx/IUir3JhyGwWBPBxjAqQJvAO5XTPCk0gDAEEBQvfPWpwB5YZQC2csB/KkDeg0bTIEzlVX7ynv704byCFyUA44605wi7T1djnjjn6U9WydrH5lGAtMlsYikhgGyrfMMnFS7VViQwxkcngD3pwTDZQADod3OKUYCorEFgeTjqaBXuKpGTl/3mPl4/WkHDdCyE5IOMj39qVz5e7g4CnOByfanxKERAeQV54/SmiWQuo3sMHcoyqjrSyxAsmdo5xzwf8AJqXdtALAbh8n0xRIAI1DfMABjJyfamxJldjtXkb0XJxjn/8AVUaxFCdqqdxJXHY/4d6skE7N64Q55yOlNaTYi4wckIABnHNJlJsiWMAglgyZ9OfrVe6QCRXfBJG0Z9P896sMjrLH1O0fIvtzk1HeIrndGGSQY3Z9PSlc0i9SLagl3OxGDgY6fT6VAMMHEcRKs2GLDrgd6tFNzSMseUwRg/dFV4SsaYIZB93J7n0NBqu6KUyKJirqxQqMZ4GSar3tsWwxkYFewGM+1a06gCUbicn5cdBUP+qDyNgnbz3yR3oNVPqjLZAbhQryKwGAwHQfTtSbI/MZ5wN+SFB5JNaCNt2sjsQxwM9/pUZUh2llHzepPC/UUFXMiW1i8tX2/vc/MSex7fWs5pZPMkACxoDhR3Iremginh3F2DIewxnFUru2DESIAxZeB3OKDWEl1KVm/koHjh/eEY65B7YbNMEKs3mk5ZB93pz7VOZCDmVlQYwIwuSxqQRkqrSyNtOfkz09qqxb0KvyhsJvVzztHc565pxyjl5nkeQjcCen41JMd4d4wA45yR39KrFtxYqNwP8AETgfj60noKO5M+1mUkAg9An8fHpTIfLMm12CkfMI8gBu+DUQVJY9+VVCeQBySPSnSWgMocZKhQcnJahj0QtvChZyg35GenP0PtU1qWiKySxBDnBBPDD296TdiZYy5QAbtxGVI9PrTTIQ5UbnjJxsAGAfbNPYNyxKr5YuhCD5gwx8wp0akxNsLDcccn9RUaMyxRuSxX7uFXP1qa3ZAJZFVuOAW6fWkyGtBwhIA2BAc4bJ5PoalKlY3MjZOCVBPHpihFaU+WDjuWHXpUMxJT92xaPBJLnkYPTFFhbuwjzqOU2jJGAfT0q2kEbRx4JA4AHUUy1Q3OwyKjZG07eOatxQAphA6hflCscDrnOetFu4ptLQcyYiYqzYTocdas2W6WQmQkYAy2OG9x6UyOANHiPG/HQtknJ5p9sZBcbHjJQnaWPANIz6Oxo22+J+MGHP3f8APanM+JVjI+ZyQMDp/wDWoiXBLr/EQGXPJpssCwtjzD93k4yQKZho3qT5C4kMeAecYxyOCKsKpIAiIiKDcCOuO2aanEbM7GSIn5COTj1pE3COfKAqG+RgADgDnp1pozeuw21JU5aM8Lkj2FTgjyyVOC2Pkx37UpjKs5HO5cZJ459KYpQNKHYjA3BB2xTZF09RyNHkEsDnOAeQT3pyqqyyDBClRwBjpUsadSNuOpwMFQemPaneUGcPnrjGTS3FzAhwWUqTu5HPXvSMCrttwq49M/l+FOwrkM+DwB9PenHnAyWBB+Y/yoJZA+ArKzByBkhRyAe9MnRfLYOAUxgg54PapGXciEblLdQTgjnpTWQ5IOSueMHnPb8KGh3GgLIApARjzwORxUJDBh8hU47GrbIQu4evfimlT98Kcg8KT0+tKwc1imsY2fKWLZ/z9KUpuYglmJ4OD/KnuBkgfIW5Pao2CtnaTuXuvFFh8wyXbkMeDz0PH/66ryjbh42BUdD3IqxISSuQvJ4XpVZ0wuwD5MncPTviiw0yqwXl0yMnnJ7VQuZMqSEyBz+tXpZMkFsKG45HNZd0RGkkkmAqLl89gOSaaHc4fxhefaNaWFG/d2i4JHUu3Jx9BgVe02/i/sQW7LJ9otJ/tMDJyoBwGD+g965COeS4lluGB3zMZDkdMmu30mC4vfCctpo6rLctPm8iQjzJEwNpGeoB6isW7tlKySuaN/qNg9heXVqsxm1V1cpJHtjjKnJIb+L5s8isJnwxzJznnJ/wrZlhu7Hwrc22sL5MYZBYwy43qwOWIHZcVglrkMfswATPPy55qZG1O1tCvIxBbLYY447YPPSqsjAyMBu8v6cfhT5XIAADNkD5TjNN52DHRuM55HpUksn8MzNa+IYg5wl0hg59eq/qP1r0OHG3OOT615LcgucxkCYHcrf3WHQivR9A1NdU0+OcDbITtkT+646/5963pu6sYvRm7GrOdrHIY8jHQY6U8RrGyGNsE/KpPQUyNQcgsc5PTtVlETK7xlRxuB71dgUug6I7dgYq3J/P6VJllUyKOc4CnjH1qJTh14O4cgg8+wqYYIIcnOP8nNKwE8ZViG4G4bs9sVJ8iAmXYuTkEnrSKC4ZWwFH4Y9/rUF1ALjaHJ2r3PU0IUbX12LSneAyfx8DPp61IRy/GV6DPB+tV4F2KACAoPBqxj7hO7PTHvTJlo9BWRjtY5JHUYx+tDKW3ANgnvSgswYnlievqe1EbbgBt2gAj8P/ANdC0JHCNHUxnBxgnJ5NJIFOTwo7ZGDx3p6lht28Mc5z2oCtJMOMAgEMei+1DAR8SMF5LDnaf0/Sq064AdSEA56ZzVyTKrhSC3Q8c5pmOGYkgZ+UeopNDTIpFDGImEMM5AYcKPb3pjwybS0p46lR8249hU78KVfkjp2H0zTZj8u4AllHJHc5/wAKRadtiDaFjIKgkHqvAzVW4iIA2csv48+pq5uUBc42joDxyar3MoLlYthAUkqfX60WLi3fQiKouVZieASPTHTP1qGQmNgXKhRxtGTnNWhGZAmB6E7uhB607YVJ3kDIC4PUc0FJ2M0qvnFlVhg7sgdRjtUZiO0vyJXXp6j/ABq8zFQuSFXHpyef5UjA+XuJZVyCxpGvMZr2zLtCsBlt2N2PyqhfifeiogwuRwccepNbDKWcKPuljk56Dtj3oeEbfmQlifwIFBqp8u5z72kgbkqCF6Adaq3EDFtuAG6Ag5wf8a6GWEqWK535yQeMenWoZrZUlC7BuXGT2/wqkUq3cyktyuRubAwcs2Onv3pJrZJCTtfy1GOfU+3tWrLCcMAoVmODgZ6dzVZ4vJRYVQTOx+bBwT6mmJTu7lCCIQ/KM88K5WrEcbfKAMZBBI4xirZQAYZXMeCCM9fSmLAxlOF8ps9HJ54oKcr7lKaDcrhGJ+bOAMEAD9aY9qjxLHuwBjCkd+v51oy2rJJ85yvqDjJ/wqJ4HlVRGyrzwTxk9x9aYlPzM9LciUrG7CMj5iBjP1qzNGUIdgDwcs36dK0Io/k3AjphSf1BFKyoAE2bueR2K9T+NK1g9q2yKHk5jj2qMfMeSf8A61OktRJOSGXewO0etTfLltgeNmHAPAwOlPzjYscRZT1kXqho1J5tbojiCIRGVJz6g8H1qwIyHbJZWIyfQD05qZVbYWUMwLEMc4KnFSOzRx+ZMDIxO3JGR7YoIcrjkb90QMb+ANw/rUhUfah54cyEAkgcLikuNpSNWyH65U1IIpDACVDYByRzx1pXuRf8SQFWZNsmwEkA45PtTnQ3Eu0JtKAYOOvrk+lV7aAtMkjHkYA7ADFaEaxq5EbgpJyxbkfh70yX7r0JIFKTbwuGYfNH06ccU9ovKhZY9ux2yOOQe+KWBSvBIUfdGepA9fSpQ20NvKiM8IT/ADoMHLXQjUGRlbaU6Bcn1pkFujCRiGJJGAccY7VZiYco42k5J29vp+FK1uphCxnceu4Hlj2FMhuw2Le2HRymD8wx1HpU6Rhc7iojIA4HJqKHerBNx24IO456+lShowQAc8HaD3PT8KBMgVUWRxGuckBc9+fSpGPyYY5GMqR/OiRQH4UrnGCOxHqaSRFMhO3cTn5u5U9vagW+4zhnO4AAjpjgHucelMIBOCueuATwv/1qeqtjBK+ZnqOnsKeuQu3C7gMcnBoC5BA25CZIwGVTk8YPpTZBjKjG1iM46j606Tc2QqARkYI70wKh27dykdgeuKA8yKVgFVScluhHU/SoJCVGDjc3U5xmp5jvwxx1HPpUROXYONm3jg5Leh9qB3IA7PuUKcHrkVBIgVcknI9+n/16tPsO1ckAdDVeViVwoOW5yDx1oGmU7iQY9iBkY59utcl46vBa6DcxqQJLhlgXnnk5P6A11d0QDuJ+YAjnr1rzf4j3G+9sbZCPkVrhsnPJ4H8jQ9EUYGnGBLqP7Sjvbq251Q4Yr3APY10Ojtpih3l07V5ZPMYo9q+Nq54UkD7w71zCfLnaMkgE5rt/Dtxqo8IldCmmNz9qzcxxH50jx8pUehPUiudbmjdkFythcxN9l07V0uyMiS5cuoUHnPHpWbayQmMtMshYsSNjYGO1dbaX3iODQ3F7LcJfS3CLYxynDyE/eUjuuPWue8Y7U8R3a2pRVBG5UTKh8Ddj8c0SXU0pSbfKZMzbiDkBcZyaYSCq55B9RzinL8jYUhm3A9Oh9DSNyC33OueeM+9QMpTqBgL37/WrGgauNFv3a4f/AEGcgS8Z2EcLJ/Q1BIepJOR/nj1qjqLCO3kZuig9aunuZVFpc9ntpVUFiR1yMHII9Qat+YqjqQAOVFeefDuW7g0C1S6Z5IuWhDcmNM8IPbviu3EnmDJHzYBA/nXQzKOquy6j7gR8o5yODkfWrSEFA3HoSB3+lUYeAFBAzzjPBrSVlAzuzx+f0pFSZIioOGPOc7s+1PiGck8g8qW4xTY/mUc4HIP/ANanCMAAZGDjt0zSuQSRKNu5gM54I6Yp0YILZ+6gIyveljYDnGETIA9acjH5i3U4GfQU7iFj8zYQWBbHHGBSx5LfOo9GGeAKcmNpZBhSCcntShU24UEY6npjFADWDq+MZDfKG9D6VKSCxJ4Undj6dqayl2JOBluoP60oX5NyFeB/F60A7EanZGzsNrnJ496jt+WHmZYdOvQmllDTEoSRkduhpUjHHHVcAZ4FMm4roC53jO0fh/8ArpsylIeBvJIHy9h9KlicE5lJU54+vpTSzFj5aqFPXPrSLTII40+f6Zww5HtTxFgLgEnpjbwx96mhOHRl5GMMRzj2NK8nzbN4UqNxIPUGiw+Z3sVQCueMgHIzxj8f6VBcRLKFUk/Oc5xnp3qwzBmkG18Lyc9MURMcAKuMDPXlj6fSpsyr21K0lscBpSDGq4bPX64pNr4dht8rH3vQ1bBJVgykg9j2P1qNowAwbrHggk8Z70WHGbIRbosZAK5Y5BIznPWq0kcry5DYVSQWYZ49hV22gEcIVdm3OVDN1z71NLECBk4c5x2yf/1U7Fc7TMia3EmwsqKG5IY5JAqvJbOxZ1VtiElc9x9K0fLRiCwBckk/XtQwG8OwOE4wvv60WLU7Gcls7yKI1IDDLcd8dTVdYwZ5HBUn+8BWpcRkZjIAUj5eeDVSbykhUsVEaqASOg9j61QKfUgMMijkjPbI/pTm2wwrGWJduS2MH/8AVVp4CUYqwYNgoxPbt9KjWJmmSQIdmMjPOT/hQPnTQx1ikgk4bPdSOWPtVRoDFIi8Bc7lBG7HHp2rUWEBfM8tsjOD1yB3qGaEs7RIxQn+6c/jmmyY1EtEZ8qsGCxkREHcR1GKnEajJLHpwcU9oyJUGQ7L8pU55GKtxIFVcAjccHvznpUsr2mhTeJJWB3EtGueemD3q7FDF5asvygnIIPQ0ggLOD5WY+gbv7/hVuNFRCq4k25AX0/+vQRKe1iuY1BAyWcYVE3Yz60y6WeWMAKqsH2Lv9fatEqwXLJ0/iAyTVWJvNkBmQsMbgD0Hvn1oHGXUkgtxuDyAs+NrZ9KYYpXaXkrH/dC9v61ddGCnduwOQF6HjoKWGJViDMrBBy28dPaixKqdSruj2xFFZivG5RxxxU+QqrlVaXOV4yM+1LGJGuAc7omGVCDjHv71Yih2JICdzk5G3jA/wAadhSmkh1u+Ym3KM5xycEjPWrDDO5iuVOQM/T0pF+VgR8xzgcVIm3H73jcRzn+X40zBvqVZIM28qp8qnGP/rmrCKkcKAFiyY3EfdB61MqggbwMMCrAHhfenRx7l8phkEbdpOf1pBz6WIuFyyBpQTnLHhc9QPYULHvG5idh644z6UjNtYIACfY8ACpSwUdOGHAPXFMl6DWO0FdpY9Rj1700ruVj0bBJ96VVji+6OCSWJPekI4b5SQTnrQO5Gfm3AgEgBuRTJchBnBGOOc1YkLMSxxx971HtVe4UlgYyoQ4OT3HtQNERBYA4GTwDmmsu3KBs+gJ6H1qUjhAAGTJ/HioyuGGQQ2OMDj8aQEEqAoismSeGx14quTkDnI/zxVuULjIfqOMetVtqrhmGSD1HWgZAwLlskKR0OMioZsA4UlQPapJ5RCylupO1cc5z3qCdyAADx6+1AFK8ySoJBOeMn9a8Y1m9GqazfXcRDQvJtjbPVF4B/rXqPiKeT+zL9osrKtrKVx2O0145pir9hQf7AAFKfwlR+KxoKeBvZsscHPP411WiW9lp+mDVr9rlxJKYYY7eUxMxAyxZhyB2wK5aIYLfd349a6HStUht7F7DUrP7XYySeYo3FHjfGCVb3rnT1N2nbQ0rhrLVLGfVNMkvoLuzZDKk0xl+VjgMrHkc9qyDEQxAkyBxkZOa1vtC3uh3cWj6etlYK6NcSPLvkck4UfTPYVmYVFUSGTJGQAxGB+FDKhoU7aV5SRMhwPmIA5HOOKFVkD7j824nPb61Zmbgts5yPlx92oT+8AIPJ9fbtUgQtlRyArjn/wDVWZqULXP2e0BIe5mWLntk8/pWk7jepA4OeM9TTdIjWfxNpcZJOx3lP1VT/U1dP4kRV+Gx6BZW0cShEXaiqAF9BWlBGw4UEnHTIpLaIdcZJ7/SrsMeG37eMfyrZsmw63GVUNuDDkDHar1vuDD5TgegpIol3KeeTjqRVtECp/eY55/GlczbI1Xc64/h5Ue/fNWgNxCZxjPBPX0qNEKscHkNn8KmCBCrLjd0yTnn3oE3YciEttb7wxyelSqSWVcK2CfxprKc5AyT3z0qRF2glTlgc880CuIflLbc/MMj0B9KMtt7DOGzT1RUDlsk9SCev/1qVVwvYnsPamhDSxYMqfeVsk+tKXKv8p+Xr06g0SZDgBf3g4z7U0ocjAOAfzHrTCw7oo2qxxwSfQ1GVXq2QV+XI6fTFStnCjPOSQPQ4pGAUBiSOmB3JoAqkZjRt7jB3c4qcBXj8xSwB/i70/AKMrELz0J6e1KoVD8nCsMY6j8KY2+gwoY1HIC9DzzmoUZ2A2gMUAzz0HvU2N2FCjcowRngjOabuGw9s9MDkeufWgFoQHLOF6xv8oUdTinTK4iYqFMpHUdxQsabT8+UUYGO47jNWN20nK5yNuB1x2xSGVGZfNkjA+YAFhjhOOtDhduwH5RwWPOD61YCfPls54yR1pFh/uncxyd2MfpQDfYY6/KFALqoBBGOcdKjPzJ5m0DPXPJ5HSnIoEm0Z27jluv6VLtwuSOMHhR/OmK9iqFyYiuAwz8o7jpx6URLyULBemM9vXNSFYwCVJAU5B65/wAKlRcOCzHlsEjr0pj5itLEGUlzg7skAdAKqTJ8jMF3NgH1BHatFwzBFziPIBLc56/kaiZViwW3fMegOaBqVimUZlB3Htgj196RoBsdCzENjJBxn3qeRVCK+0s4IAx2P1/pTWyqo4PyHjAGSR9KEO5CymRW+bBXoGOBge9DxGKQAAjceM8mpRnzcFcAH5SejcfpSr03SMu3aS2OPp+VBLZE8KuyBWyVwG46mhsZBZm7jcDwvvUwRwoKspUcBgCCP8RUWH2YUpGD8uCucj1FAJjgXXKkMFDBcnncAOo9KduLbUXcm/HzD1qQBiqoSA/GXIxmknchAVXnoQeqjtxSC+osjPbjbDGS2CcKRxzSgCRlOxi3Ug9B9arrG8TgxthXOX+X72OuPSp4AROxRNwOdxORjH9KZUrW0HB5TOrbHQqdobOcirO4h9pQ7WYjnkj0ojB8kbzwuSSaejDBXOBkZI5GD29qDPnIApWTKyMm1SpAHB/CrAPn24RWALfe7D/61JGjIw2pggHqfeniPEhVyACM4xkZ+tANpkkYOVJDbgcEMPbtQIkXMuPvEg4z0qSPPLDKIfQ/0ojmXBdWyh/j6AUE3YkEkVygeB0dDlMxsGAYcEHHQ+1SgFSUDEA4ODjgDr0psFtbQiVLWKOBZmMziNQu5v7x96mw3m7gAcE84A4/u0A2r6DI4VLBVGAD36CkEe5/uncOvOR9aWaN5kTBaN87vl6nHrQ+MrvGG3BgQSuPqfSgBpJzhcEA4IA60KgBYnhR6c9qc2XYgP74HY+1QNt2MSGUH3/SgSJmUbNxBDY4qum7byPlB5x0qZdrncMgAVGW+Y8jA7/1oGiNkOQiNkL/ABE9vpVUNl3QDBQ9G6GrxQbt+3kDBYDtVU7d+ABkdR7UikQzHzNxBKjqMiq7gnIB3A9OOatupJVACQPToajIHzNjG04FAFSdVwW4BJ4J64rLuWKiTOSzfKBjpWy0YCsQBu9OpFZ0lqhcM4Jzzz2pMcTC1a1abS7yJD+9lhkT/gRQ9K8T0dhJZxfL8wAByemK+gWjBwoYsVJ4HPNfPul7gjj/AKaNxj/aND1gUvjRt6dGZbiKLzY4i7bRJL91M92rpY/DMQBH/CQaOefvGRj/AErlYAQCGZth6H37AD+tWVCsq7cBd3IJ4b2HvXPodFn0Z2Rs7fSPDuqJHqNjdSTiLYsLkt8rcnBrllnCKAoBXsS1RRDKSBVYrnaxBJHP976VOSEAVEDAD+E4Aoeuw4qxJIpBiZiox3HHHoRUTkDjgfxEYyeewqVpPmKD7x+V/wCLkcGoGcfM3ygIOBjBJ6UtwY2ZT5YJ2ht2PXNWPCke7xZbtjlYZjn04Aqkf4QOh4H+1itfwRFv8RM204S1b9WAq6fxGc9j0a3i+VccKMZNXoYwFHYkDhvrTLZcDI4wePXP/wBariqBgFhk4JJGeK0ZDZJDGSDwcljnBzUuwBdu7gAEe9Ip4KkfKOAT3qT5GILsdpOCRSIW46NcpwCUBGT61KCFYkjqdu0DtScmMhflHQ08bvNU5HU5I/SmIco2KMKxzkcUYIk3bSBtxgdyalKtt3AjLHBHuO9Jgk5zxn5vb3p2JTHAOWKuOAME47U2QHO0EjHYdxShgJiFYF16j19qkRlZwvYknBHT/wCtTBjYQHJGPXHPOaQrgrgjGMj1BolDBFCqMYxtHr61EpJO3cCOx9/SmCRMfmUq+eTnAH6/SkKnAKdxkjFN4xvBJYcFehH/ANanKCOS2VJ4FIewnmfKGGMqMhv6VCFk3ks27suSOB7CnvG5k4B4bLZ4x/jSsPlAwHPU4X+lAwQZXbyMetRK7OhdAVbBUZOKmc5AO7jkcdfamFUA+YbjjjBzmmJMZEPl2A/LjoOuacw2k7j8vcZ6Ui8bpMMRwcYziliKGdsK20YHzDvj1pFC+TkEKzKxxt9afncdpJxnBJpMjhhn3zwQfr3pzIMlckDtkcmmJkTBhIANo2+vNI5QIMK2C2DgZx7mpWwxVcAEDI4piksCFGAeOeD+dAiNWWTeQGUZ4zwDTo12iQBCMtuPOc04j5kU5WQcnacjP1NPOxQGfgLyT6//AF6ZLa6Ffbul28Lj73y5znoc/hTJVyuRja3JAXn61NIQBz9cE8A/X6VEX3AZ2l+Oc4IBoKTIUOWyhViQT+PTpTVCh8qPxzjp7VKH2O25SCck4GT/APWpu1eihSy55xnnt06UxXGOojU4xkjkBu3rSRoGDeaAM8BeymmbmzkEYY9gOn071IoCO+eSx3EHj0HSkN6CiL9zk79rAjpjApJiq/NsyvfBBIH9akV2B+8eSQSOnf1pAPMQDb3HXjP0oFHfUrxiObY21zkZyRgH8KeH2qV4IFSJjrHxgndu6gd6S4CPGu9CVB45wSKBvccoBGeSUPHOBRsOCuSSDlT2zUh4j4IAxndzT02kZDcHkD60EhHlsZXJH8WalETBeQVUcls1HEpBByGcZ5HSlJchIpCSzgguhIC/4EUg32LEDEx/ITjBqOPDI6PhyeCAMYp43BSIXU4AIO7+Zp2GEhKhWIydpPU/WmNC7y6MY3wxGASuR78U6LbwTggHHJ46U9fLjj6L5anJwen+FQlkOdgIHrjOO340C3LG9DIFB+Z+mBxilDbWB28scHucnufQVHEhxggl/u59qnHQ5I9eOSPegWnQR8hvl6c9DTZIxyC3y9T6GrBIZdynp93H+f0qLcowi5JIz6YoAiCYVSAeTw2PSo5GVi38MmM8nn86sggYx9yo8BQykYB9Of0oGMJ2bSBkBevY1FgE/MytxzyMLUrxZicMC2PfgfhTUjQgkYDgZIIGaAIyw3AA7s8fKCeaQBRg46Z4zTkUEYP3Scn6U2UBenc5GRSCxGVAVUYcEY5qJ48gKfTgH+dWCWJyRuHVsD9Ki43cABRxj1/GkPUgdAqMSvsR6VXuEOCoA6Z69qvOuFLDo3AHXFU5Yzgh8E9sdhQxozmBMsYQrguCfT36V882KhJLhSWws0g688Oa+iZhsljKg/fGPz5rwK9hFvrWqooICXcyYPPG7ik/gZf2kaHh6KKTWLGO7+WCSZEkz0Ck8jNdXf69LFqdxp+u6ZENOEhjECxBGgQHAdGA64wfeuHsYpbi6iihHmSscKBj5iegGe9dRe+H/FF2yPe2dzcPEojQO6Eqo5x97pms1dLQ0k03qaUmmNo/hbXlR1lspWge2uF5EqFvX19RXLrC1wCyAhVO35R1x3rbutO8Q6bo8kVzFPHYMQZQZEKEk5Bxk45x0rEPmsFIkaMY4AbGff8AOlIqnrfW4+VmLBeMEktk8jtUDsV+Y7iq9CO3qR6k1LIcSbwwxyzBeePeqx6NtyQPu49e4qBsUAbS2SEPGD3rp/h3Du1S+fBKrFGnPbLE/wBK5OMBCf8Avkc9frXbfDGEH+0HkGf3sa5z6Kf8aumtTOZ31tGXwSCBnPPvVlE5IPB+6PpTIiMHcx6Z45xn0qwuAAGIHt2FbMyuOX5UGRyDxUkQbgY6n+EdKXywxUAEnHPpUqJlQoycen9akLgI2X5Sdwx0xj8qfGCwx0AHGKQr1QHBAGR349KUBtoxtGR2PT/69UIeM7MZ56ZPelIxHtyR05Pb2NIv7pcYyBwGPJJ96VSfKPJLL39c96AHBV69C3XA6e9OboWPPYn1qMxs6bGY7gMEdhSD5cL9709KYWHkEqNoIxz1yAPrTNrL8yyY7fMOtSFn8klfTOM9fqKQMzkEK5wc4U9cf0pAIeUVsDBP0pkhxhucngLSyoxPPBbjcD1oTcm5v4WH3f8ACgOgrOuXJJBHOD0+uKYZASBkk5zx+tRkbw2DtYcfPQuWcMvzNnGR2FMCZzlhkcEcnPSoZdxdcMAPpipQvy4LgYzj0pWbnAA4ABP9PegFoVgcMqgZ3E85z29KnUIybCSFx0JpwDbfmAGD2qJPvdABnGfWkU3clJBBwQR15709ST8wbb7HoajAG35WLcYoi+Ylv4u654NMTBpOD93IPGfX/CnKNsZJ+97HOBTgcAjjdjOT0P8An1prbSyscgdM4/nQQ2NbBl4wCu3Jz+tNlIVOxZvU9/ahWJfDqRgYBPQD6VGNmQWx6jHUUxEbZYAlsuBk45yKf8qnLA7QQRkVG8jLOFC/LnkqMnNKAdueMnng460A9SJipACn5h0X1HfrTBKwK44wOu7oO3TvUjbCpU4H8WG7EUmPLJI5PXCg4HH8qY7iHgLkYGOM8bfwpgBUBwc59T+gqN8M208jGVJHf0pyszP9/PckHnP+FICbcM7chiv3t3YU8Lgk4YjIHynv6+wqIMVyznnH8POfpStKScA5AI6jP40g6kjuhOARkHOTRIOVKHac8g8U1lkYqJAccDhuCPSnfdULIR82MkntQNaEgGAFALDqc8kc0K22NgA2Adu7HP4ZpIAqLtLh8ZHXmpWH3N2SCc7f/r0CGykkdCxK4JzjI/xp2MOuGBcAjGexpwBAAGRznA5piu5DBsc9gKYvQeCMZQfKOMf3frUoPAZSuO9MUsDyMbhjHoKeQ2ME5QnofWkVcmVOCWyQw9ufrQWJAyuAo4IHWmrnoWUKvUE02ME4BGP4R7GmInEhQBTyvHTtUhAfgjG0ckHGfpUcS5TAKjB7jNPOCSrABu2BQSxwDlUII2KeuMA0kqfKdo+7zn0pVBYfuycZzgn+VSBmwDKCf73NA7kfmbo8EADp1zUYU9cnOeR2+tK/L7so2T2605tp4AbPbHRqQbDSPLAycZ4IPpTByFbJBPH0pzHeSGAJHQHrmklUD5h/FnOKY7DTGGJxjIOMAYz3qL5uN3IzwKlVWVQT1A+8ORimY34ZcMQx4K0hkMnGCeueRnGR/jSt/rS25WUjGAKkYfujggY6im4ONvRgOvtQF9CGVMIOQvOeehGKqSIQpdiOpGe4qwxG5tnryPWmTgHAYfUetFgWhl3g5BQgFh8x9vavDPEkZXxTrAA6XTkYHrivdroBlPBwOOnbFeHeNlEfjHVFAPzyK/B9VFS1oWnqjMLgjLnahGCAcDjn8K6SY6trVrZGOwvJZoF8p7qNXzIuflz2JA4z6VgaKYItWs21EFbMSq0oYZG3d3rtdXg8WTahcPCLu4tCxMBtZP3W3PGADwMVCRbepzU0N3ayCO9WaNiQ5jkUjPsM0r+Su3ziGcju3T6e1dJerqFt4Vu08SO5lZkNlFO4aZWzhiOSQuK5r94/3VjOODuH8vaokrGsHdDrjDRZYMOM4PH1P61UnXL5U7vm4J71NKOhIIY8HLd8849KgkI+UhWPcEjG31BpAA6ZOGHSu2+Gj/utSTHIljb8Cp/wriAB1IwOg+tdb8OZCmq30J/jgWQAd9rYP86unuZz2PTY0CnJ5AHb0q3GcsOAGI+VscVSg+cqwztUkbs5+lWowfO3FuT2HQ1sY9S0DtO1RjAGVHaljB3KQTycZ6D8ahjGAMsWYZPpVgJlwCcEDPoaQ7EhUCL5VxhuPc+tAOSfu8HnHGaRgDt3Zz7jjFIy7n5AKnk5PSgSJY13EFyNvXGakXDZAG0DkjHX2qJQrNx0A3fUdqeWC/KrZK88d6YhWYKcEE45xmgKGO89O+etRkkvuwT6DuRUzZbmMAD1zk/nQOwKFO3HJPHt+VM2CMcHlm4Hb2pg87aTEESXIGXJIIzz0qSQLg5HHrTFaxG53NuT5fVe1NOFXJ5AO4Y7+9OUgEqo3DjA9OKilcs2HVcDk84pWHcbGdzZbjHIHr+NP24zvypADHFEIj8v1LDt2/CniRgNox06UAIRuQD5QAc5/wDrd6Mh1ydoGOmOlKORuDgHsFHSmO5DMpJAbjPfFACg/uxtbAI4J6/r1pwDE7MnjnH9Kh25kVm7cYqVThPvAFRjk5osDHcZwAvIzxxmnIm3IGAx4O719qYXAbPXHIwKGJ6+YQDz9KCRTIpXaeSTxgdqTnopwehOcCohhgc5Q9eODj0pHlUDjgZ780CYu/aS3IYngk5J+tR8Kh3dSeO4oU5cly3+19O1MbBUDnAPQnr70AMZtpUgkDH+RTxIfLJXqR94dOnHNQyOWdcZG7J6YwPrRuZkAKDHDAZ+99PSmDQmWyXJ5AJJIJPt9aDnyiW5OM5bPX39qRXwNuxlOTwRnr/tUiowXKHeSMg5zwKYhzrukAGQccHPP/6qjIflgQPUf4U9SMMcDDDqFxRkZYnOD2J6e9IaY0M2FxtDHk7u5/pUkeBlflOR2NUrjZ56RklWILY/2R6/nU2VULktzjJA6UirF3g8/dUH8DSbVk+WJjt6eo4qONsDqAwPY9qehLYZcYPAoJJSP3isQM4zkcfmKcrjBCkAg/dDU1ANw3FiMcr0zTXiyx4Ue474oKumTlSWSQdevHY0/IbdzzjBNV0ztDggNnPFKybmWQthlPI6g+1MVuhIWI3KTgHqSeKI3OxcnKqcHI6j1pWXB+XkHsx4puTy6tgDsKASJ8tInDY75xwaerEoMEA56dCfeq0eXdjvPv7U+M/N90YB/i6+1MCw5cAyKwyfmPbilYkHqc9/8ablXUb1PGcrinAtInJxjuf0FAiSIr5QYBeewFPDZAUkcZx71XUhRJ0Jxg89KfC/3VGOpIzSGPRTxtyMc8HFCjhDIDnkg9AD9Kefukg5GcYI7GmOAyEDt68CgEOIHDlQCe/emHOCQQQBwD3H0pEYoygqzAe4pRjeGGVGM4x3oCwxsEBmAAYZyOooVWVRxkHuT0pQmU4B2Hk+1I6kEYPyn8h9KQETDk7frj1ppK72wTu+nWnE5kxtX0/H1FJLtUZA3kc+9AEAA37j8vsajlLHcvy7lPIHU0+Qry28YPX1qJw3OT16t/Sgoo3JByO/T/61eIfENNvjC7PBLRxMT/wGva7kHYxznvjvXinxFYSeMLsKSPLjiX1x8uf603sHVGPpVrJe39raQkLJPKI0ZjwCT1PriuvtrTSJLqXStJ1O/tb+NyiSTnZFcP0K8H5cnpmuLsruS1uoLiF9skUgePIyAwOQDWnqt7b6lfC5tbM2ckpJmVG3AuTksP7o9qy2Ls2zYg0thpGsSXscwv7SaJQGfOMtgg561mPIc/LOAOuQM5Pc1rzeKHvtCubC8th9ulEatdL8rMingOO5xkZFZdpGFjOPkJbJCiolboawv1EAUHoCqnA74PpUDOGkyw2nJ5HQ1PMgAO35doXdu4zmoJPmcED5f1NSxgufTIznFa3hGX7L4lsiDtSQtASD3Yf4gVlJ15XjPBpJZHixLCxEkbCRCP7ynIqo6Mma0PcbWRlAAbaG/I//AF6to3JwMDjLYyDWRY3Md3YxXlsSYp41lXb2yMkfqR+FaMbgJuBJB/DFdDMDRygGxc5I6nmnCbMRCjkHBH9c1WVtpGWK5Gc1MgJA3cqODu4wfrSHYlXaFwScYycHrUhJOAuAB26ZFQKFAYR/lnp709GCAMnUnOQOv+FAE6A7iqkYyMEtxT5OCwXDYPHr71GjhDk4Mft1pxYDrtIOce9Ah5/2yCp/T6UKAXIGMEc5NNGFVhjIyMbR0/GlhOZecbSCcEUAxzhBtwcAcL71GTvBwRkDH4U6TlmOCqjGMVCx+RhtZhg/d607CQrYGRgZblfSmnBB456EdaaASDuLFj04+7QCFJ46n7w70DS6j1wFKrgMflOOh9qR1wu0Y4AI56UM/Ay2eeABg/Wonkwi4bhgeR29aQxXk82QheeOo4pXIwMs3HbHWokIEh8r5wP4vQ06VwDnLZ7kc8e1D0AlVTnJIGeS5700sOoPHqRUckuwqw5z69qjfnDBmC9SMdaZOpYYjGSANw5x60yOTGOQoJwBUTMuCVYYPXnP40hKgkYGSeCf05oETBsfNggE8g/0qGWQhtqAEdfpSvKRnOcfyqm8h34Y5B49gfSgaRZMu0AFvqDwDTSd8hBb5SOR6D2NUpJjvBPIH8VWoVdkVmXCkggdz70gsT7gwzjCHPGOD9acVBIQDC9SBz0/lUqKrEt+uamCcAupbnOM9f8ACmiWUzGykfLkdjnI59qjK7EJJ3Y5bA4Ge9W1ycvHgyLwWHQEdvpUMsYVjl2GTjLZIJPUCmTuQqWPOVPodvFM3bSMhdpOevWpJNw5OATggMcY/Ko5A6jg/LkdOaQ0JMgUcHp2zkfWmIzBSFJ47+tIz5+c8DPIzn/9VNOA6kgHjjFIrYmhYsEP3ZMcqDnb7VMspUgkDgYGfWoHc7cDg9OtORhtU53AenSgGi1A/ODnYR17mhGUEkEZBxz1Y1WG7jawYdNzfxcU9JNxVQASvQYxigEizHKACHA5pysSN0eOD8xHaq2VPJ6g4ODx+FKshAyRg5247UxpFgNk8chRjJ4/Cj5ssMrjHGT1+lMDYJZidh9u9OHAQkAkHjNAxyemOMDOKe/AKqGC9V496gOUZA+7aM8gdKVCzKGZiEA7Hv6U0JotCTkBsBcAcdCalBAJZGJJOTv6enSqlu5HH3mz0PanhgGYjkHjk/570CWpOrBmwVViflXnrT/LAUH7xBA47GoBu3fNtXjnjipIpGLkBhkAEc0A0TdRyOV680u8vtXK464JqMyqVUMCRnnjpQ7fNnAwTzx0FAEn3ccZGck5xiklG5cjAx78UgA27z8ynr6ge9OONnOAGHB/+tSAbD8pyMkY6UjcNtZQOOlReYAdm/djtStIzDDZHcnFAMTbtwJjtHb2qu+6N22hdw6YOetSM2WLNnLcYPpUZ6FWx9RQNMY3DEnOSOo6iq8uAwK9RzuqaQY3MSQ5wAaqzSMy/KwIA6Y7/WgZTvCTE/Bz1614V4sm+0+KtWcNnFwUDD0UAf0r2u9ukiikkcgLEpkYHgYAzXgAkaWVppCS8zGQ/ic/1onpEfUfDDJPcJFEGaSTCxpnGSeAB+NdJJaadpaRxT2l3qLmXyWmSTyYjKOqIQMtjuelZWhXcdjrljczEGKOUO5HYdM/h1rb1ayjkitLK81KOzmsldALlW8u4QsWWaNlBzkHn6Vl0Kb1GappS29u1xa/aI0ikCXENyP30DnkZI4ZD2NZjTCLADKARn5jkn3NdJqNxHFok0haSSF7eCxt5ZVw1z5bbmkx12jOAa5WT753LkjvUSVjWm7rUuykbsYySQM1ER36ZBNFFQxixsdgxxUUvMfTpRRTQnsd78MLmSbw7cQufltLjyYz32Mu7H4EnH1rtbeQ8IowMj3oorrOZbFq4maK3eU/NsQnaeh5qZCWgDHlcDg9efeiipLRKjnBHGByPam7iWc/3RkfWiihD6liImQ4bsuRUluckDpgAUUUEkrEqzKCT7mmRnC7v73UduuKKKYmSZ+Y5GTgnP0qDJkiDsfvHpRRQSQRsS8ajjJJP1pd5O/cAx25zRRQyx4YjcTzg7R+VNdQI1x69qKKBDAuAdpwuTkY61Cw+ZRnCsSCB34oopS2HHcYMNHtxgDnFJk+YuTn0z2oopsDIm1KY+JI7GP5ItgJPUmtkvgbsHIzjB9KKKiDve5VVJWt2Id5YKehbH4Vn3Mj7wmeO/FFFUQiOyb7RIxYAJHyEHQn3rcUbsZJ4A/WiigJF1GILYJyi9fWnsgSSNeDv5JIoooMxJOJFTr8u7J6flQEYoo3kHHOBx+VFFMCGEK8z4UKzdTjOQO1Q3CCPeRj09KKKAW5RnQAcd8GowSCMnIGMD04oopGgqsQm4HoQKcp+U44CgnA6UUUAyRWK4zz0607sSeTyfyNFFBKFGQDtOMD0qQElAW+YehooplMdkh3ychQOD705ZTtQgD5ucelFFMBUAIcgYyc9adA5dsnGQDj25oooBirIcuxALHvU20RMQBkHse1FFHQgljO6UqRyCefWpEPy47BiBRRQMBgELjinN82QONpOffiiikLqRxSGTcDxjIBHtSRyGRypAHOciiig0InJ8tWJy2BzSeczj5ufmIx9KKKGIC25FJx8wBNMdyo4+lFFAmVZuZEGSNrdj1+tVnJaEn/AGsUUU0X0RyHxBme38M6nJGfnMYjz7MwBryIKNpA+n60UVNQS+IkaIKSwJ+Xp+FaGm69qOn2hgt7g+Sp+VJFWQLk9gwOPwoorFuyNLX3C8vLi9k+0XcrzSlSu5z0A9PT8KhCqoGVDEjOTRRUvc0R/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32234=[""].join("\n");
var outline_f31_30_32234=null;
var title_f31_30_32235="Features of high risk abdominal pain";
var content_f31_30_32235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of high risk abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       History",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age over 65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunocompromised (eg, HIV, chronic glucocorticoid treatment)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism (risk of hepatitis, cirrhosis, pancreatitis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiovascular disease (eg, CAD, PVD, hypertension, atrial fibrillation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Major comorbidities (eg, cancer, diverticulosis, gallstones, IBD, pancreatitis, renal failure)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prior surgery or recent GI instrumentation (risk of obstruction, perforation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early pregnancy (risk of ectopic pregnancy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pain characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sudden onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximal at onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain then subsequent vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Constant pain of less than two days duration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Exam findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tense or rigid abdomen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Involuntary guarding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Signs of shock",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAD: coronary artery disease; HIV: human immunodeficiency virus; IBD: inflammatory bowel disease; PVD: peripheral vascular disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32235=[""].join("\n");
var outline_f31_30_32235=null;
var title_f31_30_32236="GAD-7 anxiety scale";
var content_f31_30_32236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GAD-7 anxiety scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Over the last 2 weeks, how often have you been bothered by the following problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not at all",
"       </td>",
"       <td class=\"subtitle2\">",
"        Several days",
"       </td>",
"       <td class=\"subtitle2\">",
"        More than half the days",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Feeling nervous, anxious or on edge",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Not being able to stop or control worrying",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Worrying too much about different things",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Trouble relaxing",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Being so restless that it is hard to sit still",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Becoming easily annoyed or irritable",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Feeling afraid as if something awful might happen",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total score",
"        </strong>",
"        * _____ =",
"       </td>",
"       <td>",
"        Add Columns",
"       </td>",
"       <td>",
"        _____ +",
"       </td>",
"       <td>",
"        _____ +",
"       </td>",
"       <td>",
"        _____",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Circle one",
"        </strong>",
"       </td>",
"       <td>",
"        Not difficult at all",
"       </td>",
"       <td>",
"        Somewhat difficult",
"       </td>",
"       <td>",
"        Very difficult",
"       </td>",
"       <td>",
"        Extremely difficult",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Score: 5-9 = mild anxiety; 10-14 = moderate anxiety; 15-21 = severe anxiety.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and reproduced with permission from: Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092. Copyright &copy; 2006 American Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32236=[""].join("\n");
var outline_f31_30_32236=null;
var title_f31_30_32237="Chemo met carcinoid";
var content_f31_30_32237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected chemotherapy trials in metastatic carcinoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Phase II trials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of patients*",
"      </td>",
"      <td class=\"subtitle2\">",
"       Tumor response rate, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Median overall survival, months",
"      </td>",
"      <td class=\"subtitle2\">",
"       Reference",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dacarbazine",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       Bukowski, R; 1994",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dacarbazine (second-line)",
"      </td>",
"      <td>",
"       61",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       11.9",
"      </td>",
"      <td>",
"       Sun, W; 2005",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Etoposide",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       Kelsen, D; 1987",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Paclitaxel&bull;",
"      </td>",
"      <td>",
"       24&Delta;",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       Ansell, S; 2001",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Docetaxel",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Kulke, M; 2004",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gemcitabine",
"      </td>",
"      <td>",
"       18&loz;",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"      <td>",
"       Kulke, M; 2004",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptozocin + fluorouracil + doxorubicin + cyclophosphamide",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td rowspan=\"2\">",
"       10.8",
"      </td>",
"      <td rowspan=\"2\">",
"       Bukowski, R; 1987",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptozocin + fluorouracil + cyclophosphamide",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptozocin + fluorouracil + cisplatin",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       31.5&sect;",
"      </td>",
"      <td>",
"       Turner, N; 2010",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Temozolomide + thalidomide",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       Kulke, M; 2006",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gemcitabine + oxaliplatin",
"      </td>",
"      <td>",
"       18 (previously treated&yen;)",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       23.4",
"      </td>",
"      <td>",
"       Cassier, P; 2009",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Randomized trials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of patients*",
"      </td>",
"      <td class=\"subtitle2\">",
"       Tumor response rate, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Median overall survival, months",
"      </td>",
"      <td class=\"subtitle2\">",
"       Reference",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Streptozocin + cyclophosphamide",
"       </p>",
"       <p>",
"        <strong>",
"         VS.",
"        </strong>",
"       </p>",
"       <p>",
"        Streptozocin + fluorouracil",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        47",
"       </p>",
"       <p>",
"        42",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        26*",
"       </p>",
"       <p>",
"        33*",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        12.5",
"       </p>",
"       <p>",
"        11.2",
"       </p>",
"      </td>",
"      <td>",
"       Moertel, C; 1979",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Doxorubicin",
"       </p>",
"       <p>",
"        <strong>",
"         VS.",
"        </strong>",
"       </p>",
"       <p>",
"        Streptozocin + fluorouracil",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        81",
"       </p>",
"       <p>",
"        80",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        21",
"       </p>",
"       <p>",
"        22",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        11.1",
"       </p>",
"       <p>",
"        14.9",
"       </p>",
"      </td>",
"      <td>",
"       Engstrom, P; 1984",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Doxorubicin + fluorouracil",
"       </p>",
"       <p>",
"        <strong>",
"         VS.",
"        </strong>",
"       </p>",
"       <p>",
"        Streptozocin + fluorouracil",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        88",
"       </p>",
"       <p>",
"        88",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        16",
"       </p>",
"       <p>",
"        16",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        15.7",
"       </p>",
"       <p>",
"        24.3 (p=0.03)",
"       </p>",
"      </td>",
"      <td>",
"       Sun, W; 2005",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Response rates included both radiographic tumor regression and reduction urinary 5-HIAA levels.",
"      <br>",
"       &bull; Patients also received granulocyte-colony-stimulating factor.",
"       <br>",
"        &Delta; Includes patients with carcinoid (n=14), pancreatic islet cell (n=9) and anaplastic (n=1) neuroendocrine tumors.",
"        <br>",
"         &loz; Includes patients with carcinoid (n=9), pancreatic (n=7) and pheochromoctyoma (n=2) neuroendocrine tumors.",
"         <br>",
"          &sect; Response rate is for non-pancreatic neuroendocrine tumors in a combined series with 47 pancreatic neuroendocrine tumors. Median survival is for the entire group.",
"          <br>",
"           &yen; Includes patients with well differentiated neuroendocrine carcinoma, not otherwise specified.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32237=[""].join("\n");
var outline_f31_30_32237=null;
var title_f31_30_32238="Los Angeles grade A esophagitis";
var content_f31_30_32238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Los Angeles grade A esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 282px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEaASoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyQRAMpJ7ce1PjHOBx/WgcqM8k1KikV56R7Y0ofMHOABmgfNI24cDuKlAJ60oXahPqcUNO+gIi24UFfWkYAuOevWp2+4QBUEQKS4YZxyTQ9AJ4H2XEQbgBhXeW6q0Kt1HWuC2gtk+tdvo8gks0B9KljLoAXg9D3qzDCG5B61XjQsCO9WImMeAaFuA6WEqMk0+3UeUR/FT5HUxAk8ioEb5+DxVNdQWuhctyuzB7U/jPXmq6N83I61MmN3NAOI9Mkn3qZcAe9MUZPy1IB6igQmQd3oKTvtPNSqm7kdKeiDNNvsTawxYgMUrR85qYDtimuMDihXJbIyABxQR3pcZ5PFI0iouc5IppITYm3kZ6UFABgn3JqMzEt049aZKSW4PFN2GkxsrFeOgxVUKC9TNluD06UwLhuB2octDSMUNaM4yOaidSAKtFGX73SkK54IqFqXYrMo28mq0ibifersyjGBVSYFR0poCEqCTnnjioFj5Y++BVnBOcVGFIz2qX2LsES4HzDAp08acUqoTx1702RXHTnPrUx3IlFlCaHkgcUwwBHB7Yq4Ax+8O/FPuIQYdw61V+gnoZNxGApz36VU8pO+atzbicHnFR7PY1S93QLNnIpllyvYZqeMkAe9AjMfB6Gn9B+lCJH+WMH1PSmv8A6sI3WlYny8j7/QU9FIZz94DoaFqCISrBeOgoCBgT3qyNhGGOPWmso3ZXGKGhXBEDY9K3dElMTCPt6VjQn5sdqvWrbJFcdqlpWBanYwncQQOKsuFcY71S0+UFFwavhFcDHBHX3pRuUVJ0cIAvSoFZlbBq2wePG7kVTunUPzxxTv0LgaMLAjnuKkQhjisu3nAXAOavW5zTWw3E0IzjpzmrCqcnPT1qpCwBBq7Gc0IzY5VAOBT9uKae/v3pGZskCnbUi9xWcVGz4+brSYJ6g0vlArlTVXSJ5e5VkkZ264ApsaYI3cirYgGeaa+FOMCk22WrLQAo+6BxTSgIqReKXAPv7VNrbFLcrCHnI5pTHhgSKlC7TlT+FOY5HzCk/Mq5DJmQ88VG6nbj161Z2qRwajbBJzTEU5AATVOTPPertwQARmqjHApscSNcI2GGDilcKy5FMdtwwaYOSAOmeal6F7ioShJqRV8zvTN3ygY60qgDkHFS+4NELna+BTiQYyPUYp7R7juFRPhevBp6N6ENFKeELyDVXB9Kuz/NgVDiT0q3ZhG5yr4bv17UyZPlGOvegjgk9T0PpShDgc8dh60m7GY2MHknqKsIcAep60wrsPzDAx1qSMKYz69qewMhb5m/HkUNEN2FbBpzRnBJqOM+Y7Y6igE7E0ZIkAIyPUVoWaiQkZqlENrDPWtCywJRkcdqUr9A6mtprOgCk8Ct23kBxWJbx4wQTkda1oOUAI+elsU7F6YBoyeprDvVJcgitddzcA8VQvFIBJHFPSw4OzKClYyM9607VnA4+YVhTMfMxW3psmQB2xWbXY2epqQKCOever8akAYqpEV2n1NWI9zEbTirXmYyLApwTvSoR3FSjGODTTuS1YiIx0pjqRg44qxtpCeoxTJIU+77+9VJSN3IwTV2TGBjiqsw+YN+VV01BasZHux1yKCSDyKacqfw4pPMOPm5HrUq5rYkP3eaaG+ao2lBHFMMgz1pbhYfK/U1XaQjJDZPpTpZFC8mqUky4O000Frj5puuRyKiP7wcVH5hY9qccIoz65NJuxdrIgkBVsU5OgpjlmYHr7egp8ZHH1qb3H0JkXPOKRuT0p2/YetRtueTA4HenYT1E3Y74Aqq8pc5Iq5LANuSar7AGANNabBoxiKrEYPJp2D6UsicHHHHBqLePQmkrvcl6nGxQtI21Dz705lwwGenBqRX2DP8WMn6VGNrZYHrVLuY3Ht8ygNz6U/yQFYjqcc1X+YMPSrKk/dpaBqRMGBIxkdBUIVVlJIwPWrzYA245qGRFJCn/wDVTYXInyG4NaVuC8SsOo61mTQvvwhytW9CuC4Mbc/Nil0A6OxcN9RWtCoYA1k20YU/LWjC5A2ntRGwMuNlOfSqN8xCEg8AdPerLSEDnpWTf3B5Aq0gWrM9AXZ9wwetaGnuwO3NUonBzir2ngF8nrWEkzqT0OhtFZgMitKKMg5xVazAVQe2K0FHftTi2zKTHqBto2AngcU5RxTSSAc1Zm2Jz0z3pGbIJxTCSTil7U1oJkZ6ZqOUHbxyae/XA7VECVPqaL9xoYOT8woMYzx0pXYZ4HJpjMSOtJ6miIZUX5sVWlQ7cgnNWX4bnvVe5kEfB60eg7mddSuGK9cdTUKqWPBPvUjfO5PQGpVQKuKTfQ0ikkRCNgQTThlhhqk/iODn2FRu3J7AVNmO9wA2t60yY4GVGCKkVl/GmycngU0IiVi7KD+NXYTgfMMmqyqM1aQAr15pdQYxiCvWoygOGx0qzgdSMGoymFJ/IVV9SUiowY/SmeUPerDAhcH0zUeDQ5WA4gp85zzkYpRDsU4PNWVUYBP3sUxlPOBVHORRqXGOw6U9XHIB5FMDFcgdKRl43dDSSsBYDANzTWTPQ9ajXKn19qlzvwelCvezECFgu1h+NRROLe6R14UHmnyyFTgcg1UaQs+GGB0ptdxJnaWbiSJWWr0SkHDdPX1rmdBvSoaJ+g6Vvx3O0jJ+U9DQkNstyOBHjt3rCumLPjHBrVmkV0I9azXJiVgaHoXT1ZVgiYN8p71r2cLBgapWe1wyHqtb9jGCi4PQd6xd76HQ3Y0rFfkANaUXzAk9O9UYgFUZBBqxGx7HIrSKa3OeTuWS/JIppkBPPeo1JzzSOOc1VkibEjOAMgVGz54qFyQSc80wPkYajYEh7scVExPanjgcGo3OO3FDZcbIQdST9KjkOOnQdBSO4A4NVppdvU8mkkVewssnB9aozsWz39aSa4APXiodwkBIJFDdhxV9R2aXdkc0qksMNyPWlER5x07VDfVGoK4DZxzTn2vgY96aF2k7hQCC3FPbUQ1U3HjilKlcgjBzTxlcGleT1FG7uBGenvT4nGRnioW5Ykd+adE2CNwyBQ/IC2Co96a5OcDpSRhO+QKGYDqMmi4nZCSqWjwar5P92rPmqVIzzUPHrRa4jlCysuWHtmmbAQdpwMUqc5U9BUhAK49as5yjIh2kfrUG7nac8VotEW4FVZY1IORj3FD7gQxSYYknrU6uoyD6cVTVSr5U5HXBqaHaX+fIpXBoR1ZnG37tOZSoAYcZzVraqjAORUNyrbdw7DpTI5iK2ba5ZTg5zWtb3jkAHmsaEgtnsasq21+D9KG+o0bgudpAY0t2+5lyeDVeGIuCH5A71LcQHy12noehrNzubwjZ3I7RmhuS38J7Vv2043hlPBHauYZnV9vJrTtPNgjBboamLszaaujrre5BXDHNWI5U5wcelc3DeDgMcGraXQDA7uK2tc5nobwlxnpiopbgY96zBcjcMNgd6TzwBkc5qkiX3LckxIyKgeZgcg81WM4Axmq89yAeSBxSGjQ885+Y0x74Lk5/OsSS8OSQSTVVpJXk+YHaaWnUrfY15tQU8A59qpvdOzAg5qBoAozu605ID1zScuxXKtxDIZDluKtWJRXG7laryIQvqOlEOUZd3GTWbbZqttDeiWB7gfNtU9at39tCrAWr70IrIEThfMQbgOuPStKErGqFTkMORQrEu/cpywsCcHNQ+V14IJrUuo8nKioI1+bmqa0BO5AUATg1XKknkdas3K4Ix1FRAkHGe1C7FEQIXPenEBhxSMm58dOKUKyAHr2oAFznHUUrK6nmnpjPTFOkJJxRe4MgA65FNwvoakLc07YfWjYDio96vhhz1zVtRkDnFVlfBznr3qVGyBu79Ks5SwYztNUZ1K529at7/l4bHrUZ+c/MPyo2EmZ5iHDHrTSCh6gjGa0TEDjAqndREKccHtQhvUajFtpzjNSSbgozgg1FaMGUhjyKWaY7jR6GbIQQG+XgdqUMfOBFLKPlHf6U7y1c/LwTSloaQN3T32oM1YmfcvHNZdjMVYKwyOlaMY3P8p4rO9jdLuVoYyLgOSOvHtW5tVlG4duKqCEAYK81IzmNABz2qYqzuOWo2a3b+DkVAPMiODVyKXsc8VFcTYHI+prX0M/Ii+1spKnmhb5iOlVlZGJzxSptDYyCKfNYTj3LElw56HrUeySUZDYAp5RWPynkVPAQBjFO/VE6LcrRxsuCy5weTVzYzBSuB6irJCttxxTgigEkVLV9R8xC6ByvG31oeLy3wpypqZWz6delPkaMryMepFFh81iFoCFyOaQgbArgZHetO2jEaqrMGR+Qag1CCMJuj4PcUbhz2JNHuPKDIwDBvWrcMK+Zlvun9KybT5ELirkc5CZJ4qOug763ReeIkMy/dqoT146Vbt3Lphz8tMlhGSU6GqVrDT7lFsSAnPNNSAkHd1qyIwv3lpCeCF/AGjfYu5TK4HNWPs4MIcGgoW4YY96EYx5A5HpSauO4kibBkfMO1V2574NWmYMtRFRnmqsK9ytyDgjin/nTtpLDtT/m9BSsO551G54ycrVhZvlGayoX24yeCN30pzXJ2cdD0qjlTvsaNzcBcYNSW9zubaDzisRZC65JORVuwRmmBQEt3AolJbGihc6CIBlOeD61VukJGBzVm0bcpB696bMAc8YNEdSHoY0AxcFcEZrQms3eIugyo6n0qOYeWCVGWPf0qL+1LmO1ktl4V+KL6kNgyqkY5zzStyy7abAmYCTz70kALfWlIumu5ZgG1s55rUtZCAPXsKzFBHbmrkXXNZo3bNQy8AhvqDQDnlqpIxJwenapGkITA69qCUWnYJjaevNUry4GMdzTWc5Ge3U1QuCTKSOQKpRsrsHJiLIfOIJwTTpHII2nBqGKPfcEZwferc1ttUMDkCqtpoZ8zuT2sxU4YggfrVouvJDYb0rJQM2cdKesjIQOtStBtpm5FcNsAkXPoRU6SbiQDWbBMBH14qI3m18Lz/Srv3I0uabkhuv0p0Zz8rHI9azVuWmzng+lJHcfL14Pejm00HY6C0kRDhyeOnNOkcxrvmxg9qzQ4aKP5vmHf1qw11GvyyqWXHapWgi2vlzW4Mfy1LbxwtAyq+6QnpVK3cPGCi7VqzDGiS+YvBpPQtF5GHlhW4ZRj609JQRgHpSrGLqMpwGxkGoLaOIJOsjFZE+77mhR0uhp9x0p9PxquRlvSpA2chhRtHYU7loRWw2CeKa6DJPSkC/Nk1J1XBosMiGVPGCKdtB6cUmMNxUmCVyaYEDIRyKiJOetTMxzg8Z5+lQce9NNDR5Ckh5XtipIZTMwXkNwoqstygYZ696nikSOeJ+oDAnFZ62OXS5fa1eOTa64LYxW/wCEiLLUhKyCVQNrIe4qz4rv7C91HTHsuixYkPYntWZ5txbXJm2FAemRwauFPnp+0ZUavP8ACal7LCtzI8ACxseg7VA0gaqauJm3Hjd1pxHyAL1o50tLDUb7izAF854FRS23m/6rluwpW+cfL3qaFvJZHT76nPtRe4pR0IbYH7M6MCGUkEelNjj24weg/OpZr3z7+ZyFBfqB0FMAx1pNNLUVNkyHkAdcc1PGR3ptsvzEYqdoVz8vXOazOhWHYwcdzTjweaTaN6nripW5U5HSm9BWRAFJB9KBACvPc8mp1GOtAmhWTy5jgH0oV27EyaSMqBMXziV9qk/pU9zdoI2VG+XPBqCe2xO7biQ3SoJIc7VHQVVknqZJNhDfKwIxUEk8kkm0DHNTrZBcEDH0qaO2VW3Y5P6VDlY0jTb3GKHCD5zViEgnAqQQk4XHJ/Sp7e3AfoeaHI09lYaI3CknuMVNFBwvUDHFXI4sjBAIqZRkgEVUQaIFi/d4zyKNuF555qVjtPAoRTIenWqI5WTRqBGCCcelSRzsoIpoTb8vrTNuM8fSlYLGrazZ6HmhVYThj0zVO3JV/pV13yuQaE+gWRPMFAyvfrTEB4FMjO4damwMcUWKSGvyMfjTPpU2Pl6e1MdAqnFPYYwKakK7VHNQq+0nNSFt3BFFwIpEySe1MqVwCOKiyaYHhDxszkDv1+lNBeMjaepqd2YjK4GRzTY2QAdyKlu5zuNx8V5KDhs47Gu61DxJaah4RtLN4wt/CNhkHVx6n9a4kRl13KmVxj6GnGzlZCQM46H0pKpJND9k7WTsb1jMqQqC2cVbS5QsB/Ce5rlEhuUb5d2MVYWeVAuQcd6fMmy+Ro611WN+oIIzSkgxHaeg4rDgvDsXeD7VeiuFkGCcULXclleVSt3uHTHr3q6jZUH3qVbCabTpNRCg28LhGPv/AJI/OizCbCR0PND31GrFiJvnwvpU4bHPrVWIYbjrVyJDjBGe9SzRE0aZpwHA+tPiQEYocbATjOKNGDZFKwjBz9TWdnfJvapLuUsuB940kCfJz2qrpKxFuZiqd7AMeoz+FOa3GQR3pyplix64wKnRSSBnNZNm0URiIY54xTo4cuB2q15R69easQwqDnoaCyAxYHTrUscO3nvVxYAVBpGTnbQwWpWRWAPqTirIjwo4yaWOPMgAq6IskelOFwkigIgRk1IE29KtNCBnmkMJBH0rXYgrBTu5FSmLgHHNWIouPmXmnNExAApXAokbPbFAcnAzwBViSBuQRUX2dg2SKEx2HRTFRirSSAKM9arx25596n8nCfjSb7CsPDnNK5z3qNUYfnTsEOSwo5gsQup5pVOCM1Kse7OKY8RDU7iGuTjI9ajLHPSpvL5p3l+wpAeBQsJz3GOMetXIbHdyOlSx220HIGTV62gCAspOTxipdwSsJCvlKVX7uOlW42xCBikjjzkyL8vTjvU4QYwp4qVZlNJkQUHJxUUsCuOgz/KrTRkYHapI0yOmSaegkuply28sRHk/MPQ96j+3x4xKjRSDsRW68OcY7Vk6tZeed6qN69KuDXUznG+xcstUlezazjlJt5DuZAeM1oQKI0C49q4+2iktWBTIIrr9BZr+RbcYMhXPNLmb0MlDl1LES5f6VfTlcjrVaSIwXDRSgq6nvVq36YP1p2NE9NCVOmGqtcylM7TU8sijpWZLJvlIznFPoJyuIDvkPmDH0q1sAjG05qONcrgjj0p7gdMkH2qLFJ2JAPu561PCvzVTWUjjrzwKtRTqcDGCKW2jLTLwH5ipIiOhqEMCoI5qZMEDFIpEqbskKcUsbbiC45NLuCjNMQ/NletS1bY0iWNnAZD0q1bAtnI4qoh4Pr0FXLRtp2k9s80J2Y2rkpjBPtS+STzVxNjAnFSxxA+4ra5lsVo4iEz60hh+bjg1oiPnpxUiw8dKaFczFt2GQRu96Q2ysxAPNawixT2gUYJUeppWC5lC1PpT/s3AGK1BFtwR3oZB3XHvSasDkZLW2OlRtCQelarRA/dpphPTFO1hXMo24znpTfKZQeN3c1qGLHamNFg5FLlHczggI54Pao9h9RWjImV6UzyB6U7CueHW6gtuxxir0EA24xx1qOBSFOANvQCr0eMYPbqazbu7BEVYwFUAU3ywXIK571eiTOB2FBixk45JoKRnvH8wA4z+lJC+NoZeT0FTXCMjZqtI4yCOCKpITdi6o4HNRTxHBwOKigmBQgHpxTmkK9CdoGT700TdkAgjlJ3Lg96hjLWV4rxEqVPBFWPtCmYFxjK9Kgu8MNw7dKbaehDdzVe+eZg0vzHHJqyjMwZo+fTFcxFfNGVV+Qa3tM1iC2sZg6qzE5BNU5XspGfwmw+n3H9kS6hIpFqh2+YRwTWFFImAwYZNMvvFdzd6edP34tSdxUd/aslbnaqqg6HNVK1rIUb3OhDkseeKC4PJNYiX5GOPmJ5PoKZNqWCRtJBOBWTaRd2bLTqoyOtPiuQH4PWsBJmlY4bA7Cp4N+4HPWh6lJnT28wIHoOtXraU4Xv61zFtPIrMvatSyuir4cYzU2NFI6AEEjP1pyACTIHWoYpBIhIxnGKl+8BtPakzSLJkHzmrQGFyKqK7ITnt1NThgeOhqWamjYSfwk1pogKnHfvWFCrLzWha3ZX5TyKqMrbkzjfVGrGhXgcjPepeO4xVWK6RupwauId+MHIFaJ3MWu4zBzxTd2TzU2wA8VGUbIOMk9ab2ESL0oY9u1NjPy85BpjEnPehCaHuoyMUxyVOB0xTkPGTUbtnmnYBSRwGH1NRyYb7tLuyhzUUr4XjgmgBH7U3IppfavPOeAKhLnJppXEzxu25bA71oWycAnpmqGnqMA5/OtWBG2knp2rFO+pSdicKvy4p2HyNuDn1qRFGBU0a8DjipavqUihcRB1wwIJrD1BTEM5+tde8eRnHNZuq6YtzEQPlJGMirQPyORhmYMRnrVhrk7QOpFUrqGexn2TjI7GoGuFJ+9tJoSvqiZO25oLOHJHeo5plPyq3OOfasiaeWNuOcntVrT1DuHkBxVW7mTl2G3CSPIDG2FHTNTwxyOhBBxnk1cuFFxKgjQIB6d6thCi7UwQOacncSVyra6cBcqruAvWr89vD5gWJcL6+tMaP5C561HHcHcozz71Kd0NrqWvsUYA4yD1qNrFBIdq5BqeO6RvvDaRxV2AqVJGDSUkyjPttORR8wGB0AqeOyxjZkY9auRAZwRV63iyckcVT1VhlGC02gGReTzxVyK3RiMVbSPp6VKkILZC80vJlFaOJ487SangnKvtfg1YWIqc/oajlQbvmX8agaLcbhj1qwpDH+dZqxkAspyKfDO6/f6560nqUmbaYZSBxQpZM8Z5wKqQ3QOORV1GDYNGxqpXGbyWyGIx2rRtriWMqBzmqZUZJNTRhlUFTgipV7l6NG/HKJFGeD3pXYLzWbbNIzDcOfUVogKwxnNap9Gc0lYryS5YY+lRs2T79qsGAfjVeZCpGKu4tBzyFBgnIx1pgdSOuKgcttJ7VVMjKeelC0GloXj14ORUM0nNR+YeSDg1HLKSQG5HrQ5JMSQZLHrSYNIpBzg4p3PtRcTR5BbOGUA1q2rn+E/hWNbZ4wOK3LNMJyeTWYJaF6LJxkcmrca5AqC2BzzV1FxjFKzKHLESR6U5olYBSKkUGpTz0xmh6AYesaLDfW+GGGHRh2rznWNOl0+4KSj5ezetexqM5BrH17SUv7ORGAyRwa0i+hMlc8hY5lG05AFa1oyqpDDIFZt3ZT6fqEkMwxg8H1FaNo+UBPr0okuUzj5mrEVPPepUbg1VUhSpB+9yaR5DuwvPqRUtlJXZZMmfl7GqjqNxxnPrWhZ2zuNx6dMHrVsaeuTlOaOlylEwvMkWXJPy1bguirAgmtCfTQQCvNULnTnUgpnjt60vND5bGta3W/bvA5rZtGDAYrjllkjcBgRitnTb/AKD8KGyeVo6YKDgL2qeMAEVQtrjKhs57YrQRwVGKd9LhsSyAZHrULgFqnAypqGQMDxzS3KDywykLxSND8pqeLA/GhiWJx2pNXGii0ezlcirFvcNGMuakK7jnFNMW7aBztOcHvSaGXVuVZc5qxb3AL4Y8VnGMMWC/K4qCNHD7d/vTWoc2h2NrLHjrVoEZB7e1cqks9vEJDylXLTU/NxuOPatEkZtvc6QZ2jHNRypk8jtzVaC9U4GatmTcuetVYm5WljXYMVQmhIPStVgDz61GEy2WpWLUrGQ6EKarkkHBrWuI/mPHFU2h+bFIakV+oOKdg08oVPSnZ9qAbPIrKEoQG+v0rZtAMZ7VBbJ8oyM5q9EgXkdalaaMbdy3CAelXoQMDIqlCNpBx2q3HKOPT3pIRchXmnFBg1HHJlhU7NnpQAhwUwOtQMvBAPB6A1OozQ+BznpTA5HxToa30BKqPNXkGvPwGt3aJwQ4OMGvZLhQ6YI/GuI8UaR5knnQLlgc8d6paqzCyOfhDPgA9K29MsgzBmGRWRZoyOFcEMT3rqbAEquFOCcCovZ2Gi9BaqwzjHNWRaknIGQPUVZt4wAAOcVfRMrwKQ0Zf2MDGRjHU1C9hvzxmuhW3zjAokg2jJHWlsWmcbfaTvzkY98Vly2T25+U8djXeywbx0zxzWdc2aktgY9jTv0C1zmLK8lhI3g7R3roLXUEcKVOQe1Urmy8sMMZU+lQ2qiJgPQ0NW2JcTplkz93vSlwwIzzWfBMSOOtWN2AOxoTJsSLLhtpP0zU8bAE1SZWLBh1PepkkycfpR6AXVG4ZzQF25OaiRwPpTjLlcDnNPmsIJZPLXcDye9JPamF42D7g4zxULEMME1bgHAPUDpRoBduJ1exWAj7vSskHy3IFWGbc3Wn4HGQKH5DjGw9JHUA5Iq/b6kVO05qqiZTjvUMiYbpz61SloS43ZvxXivirAlG3jnNcsZZEHyHoasW2pFG2yZFaeZm9DekYED1qu/PJqP7QGUEYOaZJKBjnrTC9iTrx60zK1A8xA60zzj7flRYV2cJABwelXYl6GqMEhIUkVdhI4waz9CrlpVHc4FPVc5pqHI5GanXHToam3YtMkjGRlTzVgfN7HtVVM9qsK4x74pDJlyRgHNDoDgHINMh5PHWrLNg9MinvsDZTlHUVm3luHQnFa0gViexqq4bODyDQmM4/VLEY3qvzLzV/Qv3kII6r1q7qap5DHoT0ql4aRlaYdeaTaZDeuhvW6c4I6elakMZCiqluuAGPrWgvIHHSpZoSp93kEGlkUFetPj3bee4pTGG46UrlWKMkWD7VWniyOma1JYmHTkVXlUA4IxQUjFuLb9azbi1JQkrz7V0s8YKjHSoDCvHHFMVznrdHUZzznoa0YwzD5hVmS2Bbp+VSxwlVOelFkJlXnp6UGPPPerbIvG4VEUwQVNFmSVY5SGKk4qfjt2qnMD5pyuKfFJztzQSTfx461bUhYxg9ulUS5VsirkeZEUjpQMfFlm6c1MqHeQamtIfL5NSuRk7h1qop9RuaGgYx6UpTc2egp6ISTzTwCPvDirS6EXIJIFx0qi8I3gHpnNap6HJxVC7JU5xwKtRIbIZpWgwAxGOajTUQTh6hndpcAjNVXhOeP1oXuonc2RcI4GG61EZeT89ZY3pyfwpu73NFxWZiQsQMHpV2EgjHr0rPi4Y56VaQgj0NQ9Ny0akTEKATzUofI54qgj9Oan8zjk0eg0+5bBO8EGpSx9KqbwAMU4SnoTU7FJl2Jvfmp9/cnpVGKVSuTS+bhRzQDZYd8jB61XkfBwDURlZmyRxTGyckGpbHqV7+QMhBHSoNBZfMcL2/Wn3XINU9PhkW7DxjApNgkdfD2B9M1et139etUbZGAyOa1LYdM8etJ+RaTRLGhAqQAd+TT2X5Cyc4pE4HrQURuuSMGq1wuBz1q8QGbI61BcIShGKF5AZsgDD5ahfcBz61MeCAabLwwHWmJ6CBVKimhfepcgYBFRvjcuOMVXQljJASuD3qrIuOhxVtn7Yz71BNtJFHoBUkBBx2NV5VAbK9cYq03U1Xm7j2pWAj3EqcGr2lS/OEftWXyMEGrFpJtfce9SyWdSSMAA1GW6A1TjnDYOaGm+Yelbw2M7mgjjPFSOxA56VQWQbs5qwZQVxVCfcWRwRWdeMScDp3qWaYYx6VUL7iSaokYBtX5hyaa/SpGfIyRwKjJBB7VK13GQzHAqtk1LcMQOOgFVtzHnFOwkYdu5xyauIQVBPWs23+7WhB92pauNMtRplc55qUE46ZqGPrVgVnfoaXuO3ZwOhFSKhYdaj7rT4TwKm5fQd8wXFPQZbg/nUh+7TRw5pbiRMqEjpz609ol8sgdcUsXQ0kvUfSp8h7lIwM8mByK07OyVCARg9TTbf71aSfdNJLUpEqJtwB0q1CPnBI4qFfvVcX/U1Q0SwAbMUhXYxz07U63+7Ukn3VoGiDA7dSeabLnseKJev40w9DQtAM2QgyZxjJqBjmX1q3L96s5f9YKb0EyZjzzTGOW5605vvGkP3DVWJRGGPOOaYRk5NSL0NNl7fSlsUirIpDcVWm++Se3erj9aqT0eYmiAgHpSQ5BIPXtSz/eH1FNiP74/ShmcnYmWYocVZjmLDg1Tk6VJadK0TsZGijgr7ileXaetV4jyv1qKYnzW571ol1AfPcEHB5zTUkBHBqrOeRSxdT9KJvQRbL7Vqs8uaaSd3WoH6GmgFmm4yOwqISkj7tQTE4pgPFBJ//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Los Angeles grade A esophagitis: One or more mucosal breaks no longer than 5 mm, not bridging the tops of mucosal folds. Mucosal breaks are defined as an area of slough or erythema with a discrete line of demarcation from the adjacent, more normal looking mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32238=[""].join("\n");
var outline_f31_30_32238=null;
var title_f31_30_32239="Morbilliform eruption 2";
var content_f31_30_32239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exanthematous (morbilliform) drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Drug-induced exanthems, such as this morbilliform eruption, often begin in dependent areas and generalize.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_30_32239=[""].join("\n");
var outline_f31_30_32239=null;
